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Abstract 
 
One third of human cancers are driven by oncogenic mutations in the KRAS loci. In 
particular, KRAS lesions are predominantly found in the most recalcitrant cancer types of 
internal organs such as pancreas, colon and lungs. A vast variety of signaling pathways 
is aberrantly activated downstream mutated KRAS, thus rendering tumours highly 
aggressive in terms of disease progression, chemoresistance and metastatic potential. 
Although several attempts have been made to design effective treatment strategies to 
eradicate these tumours, poor patients’ prognosis still remains a key issue in clinical 
oncology. One of the main limitations of therapies that selectively target kinase-signaling 
pathways is the emergence of secondary drug resistance. Therefore, new therapeutic 
approaches are based on combinatorial therapies, which concomitantly hit the tumour 
from different sides. 
Herein, we firstly show a synthetic lethal interaction of Smac-mimetic 83 (SM83) and 
Camptothecin (CPT) in presence of mutated KRAS employing a model of premalignant 
tumour cells. Mechanistically, we find that knock-in introduction of mutated KRAS 
upregulates Noxa via MAPK ERK2. At the same time, SM83, targeting the inhibitors of 
apoptosis proteins (IAPs) displaces caspase and enhances TNF-mediated cell death. 
Thus, specific KRAS mutations offer an unusual death-prone scenario in which, together 
with SM83, CPT efficiently triggers the mitochondrial apoptotic pathway in premalignant 
cells. Contrarily, in colorectal cancer settings the combination of SM83 and CPT is not 
lethal when KRAS is mutated suggesting that other pathways are aberrantly activated 
and render cancer cells resistant to death.  
Secondly, we propose a novel therapeutic strategy based on selective inhibition of 
Cyclin Dependent kinase 9 (CDK9) and concomitant induction of apoptosis via death 
ligand TRAIL in KRAS-mutated non-small cell lung cancer (NSCLC) cell lines. We 
indeed demonstrate that SNS-032, the most specific and clinically used inhibitor of 
CDK9, strongly synergizes with TRAIL in killing a panel of human TRAIL-resistant 
NSCLC cell lines. Moreover, we provide evidence of the efficacy of this novel 
combination in vivo. In fact, SNS-032 and TRAIL co-treatment totally eradicates 
established lung tumours. However, as the mice engrafted are immunosuppressed, this 
model does not provide any information regarding the interaction of the treatment with 
the murine immune system. Therefore, to further validate the efficacy of our novel 
combination, we establish an autochthonous mouse model of NSCLC. Preliminary in 
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vitro treatments with TRAIL and CDK9 inhibitor confirm the efficacy of the combination; 
nevertheless, the setting of the in vivo experiments is still ongoing.  
Despite several combinatorial approaches have been so far entered clinical trials, 
patients often relapse and metastasis is still the main cause of cancer-related deaths 
especially in presence of mutated KRAS, which provides cancer cells with high 
metastasising potential. Therefore, we finally focus on the mechanisms by which KRAS-
mutated tumours metastasize. Indeed, we point out that endogenous TRAIL and TRAIL-
R2-mediated signaling is required to promote migration, invasion and metastasis via 
activation of Rac-1/PI3K signaling axis in KRAS-mutated cancers. Interestingly, we 
provide genetic in vivo evidence that mouse TRAIL-R is a key driver of cancer 
progression and metastasis.  
 
Significance: KRAS-mutated cancers are still refractory to current targeted therapies. 
Therefore, we propose two drug-combination approaches, which aim to induce cell 
death in tumour cells: whereas SM83 in combination with CPT acts at premalignant 
stages of cancer development, CDK9 inhibition is capable to overcome TRAIL 
resistance in NSCLC even in vivo, thereby supporting further preclinical investigations. 
Moreover, we provide new insights on the mechanisms regulating the metastatic 
process mediated by endogenous TRAIL/TRAIL-R2 pathway. We thus envisage both 
TRAIL and TRAIL-R2 as potential candidate-targets in clinic. 
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1   Introduction 
 
1.1 Apoptosis 
 
Apoptosis is a programmed process of cell death triggered to eliminate non-functional 
cells during developmental stages and tissue homeostasis [Steller, 1995]. Remarkably, 
induction of apoptosis constitutes an attractive approach to kill cancer cells and could 
offer a chance to prevent tumorigenesis and eradicate tumours already established. 
However, tumour cells evolve a variety of strategies to limit or circumvent apoptosis 
[Hanahan and Weinberg, 2011]. Therefore, apoptosis resistance represents one of the 
six hallmarks of cancer originally proposed in 2000 by Hannah and Weinberg [Hanahan 
and Weinberg, 2000]. Accordingly, most current anti-cancer therapies aim to target 
signalling factors, which govern apoptotic resistance. 
In contrast to necrosis, a form of cell death that results from acute tissue injury and 
provokes an inflammatory response, apoptosis is precisely regulated [Newsom-Davis et 
al, 2009]. There are two well-characterised apoptotic pathways in mammalian cells: the 
intrinsic and the extrinsic pathway, which both depend on the balance between pro- and 
anti- apoptotic downstream effectors. The intrinsic apoptotic pathway is caused by 
unbalanced homeostasis and intracellular stresses such as oxidative stress and DNA 
damage [Galluzzi et al, 2012]. In response to these stimuli, cells employ mithocondria 
and their related proteins to orchestrate and activate a protein complex called 
apoptosome, thus leading to cell death. As this pathway relies on mithochondria, it is 
also referred to as the ‘mitochondrial’ apoptosis pathway [Green and Kroemer, 2004]. 
The extrinsic apoptotic pathway is mediated by the interaction of death ligands belonging 
to Tumour Necrosis Factor (TNF) superfamily with their cognate receptors, the TNF-
Receptors (TNF-R) family members located in the plasmatic membrane. The binding 
between death ligands and their receptors leads to the recruitment of several adaptor 
proteins that act in concert forming the Death Induced Signalling Complex DISC [Scaffidi 
et al, 1998], a phenomenon which was first described for the CD95/CD95 Ligand (L) 
system [Kischkel et al, 1995]. This event initiates an intracellular signal transduction 
cascade that results into apoptosis. Cells undergoing both DISC- and mitochondria- 
6 
 
mediated apoptosis engage the activation of ‘initiator’ caspases, which then activate 
‘effector’ caspases. Caspases are cysteine-dependent, aspartate-specific proteases that 
can be rapidly activated by proteolitic cleavage [Falschlehner et al, 2007]. 
 
 
1.1.2 Type I versus Type II cells 
 
Depending on the pathway employed to induce apoptosis, cells can be classified in two 
different groups. In cells termed ‘type I cells’, assembly of the DISC is stable and robust 
enough to fully activate caspase-8 which, in turn, directly and completely activates the 
processing of caspase-3 into its cleaved form, thus enabling apoptosis [Chaigne-
Delalande et al, 2008, Dickens et al, 2012]. In so-c alled ‘type II cells’, DISC-activation is 
not sufficient to immediately trigger caspase-3 activation and consequent induction of 
apoptosis. Hence, cells additionally require the mithocondrial machinery to die. To make 
mitochondria death-promoting organs, caspase-8 cleaves Bcl-2 homology 3 (BH3) 
interacting-domain death agonist (Bid) [Kantari and Walczak, 2011]. The resulting 
truncated (t) form of Bid, tBid, mediates the activation of Bcl-2-associated X protein 
(Bax) and Bcl-2 homologous antagonist/killer (Bak), two pro-apoptotic Bcl-2 family 
members, which subsequently lead to mithocondrial outer membrane permeabilisation 
(MOMP) [Waterhouse et al, 2002, Wei et al, 2001, Westphal et al, 2014]. 
This phenomenon allows the release of cytochrome-c that, together with cytosolic Apaf-1 
and pro-caspase-9, forms the apoptosome. Consequent activation of caspase-9 drives 
processing of effector caspase-3 and -7, resulting in apoptosis induction [Barnhart et al, 
2003]. In this scenario, X-linked inhibitor of apoptosis protein (XIAP), one of the 
members of the inhibitor of apoptosis proteins (IAPs) family, can tightly bind active 
caspase-3, -7 [Barnhart et al, 2003, Chai et al, 2001] and -9 [Srinivasula et al, 2001], 
thus blocking the final steps of the apoptosis process. Nevertheless, mithocondria 
permeabilisation allows the Second Mitochondria-derived Activator of Caspases/Direct 
IAP Binding protein with LOw isoelectric point (SMAC/DIABLO) to translocate to the 
cytoplasm and neutralise XIAP, thus preventing caspase inhibition [Verhagen et al, 
2000]. Moreover, mithocondria release additional pro-apoptotic factors belonging to 
BH3-only proteins such as Bcl-2-like protein 11 (Bim), p53 upregulated modulator of 
apoptosis (PUMA) and Noxa (damage in latin) [Zhang et al, 2013], which can enhance 
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apoptotic process unless antagonised, by the anti-apoptotic proteins such as B-cell 
lymphoma 2 (Bcl-2), B-cell lymphoma-extra large (Bcl-xL), Myeloid leukemia cell 
differentiation protein (Mcl-1), which will be described in details in Paragraph 1.2.7. 
A schematic overview of the apoptosis pathways is shown in Figure 1. 
 
 
 
Figure 1Overview of cell death pathways [Fulda and Vucic, 2012]. 
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1.2 The TNF/TNF-R superfamily 
 
One of the key molecules in tumour immunology and pro-inflammatory signalling is TNF. 
In 1975, Carswell et al. made the interesting finding that tumour-bearing mice produce a 
bacterially-induced substance, later named TNF due to its capability to induce necrotic 
death of tumours [Carswell et al, 1975]. The discovery of Lymphotoxin (LT), which 
shares high homology with TNF and even binds the same receptor at high 
concentrations, has given the first hints of the existence of a family comprising related 
proteins such as TNF, LT and possibly others. These studies allowed the discovery of a 
whole range of cellular factors involved in the regulation of the immune system, which 
are homologous to TNF and therefore classified in the TNF-superfamily (TNF-SF) of 
cytokines. Interestingly, the TNF-SF members bind to the cognate receptors, referred to 
as the TNF-receptor superfamily (TNF-R-SF), which comprises more members than the 
TNF-SF, suggesting that some ligands can bind to several receptors. The TNF-R-SF 
members are characterized by the repetition of up to six cysteine rich domains (CRD) in 
the extracellular portion of the type I transmembrane proteins. Moreover, six TNF-R-SF 
members contain intracellular domains which have been described to be required for cell 
death-induction and are therefore called death domains (DDs) of which the most 
intensively studied are TNF-receptor 1 (TNF-R1), CD95 and Tumour necrosis factor-
related apoptosis-inducing ligand-receptor 1/2 (TRAIL-R1/2). Although TNF-R1 contains 
a DD, it primarily induces gene induction via the mitogen activated protein kinase 
(MAPK) pathway and activation of the transcription factor Nuclear factor KappaB (NF-
κB) [Wajant et al, 2003]. It is interesting to note that local high-doses of TNF can destroy 
tumour blood vessels but at the same time induce angiogenic factors [Kollias et al, 1999, 
Lejeune et al, 1998]. Contrarily, continuous presence of low-doses of TNF and 
consequential NF-κB activation have been shown to be tumour-promoting in mouse 
models of skin, liver, colorectal and pancreatic cancer [Egberts et al, 2008, Pikarsky et 
al, 2004, Popivanova et al, 2008, Scott et al, 2003]. 
CD95 (APO-1/Fas) is another member of the TNF-R-SF which was initially thought to 
primarily induce apoptosis and recently discovered to trigger also necroptosis. In 1995, 
Kischkel et al. immuno-precipitatied the protein complex DISC which forms at the DD of 
CD95 upon CD95L stimulation of intact cells [Kischkel et al, 1995]. This complex 
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comprises FADD [Boldin et al, 1995, Chinnaiyan et al, 1995] and caspase-8 [Boldin et al, 
1996, Muzio et al, 1996].  
Another member of the TNF-SF, named TNF-related apoptosis inducing Ligand (TRAIL) 
was later demonstrated to induce apoptosis in a way similar to CD95L [Pitti et al, 1996, 
Wiley et al, 1995]. Due to its high sequence homology to CD95L, a similar mechanism of 
DISC forming at the DD of the receptor was suggested. TRAIL-induced apoptotic and 
non-apoptotic signalling will be discussed in the following chapters more in detail.  
Since TRAIL and CD95L are potent apoptosis-inducing agents, they sparked a lot of 
interest regarding the development of cancer therapeutics. However, apoptosis induction 
by CD95L turned out to be clinically inapplicable since systemic administration of an 
agonistic monoclonal antibody against CD95 is highly toxic and leads to severe liver 
damage in mice [Ogasawara et al, 1993]. CD95 is highly expressed on hepatocytes, 
likely explaining the hepatotoxicity [Tanaka et al, 1997]. A hexameric version of CD95L 
has been shown to be less hepatotoxic and is therefore currently in phase-I clinical trials 
(www.clinicaltrials.gov.). On the contrary, TRAIL potently induces apoptosis in tumour 
cells but not in normal cells [Walczak et al, 1999]. Ongoing clinical trials employing 
recombinant TRAIL or agonistic antibodies specific for TRAIL-R1 or TRAIL-R2 have not 
reported any gross toxicity so far [Newsom-Davis et al, 2009]. These findings placed 
TRAIL in the centre of attention within the TNF-SF concerning bio-therapeutic agents for 
cancer therapy [Johnstone et al, 2008, Wajant et al, 2002]. 
 
 
1.2.1 TNF/TNF-Rs signalling: between gene activation and cell 
death 
 
TNF can trigger two apparently divergent cellular responses through the interaction with 
its cognate membrane receptors: gene activation and cell death [Wajant et al, 2003]. 
One of the most surprising observations about this cytokine is that it can kill only very 
few cells [Walczak, 2011]. In general, it contributes to stimulation of immunity [Aggarwal, 
2003, Hayden and Ghosh, 2008, Wajant et al, 2003], and can also sustain cancer and 
play a role in tumour immune evasion [Verhoef et al, 2007]. 
Upon TNF binding, the cytosolic portion of TNF-R1-trimers recruits the receptor 
interacting protein 1 (RIP1) and TNFR1-associated death domain (TRADD) [Emmerich 
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et al, 2011a, Walczak et al, 2011]. TRADD then serves as an adapter protein for TNFR-
associated factor 2 (TRAF2), which in turn associates with cellular IAP 1 (cIAP1) and 
cIAP2. Once this core complex is assembled, several ubiquitination events promote full 
assembly and functionality of the TNF-receptor signalling complex (TNF-RSC). The E3-
ligase activity of cIAP1/2 forms ubiquitin chains that provide the binding sites for the 
recruitment of Linear Ubiquitin Chain Assembly Complex (LUBAC) to the TNF-RSC 
[Emmerich et al, 2011a, Haas et al, 2009]. LUBAC is a heterotrimer composed of HOIL-
1, HOIP and SHARPIN [Gerlach et al, 2011, Ikeda et al, 2011] as shown in Figure 2. 
 
                                          
 
Figure 2Schematic representation of the interactions between the three LUBAC 
components and with ubiquitin [Walczak, 2011]. 
 
As illustrated in Figure 3, LUBAC attaches Met1-linked (also known as linear) Di-
Ubiquitin chains to NF-kB essential modulator (NEMO) and RIP1, thus strengthening the 
TNF-RSC [Gerlach et al, 2011, Schmukle and Walczak, 2012]. Ubiquitination by cIAPs 
and LUBAC enables recruitment of the Inhibitor of kB (IkB) kinase (IKK) and TNF-
associated kinase (TAK)/TAB complexes, leading to the activation of canonical NF-kB 
and MAPKs, respectively [Emmerich et al, 2011a]. LUBAC activity is not essential for 
TNF-induced activation of NF-kB; nevertheless, by retaining RIP1, TRAF2, cIAP1/2 and 
TAK1 in the complex, it extends the half-life of the TNF-RSC. Hence, LUBAC is 
important for regulating the strength of the signal transduction and gene expression, and 
for preventing TNF-induced apoptosis [Emmerich et al, 2011b]. Interestingly, it has been 
recently published that LUBAC and its linear-ubiquitin-forming activity are required for 
maintaining vascular integrity during embryogenesis by preventing TNF-R1-mediated 
endothelial cell death [Peltzer et al, 2014]. This further highlights the importance of 
LUBAC-mediated gene induction. 
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Figure 3Model of TNF-RSC proposed by Walczak [Walczak, 2011]. 
 
 
1.2.2 Regulation of LUBAC at the TNF-RSC 
 
Unlike other death ligands, TNF does not kill cells in most circumstances and instead 
stimulates NF-κB and MAPKs, leading to cell survival and stimulation of inflammation. 
Interestingly, gene expression induced by LUBAC can be ‘switched-off’ by either 
preventing the recruitment of LUBAC to the TNF-R complex or impeding LUBAC-
mediated ubiquitination and consequently activation/stabilisation of its targets. Firstly, 
treatment with IAP targeting compounds named Smac-Mimetics (SMs) known to induce 
rapid auto-ubiquitination and proteosomal degradation of cIAPs [Vince et al, 2007], can 
block gene induction [Gerlach et al, 2011]. Secondly, linear ubiquitin activity associated 
to LUBAC can be modulated by deubiquitinases (DUBs). In particular, it has recently 
been discovered a previously unnoticed human DUB called OTULIN, belonging to the 
ovarian tumour (OTU) DUB family, which hydrolises linear ubiquitin chains of LUBAC 
[Keusekotten et al, 2013]. Furthermore, Gumby was identified as another member of the 
OUT linear DUB family, which interacts with HOIP, thus regulating LUBAC-mediated 
   
12 
 
Wnt signaling [Rivkin et al, 2013]. An additional DUB, named cylindromatosis (CYLD) 
can cleave linear polyubiquitin chains on HOIP and, together with OTULIN, 
synergistically suppresses LUBAC-mediated linear polyubiquitination and TNF-induced 
NF-kB activation [Takiuchi et al, 2014]. Additionally, A20 is a potent inhibitor of NF-kB 
whose mechanism of action is still unknown. Intriguingly, A20 is characterised by two 
ubiquitin-editing domains that cooperate in their activity: the N-terminal domain, which is 
a de-ubiquitinating (DUB) enzyme of the OTU family, removes ubiquitin chains from 
RIP1, while the C-terminal domain functions as a ubiquitin ligase by polyubiquitinating 
RIP1, thereby targeting RIP1 for proteasomal degradation [Wertz et al, 2004]. TNF-RSC 
is then destabilised and, as a consequence, NF-kB signaling is downregulated. Although 
the regulation of the linear ubiquitin chain generation by LUBAC is not well characterised 
yet, these findings highlight that OTULIN, Gumby, CYLD and A20 can be so far 
considered as NF-kB switch-off players, thus representing another way to balance 
signalling pathways downstream of the TNF-R. 
A summary of the outcome generated by the presence or the absence of LUBAC at the 
TNF-RSC is shown in Figure 4. 
 
                           
 
Figure 4Model of TNF-R1 signaling with and without LUBAC [Walczak et al, 2012]. 
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1.2.3 TNF-induced necroptosis 
 
Beside influencing TNF-induced gene activation, in the absence of cIAPs, TNF 
stimulates the formation of a secondary cytoplasmic complex, named Complex II which 
contains RIP1, FADD and Caspase-8 [Micheau and Tschopp, 2003, Petersen et al, 
2007]. In most cases, activated Complex II leads to apoptosis, however, in some cells, 
exposure to caspase inhibitors or intracellular factors like cellular FLICE-like inhibitory 
protein (cFLIP) which prevents caspase-8 activation switches the apoptotic response to 
necrosis [He et al, 2009]. It is currently in use the term necroptosis as a cell death 
mechanism that complements the conventional cell death pathway, apoptosis, in 
multicellular organisms. Receptor interacting Protein 3 (RIP3) is the key effector of 
necroptosis and exerts its role phosphorylating and consequently activating RIP1, and 
the pseudokinase Mixed Lineage Kinase Domain-Like (MLKL) [Sun et al, 2012]. Yet, the 
molecular events following RIP3-mediated phosphorylation of MLKL required to induce 
cell death still need to be elucidated [Hildebrand et al, 2014]. 
 
 
1.2.4 TRAIL/TRAIL-R system 
 
When human TRAIL was identified as a CD95L homologous molecule its transcript was 
found to share 65% sequence identity with murine TRAIL and to be expressed in many 
tissues with the highest expression in spleen, thymus, prostate and lung [Wiley et al, 
1995]. Among all death-inducing ligands of the TNF-SF, the TRAIL/TRAIL-R system 
seems to be the most complex with five different receptors for TRAIL being reported 
[Newsom-Davis et al, 2009]. Nevertheless, only two of them are able to transmit an 
apoptotic signal, namely TRAIL-R1 (DR4) and TRAIL-R2 (DR5) [Walczak et al, 1997]. 
Two additional receptors, which are incapable of transmitting an apoptotic signal, TRAIL-
R3 and TRAIL-R4 [Degli-Esposti et al, 1997], were subsequently cloned and 
characterised. Whilst TRAIL-R3 lacks a DD, TRAIL-R4 only comprises a truncated DD 
and can induce activation of NF-kB upon overexpression [Degli-Esposti et al, 1997]. 
Both receptors have been suggested to act as “decoy” receptors not only by sequestring 
TRAIL molecules and thereby decreasing the probability of this ligand to bind TRAIL-R1 
and TRAIL-R2 [Riccioni et al, 2005], but also by negatively influencing TRAIL-DISC 
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formation [Merino et al, 2006]. However, these observations were made only in 
overexpression systems. A decoy function of these receptors still needs to be confirmed 
in physiological settings. Lastly, TRAIL also binds a soluble receptor called 
osteoprotegerin (OPG) which is involved in regulation of bone formation and normally 
functions as a decoy receptor for Receptor Activator of Nuclear factor Kappa B Ligand 
(RANKL). RANKL is the natural ligand for Receptor Activator of Nuclear factor Kappa B 
(RANK), which, upon ligand-induced interaction on osteoclasts, activates NF-kB 
resulting in osteoclast-mediated bone resorption [Wilson, 2011]. Consequently, TRAIL 
binding to OPG prevents RANKL binding to OPG thereby promoting RANKL binding to 
RANK which leads to an increase in bone resorption [Vitovski et al, 2007]. Moreover, a 
role of OPG in cancer cell survival, by functioning as a TRAIL decoy receptor, has also 
been proposed [Holen et al, 2002]. 
 
 
1.2.5 TRAIL-induced apoptosis 
 
Upon binding of TRAIL to its respective DD-containing receptors, receptor trimerisation 
and subsequent recruitment of FADD, caspase-8 and -10 as well as cFLIP are triggered 
[Sprick et al, 2000]. DISC formation leads pro-caspases-8 and -10 to cluster around 
adaptor proteins at the intracellular portion of the death receptor. The clustering and not 
the cleavage of the pro-domains of pro-caspases leads to their activation [Salvesen and 
Riedl, 2008]. Furthermore, the ubiquitin ligase Cullin 3 (CUL3) was shown to associate 
with caspase-8 upon TRAIL stimulation and to mediate poly-ubiquitination of caspase-8, 
which is required for caspase-8 aggregation and activation [Jin et al, 2009]. Following 
their activation, initiator caspases are cleaved in an autocatalytic process, generating 
large and small subunits. These large and small subunits form active hetero-tetramers, 
which activate the downstream effector caspases-3 and -7 [Stennicke et al, 1998]. 
Cleavage of their substrates leads to the key morphological changes observed during 
apoptosis. 
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1.2.6 TRAIL-induced necroptosis 
 
Although necroptosis was originally discovered as a TNF-mediated cell death, soon 
thereafter it was found that cell death triggered by CD95L and TRAIL can, under certain 
circumstances, also be necroptotic [Vandenabeele et al, 2010]. It was further shown that 
Necrostatin-1 (Nec-1), an inhibitor of RIP1 kinase activity, can block this kind of cell 
death [Degterev et al, 2005]. The molecular mechanisms of necroptosis at least as far as 
we understand to date, have been reviewed [Vandenabeele et al, 2010].  
 
 
1.2.7 Mechanisms of resistance to TRAIL-induced cell death 
 
In order to escape TRAIL-induced cell death, tumour cells engage anti-apoptotic 
mechanisms at DISC- and mitochondria- levels.  
The protein cFLIP is responsible for preventing DISC activation and is characterised by 
three splice variants: cFLIP-long (cFLIPL), cFLIP-short (cFLIPS) and cFLIP-Raji (cFLIPR). 
The first isoform, if expressed at low levels, favours pro-caspase-8 recruitment to the 
DISC [Micheau and Tschopp, 2003], otherwise, as well as cFLIPS and cFlipR, it exerts its 
anti-apoptotic activity competing with caspase-8 and -10 for binding to FADD, thereby 
obstructing the DISC-mediated induction of apoptosis [Krueger et al, 2001]. These 
isoforms can also interfere with the necroptosis pathway: whereas cFLIPS, preventing 
caspase-8 recruitment to the DISC, enhances caspase-8 enrollment to RIP1/3 complex, 
thus leading to necroptosis induction, cFLIPL sequesters caspase-8 and, as a result, 
impedes the activation of RIP1/3-mediated necroptosis [Feoktistova et al, 2011, Oberst 
et al, 2011, Tenev et al, 2011]. Mechanisms of resistance to mitochondria-mediated 
apoptosis assume high importance in type II cells that usually necessitate of this 
organelle to undergo apoptosis. MOMP is governed by the interaction of the so-called 
Bcl-2 family members: Bax and Bak, together with the BH3-only proteins such as Bid, 
Bim, PUMA and Noxa act as pro-apoptotic factors and Bcl-2, Bcl-xL and Mcl-1 as pro-
survival factors [Shamas-Din et al, 2013]. All together these molecules orchestrate the 
response to apoptotic stimuli, hence the resulting balance tightly regulates the cell fate 
between survival and death. Accordingly, cancer cells aberrantly express the Bcl-2 
family members via down-regulating and up-regulating respectively pro- and anti- 
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apoptotic effectors. This cancer cell strategy to escape apoptosis partially explains why 
type II tumour cells are resistant to conventional chemotherapy and/or radiotherapy. 
Concerning TRAIL-based therapy, several groups demonstrated that both 
overexpression of Bcl-2, Bcl-XL or Mcl-1 and lack of Bax and Bak can be responsible for 
TRAIL-resistance in many cancer cell types as reviewed by Lemke et al. [Lemke et al, 
2014b]. Another family of proteins, which play a role in resistance to TRAIL-induced cell 
death is represented by IAPs. A detailed description in terms of their structure, functions 
and relevance in cancer therapy is intensively expanded in Paragraph 1.3 and 1.4. 
 
 
1.2.8 Roles of TRAIL/TRAIL-Rs in promoting tumour growth and 
metastasis 
 
Recombinant TRAIL can selectively kill tumour cells in vivo [Ashkenazi et al, 1999, 
Walczak et al, 1999]. These findings have initiated the development of TRAIL and other 
TRAIL-R agonists for clinical applications as novel promising anti-cancer drugs.  
More recent studies have, however, revealed that many tumour cell lines and, 
importantly, the majority of primary tumours, are resistant to TRAIL-induced apoptosis 
[Todaro et al, 2008]. This can in part explain the limited therapeutic benefit of TRAIL-R 
agonists in clinical trials [Micheau et al, 2013]. Moreover, recent preclinical findings 
indicate pro-survival, proliferation and even metastatic activity of TRAIL, suggesting 
more caution when applying TRAIL-R agonists, particularly as single agents [Azijli et al, 
2012]. In fact, TRAIL- and TRAIL-R agonists-based combination therapies are required 
in order to additionally block non-apoptotic TRAIL signalling pathways. 
More in detail, as shown in Figure 5, TRAIL can induce survival and proliferation by 
activation of Src [Azijli et al, 2012] and of MAPK family members such as c-Jun N-
terminal kinases (JNK), p38 MAPK [Varfolomeev et al, 2005] and Extracellular signal-
Regulated Kinase 1 and 2 (ERK1/2) [Belyanskaya et al, 2008]. Moreover, proliferation, 
together with migration of primary human vascular endothelial cells can be positively 
regulated by TRAIL stimuli of the Phosphoinositide 3-kinase (PI3K)/AKT axis [Secchiero 
et al, 2003, Secchiero et al, 2004]. Another effector, which plays a role in TRAIL-
mediated non-cell death signaling is NF-kB [Harper and Adams, 2001, Varfolomeev et 
al, 2005, Wajant, 2004].  
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Figure 5 Schematic representation of the identified kinases involved in non-
canonical TRAIL signaling [Azijli et al, 2012]. 
 
In line with these findings, it has been shown that TRAIL-mediated proliferation is 
completely abrogated by blockage of NF-kB activation in a model of TRAIL-resistant 
cancer cells [Ehrhardt et al, 2003]. Current studies reveal that the effectors downstream 
TRAIL signalling responsible for survival and proliferation are also involved in promoting 
migration, invasion and metastasis, thus favouring tumour aggressiveness [Azijli et al, 
2012]. In fact, TRAIL-R2-mediated signaling is also shown to promote lymph node and 
lung metastasis in an orthotopic model of triple negative breast cancer, thereby 
suggesting the employment of monoclonal antibody targeting TRAIL-R2 as effective 
therapeutic strategy for metastatic breast cancer [Malin et al, 2011]. On the contrary, it 
has been published that TRAIL-R inhibits lymph node metastases without affecting 
primary tumour formation in a mouse model of multistage skin tumorigenesis [Grosse-
Wilde et al, 2008]. In this paper, they also demonstrated that adherent TRAIL-R-
expressing skin carcinoma cells were TRAIL-resistant in vitro but were sensitive to 
TRAIL upon detachment by inactivation of the ERK signaling pathway [Grosse-Wilde 
and Kemp, 2008]. Since detachment from primary tumour is an obligatory step in 
metastasis, this could be a mechanism by which TRAIL-R exerts its metastasis 
suppressor role. However, other groups demonstrate the opposite concept, which 
18 
 
supports the idea of TRAIL/TRAIL-R as a tumour-promoter system [Bertsch et al, 2014, 
Haselmann et al, 2014]. 
Furthermore, it has been reported that treatment with TRAIL was capable of promoting 
liver metastasis of Bcl-XL-overexpressing, TRAIL-apoptosis-resistant human orthotopic 
Pancreatic Ductal AdenoCarcinoma (PDAC) xenografts [Trauzold et al, 2006]. Likewise, 
it was previously demonstrated that KRAS-mutated colorectal cancer cell lines are more 
resistant to TRAIL-induced apoptosis than their isogenic KRAS-wild-type (WT) 
counterparts and, instead, exhibit increased migration when exposed to recombinant 
TRAIL [Hoogwater et al, 2010]. Further studies to support the potential negative 
implication for TRAIL in cancer therapy confirm that TRAIL promotes cell migration and 
invasion by a NF-kB-dependent pathway in human Cholangiocarcinoma (CCA) cells 
[Ishimura et al, 2006]. Interestingly, even Thyroid hormone Receptors (TRs) have been 
shown to induce TRAIL expression, and TRAIL thus synthesised acts in concert with 
simultaneously synthesised Bcl-XL to promote metastasis, but not apoptosis in TR-
overexpressing hepatoma cell lines [Chi et al, 2012]. 
In summary, these findings highlight that treating certain TRAIL-resistant cancers with 
TRAIL/TRAIL-R agonists might even worse disease prognosis [Lemke et al, 2014b]. It is 
therefore imperative to investigate in depth the molecular mechanisms based on TRAIL-
mediated non-cell death pathway in order to pre-empt it.  
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1.3 Inhibitor of apoptosis proteins (IAPs) family. 
 
IAP family is formed by eight members: Survivin, cIAP1, cIAP2, XIAP, NAIP, Livin, 
Apollon and ILP-2 (Figure 6). The defining feature of IAPs is the presence of one or 
more baculoviral IAP repeat (BIR) domains, which mediate protein-protein interactions 
with other IAPs or with caspases, hindering their activity.  
 
 
  
Figure 6Structural organization of the human IAP family members [Fulda and 
Vucic, 2012]. 
 
XIAP is shown to be a potent inhibitor of caspase -3, -7 [Chai et al, 2001, Riedl et al, 
2001] and -9 [Srinivasula et al, 2001]. Other IAPs, as cIAP1 and cIAP2, interact with 
caspases, but the biological significance of this event is less understood [Eckelman and 
Salvesen, 2006]. 
XIAP, cIAP1 and cIAP2 are also characterised by a C-terminal Really Interesting New 
Gene (RING) domain endowed with E3-ubiquitin ligase activity. The dimerisation of the 
RING domain of cIAP1 and cIAP2 activates these proteins [Darding et al, 2011, Feltham 
et al, 2011], allowing the regulation of several signalling cascades involved not only in 
cell death but also in inflammation, cell proliferation and migration [Damgaard and Gyrd-
Hansen, 2011, Gyrd-Hansen and Meier, 2010, Lopez et al, 2011]. Intriguingly, cIAP1 has 
been shown to be essential for maintaining endothelial cell survival and blood vessel 
homeostasis during vascular development, thereby providing an additional target 
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pathway for the control of angiogenesis [Santoro et al, 2007]. The proteins cIAP1 and 
cIAP2 also contain an UB-associated (UBA) domain for binding to poly-Ubiquitin chains 
and a caspase recruitment domain (CARD). The role of CARD is not well understood 
yet, but, together with the BIR3 domain, it is known to inhibit the E3-ligase activity of 
cIAP1, preventing RING dimerization as shown in Figure 7 [Lopez et al, 2011]. 
 
 
 
Figure 7 Model of RING dimerization [Lopez et al, 2011, Lopez et al, 2011] 
 
IAPs are frequently overexpressed in cancer and contribute to chemoresistance, disease 
progression and poor prognosis [Gyrd-Hansen and Meier, 2010]. In addition, the 
comprehension that IAPs help tumour cells to bypass the apoptotic programme 
suggested that IAPs are promising targets for therapeutic intervention and lead to the 
development of small pharmacological IAP-targeting compounds named Smac-Mimetics 
(SMs) to be employed in clinical oncology. 
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1.4 Design of Smac-Mimetics as IAPs-targeting 
compounds 
 
SMs were originally designed to target XIAP, preventing its inhibition on caspases by 
favouring their displacement from the BIR domains of XIAP. In fact, SM compounds, 
mimicking the N-terminal IAP-binding motif (AVPI tetrapeptide: Alanine-Valine-Proline-
Isoleucine) of mature Smac/Diablo [Oost et al, 2004, Seneci et al, 2009, Sun et al, 
2004], selectively bind the BIR2 and BIR3 domains of XIAP [Mastrangelo et al, 2008]. 
The monomeric SMs are smaller, more stable and pass easier through the cellular 
barriers [Bianchi 2012], while the dimeric SMs [Cossu et al, 2012, Lecis et al, 2012, 
Manzoni et al, 2012], composed by two AVPI-mimicking molecules, are less favourable 
as drugs due to their heavy mass. Nonetheless, because of their ability to target 
simultaneously two BIR domains of the same protein [Cossu et al, 2009], dimeric SMs 
are usually more active in inducing cell death [Sun et al, 2008]. Furthermore, SMs target 
cIAP1 and cIAP2 [Cossu et al, 2010] and trigger their self-ubiquitilation and proteosomal 
degradation [Petersen et al, 2007, Varfolomeev et al, 2007, Vince et al, 2007]. However, 
the absence of cIAP1- and cIAP2- E3 ligase activity does not allow auto-ubiquitilation in 
response to SM treatment [Darding et al, 2011]. Besides controlling caspases, cIAPs 
display other activities: cIAP1 and cIAP2 regulate NF-kB by ubiquitylation and 
proteosomal degradation of NF-kB-induced kinase (NIK) thus leading to the suppression 
of the non-canonical NF-kB signalling [Darding et al, 2011, Haas et al, 2009]. As shown 
in Figure 8A, by causing the degradation of cIAPs, SMs stimulate the non-canonical NF-
kB signalling thereby inducing the production of high amount of TNF, an NF-kB target, 
which overstimulates TNF-R1; RIP1 is then released from TNF-R1 and subsequently 
incorporated into a complex with caspase-8 and FADD thus promoting cell death 
[Varfolomeev et al, 2007]. This response can be engaged only by cells sensitive to SM 
as single agent [Petersen et al, 2007]. 
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Figure 8SM-induced cell death by non-canonical NF-kB-mediated transcription of 
TNF [Darding and Meier, 2012]. 
 
Unluckily, few cancer cells can be treated by SMs as single agents [Gatti et al, 2014, 
Scavullo et al, 2013]. On the contrary, despite TNF-R1 expression is quite ubiquitous 
among several cancer cell types [Wajant et al, 2003], most cancer cells tested to date 
are not responsive to SMs [Petersen et al, 2010]. It has been suggested that these cell 
lines can upregulate cIAP2 by TNF-dependent stimulation of the NF-kB pathway. 
Importantly, the newly generated cIAP2 is no longer subjected to SM-induced 
degradation because this event is dependent on the presence of cIAP1 that rapidly 
undergoes degradation after SM administration and is not expressed back as quickly as 
cIAP2 [Petersen et al, 2007]. Due to the similarity of the two proteins, cIAP2 might 
assume the role of cIAP1 in preventing further release of RIP1 from the TNFR1 [Darding 
and Meier, 2012, Petersen et al, 2010]. A further possible explanation of SM-resistant 
mechanisms has been recently suggested by Wang’s group: breast cancer cells 
resistant to SM-164 downregulate Leucine-Rich repeats and immunoglobulin-like 
domain 1 (LRIG1), thus increasing the expression of receptor tyrosine kinases (RTKs) 
and attenuating SM-induced TNF gene expression [Bai et al, 2012]. Nevertheless, SM 
activity can also be independent of TNF by inducing the formation of a large complex (~2 
MDa) called ‘ripoptosome’, composed by RIP1, FADD and Caspase-8. Its assembly 
requires RIP1 kinase activity and can stimulate caspase-8-mediated apoptosis as well 
as caspase-independent necrosis [Tenev et al, 2011]. The ripoptosome forms 
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independently of TNF, CD95L, TRAIL, death receptors and mitochondrial pathways and 
is regulated by cIAP1, cIAP2 and XIAP [Feoktistova et al, 2011, Tenev et al, 2011]. 
 
 
1.4.1 Smac-Mimetics as potential sensitisers in the treatment of 
cancer 
 
Most cancer cells are resistant to SMs as monotherapy [Petersen et al, 2010]. 
Therefore, since SMs deplete cIAPs and inhibit XIAP, they can be employed as potential 
sensitisers towards death-inducing ligands such as TNF, TRAIL and CD95L. Indeed, it 
has been reported that SMs can particularly enhance cell death triggered by TNF 
[Gaither et al, 2007] and TRAIL [Li et al, 2004]. Focusing on the synergism between SMs 
and TRAIL, SM-mediated depletion of cIAP1 can favour TRAIL-induced apoptosis, 
because cIAP1 is a determinant of TRAIL resistance, as recently demonstrated by 
Guicciardi and co-workers [Guicciardi et al, 2011]. Notably, SMs have shown broad 
preclinical activity in sensitising cancer cells especially to TRAIL-induced apoptosis in 
vitro and in vivo in a variety of cancer types [Fakler et al, 2009, Fulda et al, 2002, Lecis 
et al, 2010, Raulf et al, 2014]. In line with this, a clinical trial in ovarian cancer patients 
has been started to test the efficacy of SM Birinapant in combination with the TRAIL-R2 
agonist Conatumumab and also the preclinical results support the employability of this 
kind of combination in clinic [Lemke et al, 2014b]. Despite the great interest towards the 
development of SMs and the presence of many groups that are studying their 
mechanism of activity, there are still some aspects that need to be clarified. Why some 
cancer cells respond to SMs as monotherapy and others require the addition of TRAIL to 
be killed is a key issue facing cancer therapy. 
There is a huge spectrum of possible SM-based combinations employed in the treatment 
of several tumour types. For instance, SM (i) can synergise with Cytarabine, Etoposide 
and with TRAIL in human leukemic cell lines [Servida et al, 2011], (ii) can stimulate 
melanoma cell death in combination with TRAIL in the presence of the proteasome 
inhibitor Bortezomib [Lecis et al, 2010], (iii) can enhance the anti-proliferative effects of 
ErbB antagonists such as Trastuzumab, Lapatinib and Gefitinib in breast cancer [Foster 
et al, 2009] and (iv) can sensitise prostate cancer cells to TRAIL-induced apoptosis via 
modulation of both IAPs and NF-kB. Wang’s group developed the bivalent SM-164 [Lu et 
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al, 2008] which has been shown to be active with recombinant TRAIL in a panel of 19 
human breast, prostate and colon cancer cell lines in vitro and in a breast cancer 
xenograft model in vivo [Lu et al, 2011]. SM JP1201 from Minna’s lab is able to act in an 
IAP-dependent but TNF-independent manner to sensitise non-small cell lung cancer 
NSCLC to multiple chemotherapeutic agents such as Doxorubicin, Erlotinib, 
Gemcitabine, Paclitaxel, Vinorelbine and Carboplatin [Greer et al, 2011]. Likewise, it has 
recently been shown that SM BV6 can sensitise glucocorticoid-triggered cell death by 
promoting ripoptosome formation in Acute Lymphoblastic Leukemia (ALL) [Belz et al, 
2014]. Furthermore, Probst et al found that the combination effects resulting from SM 
and various chemotherapeutics (Gemcitabine, Cisplatin, SN38, Paclitaxel, 5-Fluorouracil 
and Etoposide) is caused by a multifacing mechanism involving either inhibition of cell 
proliferation by the chemotherapy agents and an enhanced autocrine TNF feedback loop 
by the SM/chemotherapy agent combination [Probst et al, 2010]. Interestingly, SMs also 
synergise with a diabody format of tumour-targeted TRAIL termed DbαEGFR-scTRAIL 
from Pfizenmeier’s lab, comprising single-stranded TRAIL (scTRAIL) molecules and the 
variable domains of a humanised variant of the EGFR blocking antibody Cetuximab 
[Moller et al, 2014]. 
 
 
1.4.2 Role of Smac-Mimetics in cancer-related inflammation and 
immune response 
 
Tissue stress and malfunction, key characteristics of human tumours, can induce an 
inflammatory response that is similar to the one elicited by invading microbes, in 
particular necrotic death of tumours stimulates macrophage recruitment and triggers 
tissue repair and modelling, which in turn fuels tumour growth [Gyrd-Hansen and Meier, 
2010]. Since cIAPs are involved in inflammation, SMs can modulate immune response in 
the treatment of cancer. It has been published that oncolytic viruses as well as microbial 
RNA and DNA (Poly (I:C) and CpG, respectively) induce bystander death of cancer cells 
treated with SM compounds, death that is mediated by interferon beta (IFNβ), TNF 
and/or TRAIL. This combinatorial treatment results in tumour regression and extended 
survival [Beug et al, 2014]. Furthermore, IAPs have lately emerged as important 
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regulators of innate immune signalling downstream of Pattern Recognition Receptors 
(PRRs), such as Toll-like-receptor 4 (TLR-4), the Nucleotide-binding Oligomerisation 
Domain 1 (NOD1)- and NOD2- receptors and the Retinoic acid-Inducible Gene-I-
Receptor (RIG-I-R), thus activating NF-kB, p38 and JNK [Bertrand et al, 2009, 
Damgaard and Gyrd-Hansen, 2011]. 
Taken together these findings support the idea that, even though SMs were originally 
designed to enhance cancer cell death and since their targets (IAPs) are components of 
receptor complexes involved in immunity, SMs can play novel roles in modulating 
immune system-related responses within cancer treatment. 
 
 
1.4.3 SM83-mediated host-induced inflammatory response 
eradicates xenograft cancer ascites 
 
We newly described the synthesis of novel dimeric molecules that target XIAP, cIAP1 
and cIAP2. One of these molecules, SM83, inhibited the growth of SM-sensitive human 
mammary adenocarcinoma MDA-MB-231 and Rhabdomyosarcoma Kym-1, but not of 
other cell lines [Cossu et al, 2012, Lecis et al, 2012, Manzoni et al, 2012] 
We recently published [Lecis et al, 2013] that SM83, when administered in monotherapy, 
by targeting tumour-associated macrophages, increases the survival of two murine 
xenograft models of cancer ascites: athymic nude mice injected intraperitoneally with 
IGROV-1 human ovarian carcinoma cells and immunocompetent BALB/c mice injected 
with murine Meth A sarcoma cells. SM83 rapidly killed ascitic IGROV-1 and Meth A cells 
in vivo, nevertheless was ineffective against the same cells in vitro. IGROV-1 cells in 
nude mice were killed within the ascites by a non-apoptotic, TNF-dependent mechanism. 
SM83 administration triggered a rapid inflammatory event characterised by host 
secretion of TNF, interleukin-1beta (IL-1β) and interferon-γ (IFN-γ). This inflammatory 
response was associated with the reversion of the phenotype of tumour-associated 
macrophages from a pro-tumoural M2- to a pro-inflammatory M1-like state. SM83 
treatment was also associated with a massive recruitment of neutrophils that, however, 
was not essential for the antitumoural activity of this compound. 
Therefore, our work shows that SM83 displays different mechanisms of action in vitro 
and in vivo, and that in vivo it exerts its antitumoural activity by stimulating the immune 
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system. In conclusion, our data demonstrate that the SM SM83 is active in monotherapy 
by promoting inflammation and immunogenic cell death. These observations likely 
provide an explanation for why SMs increase the effectiveness of standard therapies, 
namely by stimulating the immune system. Finally, the evidence that SMs can induce an 
inflammatory response and activate the immune system provides an interpretation of 
why SMs can be more effective in vivo than in vitro. 
 
 
1.4.4 Smac-Mimetics as regulators of migration, invasion and 
metastases 
 
Since IAPs have been related to the control of cell motility, migration, invasion and 
metastasis, it is relevant for cancer therapy to understand whether SM-mediated 
targeting of IAPs can affect the steps of the metastatic process, even because this issue 
is still controversial. Different works proposed that IAPs both positively and negatively 
control these processes [Fulda, 2013, Fulda, 2014]. Whereas Fulda’s group sustains 
that SM BV6 at non-toxic concentrations promotes the migration and invasion of 
Glioblastoma cells (GBCs) via non-canonical NF-kB signaling [Tchoghandjian et al, 
2013], Tomonaga demonstrates that LUBAC-mediated activation of NF-kB contributes to 
lung metastasis in osteosarcoma cells, thereby suggesting that treatment with IAP 
antagonists would prevent this event [Tomonaga et al, 2012]. Furthermore, it has been 
reported that SMs, beside acting on TNF-R pathway, can switch-off TRAIL-mediated NF-
kB-induced upregulation of Matrixmetalloprotease 9 (MMP9), thus blocking one of the 
first stages of metastatisation in CCA cells [Fingas et al, 2010]. Apart from influencing 
NF-kB pathway in regulating migration and invasion, it has been published that cIAP1 
and XIAP can directly bind to Rac-1 to promote its poly-Ubiquitilation and proteosomal 
degradation. Hence, SM treatment leads to an increase of Rac-1 protein levels in 
primary and tumour cells, thus guiding to an elongated morphology and enhanced cell 
migration [Oberoi et al, 2012]. Conversely, a Survivin/XIAP complex has been shown to 
activate NF-kB, which, in turn, leads to an increased gene expression of fibronectin, a 
more intense signaling by beta (β) 1 Integrins and a high activation of cell motility 
kinases Focal adhesion kinase (FAK) and Src [Mehrotra et al, 2010]. Another study 
supports the idea that XIAP promotes Heat Shock Protein 90 (Hsp90)-mediated 
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ubiquitination and, consequently, de-stabilisation of C-RAF kinase, thereby negatively 
modulating the migration capacity of the cell [Dogan et al, 2008]. On the other hand, in a 
model of colorectal cancer, XIAP was found to downregulate RhoGDP dissociation 
inhibitor RhoGDI SUMOylation, thus leading to a marked reduction of β-actin 
polymerisation and cytoskeleton formation [Liu et al, 2011]. Consistently, cell migration 
and invasion were also decreased. In accordance to these findings, XIAP can recruit 
alpha (α) 5-Integrin, Caveolin 1 and FAK to form a multicomplex that regulates 
endothelial cell migration via a mechanism that involves shear-dependent ERK 
activation [Kim et al, 2010]. Interestingly, a study conducted by Pascal Meier’s lab 
demonstrates that depletion of cIAP1 and/or treatment with SMs mostly decreases 
migration capability of triple-negative breast cancer cell lines. Moreover, his group 
showed that specific loss of cIAP1 determines vascular tree degeneration in vivo, thus 
suggesting that cIAP1 can be considered as a promoter of motility and maintenance of 
vascular integrity [Lopez et al, 2011]. Hence, SMs might potentially interfere with both 
the migratory capacity of cancer cells and tumour vasculature in a negative manner. 
In conclusion, we might presume that most of the discrepancy observed with respect to 
pro- and anti-migratory effects of IAPs could be attributed to the difference in the cell 
types employed, as many of the migration-regulating molecules controlled by IAPs could 
promote or inhibit migration in a context-dependent manner [Oberoi-Khanuja et al, 
2013]. 
 
 
1.4.5 Clinical testing of Smac-Mimetics 
 
So far, five distinct SM compounds have been evaluated in clinical early trials. The first-
in-human phase-I dose-escalation study of LCL161 was conducted in patients with 
advanced solid malignancies [Infante et al, 2014]. In these settings, it was responsible 
for toxic adverse effects such as cytokine release syndrome (CRS), thus supporting the 
idea that cytotoxicity is still a major drawback for many SMs in the cancer clinic. 
Moreover, in preclinical cancer models, a variety of rationally designed SMs-based 
combinations have been developed, involving chemotherapeutic drugs, signal 
transduction inhibitors and radiotherapy. An ongoing phase-I clinical study of Birinapant 
(TL32711) combined with multiple chemotherapeutics evaluates tolerability and clinical 
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activity for solid tumours. This trial indicates that such combination may be tolerable and 
yield clinical benefits [Krepler et al, 2013]. 
In summary, since SMs, in monotherapy or combination, have entered the stage of 
clinical evaluation as cancer therapeutics, a better understanding of the various cellular 
effects will be decisively needed for their rational use in the treatment of cancer. 
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1.5 Ras in cancer 
 
Ras is a 21 KDa protein belonging to the Ras subfamily, which comprises small GTP- 
hydrolysing proteins, GTPases, considered as molecular switches. When bound to GTP, 
these enzymes are active and transmit signals to downstream molecules. They possess 
weak intrinsic GTPase activity, which is however too slow in causing rapid signalling 
processes and therefore requires acceleration mediated by GTPase Activating Proteins 
(GAPs). When bound to GDP, Ras proteins are inactive and require assistance from 
Guanosine Exchange Factors (GEFs) in order to be loaded with GTP and to be activated 
[Bos, 1989]. Supported by GAPs and GEFs, Ras proteins can undergo rapid cycles of 
activation and facilitated self-inactivation, which is crucial for controlling Ras signalling 
dose. 
30% of all cancers bear activating mutations in Ras [Bos, 1989]. These Ras-driven 
cancers are the example of what can happen when the tight network of Ras activity 
regulation is perturbed. Spontaneous single amino acid mutations in the GTP binding 
pocket of Ras at codon 12, 13 or 61 result in failure of GAP binding and, in turn, 
constitutively activated Ras, which is intrinsically very slow in hydrolysing bound GTP 
[Downward, 2003]. Consequently, downstream signalling pathways are hyperactivated in 
Ras-mutated cancers providing them with the ability to grow independently of growth 
factor stimulation and attachment, and thereby increase proliferation and migration rate. 
The proteins of the Ras subfamily are NRas, HRas and KRas [Castellano and Santos, 
2011]. In human cancers KRas mutations are observed with a frequency of 21% 
followed by 8% mutations in NRas and 3% HRas mutations [Bos, 1989]. Ras isoforms 
share about 80% sequence homology and mainly differ in their C-terminal so-called 
Hyper Variable Region (HVR) that contains lipid anchoring post-translational 
modifications which are required for membrane-anchoring of Ras proteins [Karnoub and 
Weinberg, 2008]. Ras isoforms are ubiquitously expressed in all the tissues with some 
preferential localisations [Leon et al, 1987]. Based on overexpression experiments it was 
originally believed that different Ras isoforms might have overlapping and redundant 
functions. However, studies in isoform-specific knock-out mice have demonstrated that 
KRas deficiency [Johnson et al, 2001], but not NRas [Umanoff et al, 1995] or HRas 
[Esteban et al, 2001], is embryonically lethal. KRas knock-out mice die between 
embryonic day 12 and 14 and present anaemia and liver defects [Johnson et al, 2001]. 
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Although these results suggest that KRas can fulfil a unique function during 
development, it is also possible that its expression pattern during embryogenesis is 
distinct from the other isoforms, which are not present in that particular tissue at 
sufficient levels to compensate the loss of KRas. Besides the evidence from knock-out 
mice, different cancers typically are characterised by distinct Ras isoform mutations 
supporting the idea of isoform-specific effects. NRas mutations have high incidence in 
acute leukaemia, whereas HRas mutations are mostly found in bladder, thyroid and 
kidney cancer [Castellano and Santos, 2011]. KRas mutations are predominantly found 
in the most aggressive cancer types of internal organs such as 95% of all pancreatic 
cancers [Jaffee et al, 2002], 50% of colon cancers [Grady and Markowitz, 2002] and 
about 30% of lung cancers [Mitsuuchi and Testa, 2002]. 
 
 
1.5.1 Ras isoform-specific signaling 
 
All Ras isoforms respond to the basic signalling principle that an upstream activator 
which can be a non-receptor or receptor tyrosine kinase such as platelet-derived growth 
factor receptor (PDGFR) is activated by ligand binding [Downward, 2003]. The receptor 
tyrosine kinase auto-phosphorylates and provides a binding site to recruit the adaptor 
molecule growth- factor-receptor-bound protein 2 (Grb2) via its SH2 domain. Grb2 in 
turn recruits the Ras GEF Son of sevenless (Sos), which binds to Grb2’s SH3 domain 
[Bos, 1989]. Due to the resulting membrane-proximal localisation of Sos it is now placed 
within the membrane-associated Ras molecules. Furthermore, Sos facilitates GDP 
release from Ras molecules, which, as a result of chemical equilibrium, then bind with 
GTP, present at much higher concentrations in the cytosol. GTP-bound Ras 
subsequently activates a variety of downstream signalling molecules until the GTP is 
hydrolysed by Ras, which serves as an auto-inactivatory function for self-regulation 
[Downward, 2003]. 
KRas mutational status is nowadays screened in colon cancer patients in order to 
determine whether they would benefit from an Epithelial Growth Factor Receptor 
(EGFR)-blocking treatment, which is only effective when wild-type KRas is expressed 
downstream of EGFR and therefore responsive to upstream blocking. Downstream of 
Ras molecules, a vast variety of pathways has been described to be activated and ERK 
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and PI3K pathways are the most widely studied. Additional Ras effector pathways were 
also discovered [Cellurale et al, 2011, Meylan et al, 2009, Shields et al, 2000]. ERK 
activation is triggered via GTP-bound Ras that interacts with one of the Raf kinase 
isoforms (Raf1/cRaf, BRAF or ARAF). Activated Rafs trigger downstream activation of 
MEK1/2 kinases, which in turn activate ERK1/2. Again, different Ras isoforms were 
shown to have preferences between Raf isoforms. KRas is a much more potent activator 
of Raf1 than HRas whereas HRas is more potent in activating PI3K [Yan et al, 1998]. 
Furthermore, KRas was shown to be more efficient than HRas in activating the small 
GTPase Rac-1 [Walsh and Bar-Sagi, 2001], a member of the Rho GTPase-family 
regulating cell motility. Both H- and K-Ras can induce NF-κB activation upon 
overexpression whereas N-Ras is a rather weak inducer of NF-κB [Millan et al, 2003]. 
Considering the high sequence similarity between the isoforms with main differences 
only present in the C-terminal HVR, it is plausible that the post-translational 
modifications present in this region, deriving from tissue expression pattern and 
intracellular localization, are decisive for isoform-specific signalling.  
 
 
1.5.2 Mutant KRas promotes enhanced motility 
 
There are multiple reasons why KRAS-mutated cancers are highly metastatic. Enhanced 
KRas-mediated downstream signalling provides the increased capacity to proliferate, 
migrate, invade and survive anoikis. The metastatic process requires initial invasion and 
migration of tumour cells into the surrounding tissue and, importantly, crossing of the 
endothelial barrier to enter the bloodstream, a process termed intravasation [McCarthy, 
2009]. While travelling in the bloodstream, cancer cells need to overcome anoikis (i.e. 
avoid cell death due to detachment) and evade recognition by the immune system. For 
long-term survival in the body they will however need to adhere again, cross the 
endothelial barrier and migrate into the tissue at a secondary site. This step is referred to 
as extravasation [Pantel and Brakenhoff, 2004]. As can be seen from the described 
requirements, the capacity to migrate and invade is both important at the initiating 
intravasation step as well as the final extravasation step. Although PI3K-signalling 
downstream of Ras has been mainly associated with cell survival and proliferation it can 
also promote Ras-mediated migration either via activation of the small GTPase Rac-1 
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[Nimnual et al, 1998] or independently of Rho-family GTPases [Cain and Ridley, 2009]. 
A PI3K-independent mechanism of Ras-mediated Rac-1 activation has been 
characterised in which the Rac-1 GEF T-cell lymphoma invasion and metastasis-
inducing protein 1 (Tiam1) directly binds Ras via a Ras-binding domain and activates 
Rac-1 even in cells expressing PI3K- binding mutants of Ras [Lambert et al, 2002]. 
 
 
1.5.3 Synthetic lethal interactions associated to oncogenic 
KRAS 
 
KRAS-mutated cancers are notoriously difficult to be treated in clinic. Small molecule 
Ras inhibitors, which have been developed to decrease Ras activity, have, however, 
only led to marginal success so far [Sebti and Adjei, 2004]. At the moment, new targeted 
therapeutic strategies consists in inhibiting common proteins aberrantly regulated in 
KRAS-mutated cancers: therapies include inhibition of MEK in combination with 
inhibition of Bcl-2/Bcl-xL or PI3K, STK33, TAK1, GATA2, CDC6, APC/C, and PLK1 
[Faber et al, 2014]. In order to exploit KRAS oncogene addiction and circumvent the 
problem that inhibition of neither KRas nor KRas-downstream effectors is potent enough, 
an approach of synthetic lethality was used to develop therapeutic strategies against 
KRAS-mutated cancers. The concept of synthetic lethality was first coined in a study in 
Drosophila showing that two single mutations alone can be viable, while the combination 
of both is lethal [DOBZHANSKY, 1946]. Consequently, synthetic lethal drugs can target 
factors that are only essential for cell survival in combination with Ras-mutation in cells, 
but are dispensable for the survival of cells, which are Ras wild-type [Hartman et al, 
2001]. Accordingly, factors that mediate oncogene addiction and therefore result in 
synthetic lethality when inhibited can be identified in comparative screens of Ras 
mutated and Ras wild-type cells [Weidle et al, 2011]. 
One recently published study has tested a combinatorial treatment designed from the 
results of a genome-wide siRNA screen that searched for factors whose inhibition would 
induce cell death specifically in KRas-mutated cancer cells. This screen identified 
addiction to the transcription factor GATA2, which upregulates TRAF6, ROCK1, CDC42 
and ephrin type-A receptor 3 (EPHA3) specifically in KRas-mutated cells, as well as 
proteasome components in mutated and wild-type cells. A co-treatment of ROCK 
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inhibition with proteasome inhibition significantly reduced lung tumour burden in a KRas-
driven lung tumour model [Kumar et al, 2012]. Another siRNA screen performed in 
KRAS-transformed colorectal cancer cells compared with their derivatives lacking this 
oncogene reveals that either topoisomerase inhibitors or proteasome inhibitors can be 
efficient in killing selectively KRAS-mutated tumours [Steckel et al, 2012]. A different 
approach to study synthetic lethal interactions reveals that knock-in (KI) of single or 
multiple cancer alleles in non-transformed human cells can sensitise or protect cells to 
pathway-targeted drugs i.e. MEKK inhibitors, mTORC inhibitors and PI3K inhibitors, 
currently used in clinical trials [Di Nicolantonio et al, 2008, Di Nicolantonio et al, 2008, Di 
Nicolantonio et al, 2010]. This KI technology can then be used as a tool to study the 
molecular mechanisms originating from common cancer lesions, thus providing a 
pharmacogenomic platform for the rational design of targeted therapies. An interesting 
study by Engelman’ s lab demonstrated that combined Bcl-XL and MEK inhibition 
induces dramatic apoptosis in a panel of KRAS-mutated cancer cell lines and promotes 
marked tumour regression in KRAS-mutant xenografts and in a genetically engineered 
KRAS-driven lung cancer mouse model [Corcoran et al, 2013]. Along with this finding, 
novel ideas have been recently developed regarding the employment of targeted 
therapies to treat these KRAS-mutated recalcitrant tumours. Firstly, in January 2014, 
Engelman’s group published that Mcl-1-mediated TORC1/2 inhibition via AZD8055 
sensitises KRAS-/B-RAF-mutated but not wild-type colorectal cancers to Bcl-2 family 
inhibitor ABT-263 [Faber et al, 2014]. Soon after, in June 2014, the same group 
elucidated the cellular mechanisms through which several subtypes of non-small cell 
lung cancers are still resistant to the standard-of-care therapy i.e. MEK- and PI3K-
inhibitors (MEKi/PI3Ki). This group indeed identified in the downregulation of Bim and 
PUMA the main cause of the limited effectiveness of MEKi/PI3Ki-based conventional 
therapeutic strategy [Hata et al, 2014]. A different and singular synthetic lethal 
interaction proposed for the treatment of lung cancer involves SM and TRAIL in KRAS-
mutated cell lines. Hyperactivation of KRas led to upregulation of TRAIL-R1/-R2 and 
downregulation of Decoy Receptors on one side and MAPK-mediated repression of 
cFLIP on the other side. Furthermore, concomitant SM-inhibition of XIAP enhances 
TRAIL-induced apoptosis, thus completely killing tumour cells and reducing tumour 
burden in vivo [Huang et al, 2011]. Another example of how selective can be KRas 
lesions in favouring cell death, has been reported by Matallanas et al who show that 
mutant KRAS activates the MST2-LATS21-mediated apoptotic pathway. However, the 
34 
 
co-expression of KRAS and MST2 is necessary to trigger apoptosis, otherwise WT-
KRAS allele would repress this pro-apoptotic signaling via AKT [Matallanas et al, 2011]. 
So far, many targeted therapeutic strategies have been developed in order to treat 
KRAS-mutated cancers. However, it is difficult to predict which approaches are more 
likely to enter the clinic trials in oncology. Even the most potent treatment(s) may not be 
vastly efficient for a certain type of cancer as there are different subsets of KRAS-mutant 
cancers, which are susceptible to particular combinations even though the tumour arises 
from the same tissue of origin. 
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2   Aims of the thesis 
 
Task I 
 
 Explore possible synthetic lethal interaction(s) between combination of     
SM83/CPT and cancer-associated mutation of KRAS in human premalignant 
cells and elucidate the molecular mechanisms of this phenomenon. 
 Study whether SM83/CPT combination is efficient in killing KRAS-mutated 
cancer cells, with particular focus on colorectal cancer cell lines.  
 
This task was carried out at Istituto Nazionale dei Tumori di Milano. 
 
Task II 
 
 Test whether the specific inhibition of CDK9 in combination with TRAIL would 
synergistically and selectively kill human non-small cell lung cancer cells in vitro 
and in vivo highly resistant to TRAIL. 
 Estabilish an autochthonous lung tumour model to evaluate the efficacy of 
combined CDK9 inhibition and TRAIL. 
 
This task was carried out at UCL, as part of Johannes Lemke’s Medical Internship. 
 
Task III 
 
 Clarify whether the endogenous TRAIL/TRAIL-R2 system may promote 
invasion/migration/metastasis in KRAS-mutated cancers 
 Investigate which effectors are involved in TRAIL/TRAIL-R2-mediated pro-
metastatic signalling pathway. 
 
This task was carried out at UCL, as part of Silvia von Karstedt’s PhD project. 
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3   Matherial & Methods 
 
3.1 Material – Task I 
 
3.1.1 Cell lines 
 
Isogenic human mammary epithelial cell lines HME +/+, HME D13/+ and MCF10A 
together with the isogenic colorectal cancer cell lines SW48 +/+ and SW48 D13/+, 
HCT116 +/- and HCT116 D13/-, Lim1215 +/+ and Lim1215 D13/+, DLD-1 D13/- and 
DLD-1 +/- were kindly provided by Prof. Alberto Bardelli [Di Nicolantonio et al, 2008, Di 
Nicolantonio et al, 2008, Misale et al, 2012]. HME isogenic pairs and MCF10A cell lines 
were cultured in DMEM-F12 from Gibco, supplemented with 10% FBS from LONZA, 
2mM Glutamine from LONZA, 20 ng/ml EGF from Immunological Science, 10 ug/ml 
Insulin from Sigma, 500 ug/ml hydrocortisone from Sigma. SW48 and DLD-1 isogenic 
pairs were cultured with DMEM from GIBCO, supplemented with 10% FBS and 2 mM 
Glutamine. Lim1215 isogenic pairs were cultured with RPMI from LONZA, supplemented 
with 10% FBS, 2 mM Glutamine and 1 ug/ml Insulin. HCT116 were cultured in RPMI, 
supplemented with 2mM Glutamine, Sodium Pyruvate, and Non-Essential Amino Acids 
(NEAA) from LONZA. All cell lines were mycoplasma-free as determined by Takara 
Mycoplasma Detection Kit (Clontech). 
 
3.1.2 Reagents 
 
3.1.2.1 Buffers and Solutions 
 
- Blocking Buffer: 
4% milk powder (CalBiochem), 
0.01% Tween-20 (Sigma), 
1X PBS. 
- Freezing medium (for cells), Lysis Buffer I (for lysis): see Paragraph 3.3.2.1.  
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- Lysis Buffer II (it additionally allows the lysis of the nuclei): 10% SDS (LONZA). 
- MES and MOPS (Running Buffers) were purchased from Invitrogen. 
- Transfer Buffer (blotting): 
1X NuPage Transfer Buffer (Invitrogen), 
10% MetOH (VWR Chemicals), 
water. 
- 10X PBS (pH = 7.4) (LONZA). 
- PBS/Tween-20: 
0.05% Tween-20, 
1X PBS. 
- Antibody solution: 
5% Albumin from Bovine Serum (BSA) (Sigma), 
0,01% Tween-20, 
0,01% Sodium Azide purchased from Sigma, 
1X PBS. 
- ECL-HRP Linked Secondary Antibodies (Novex). 
- Peroxide Buffer LiteAblot – PLUS/ - EXTEND/ - TURBO  (Euroclone). 
- Hyperfilms (Amersham). 
 
 
3.1.2.2 Antibodies 
 
α-pan-RAS from CalBiochem, α-β-Actin and α-ERK1/2 from Sigma, α-Cleaved-PARP, α-
Cleaved-Caspase-3, α-phospho ERK1/2 (Thr202/Tyr204), α-pAKT and AKT were 
purchased from Cell Signaling, α-cIAP1 from R&D Systems, α-cIAP2 and α-XIAP from 
BD Biosciences, α-Caspase-8 from Enzo Life Sciences and α-Noxa from CalBiochem. 
 
 
3.1.2.3 Inhibitors 
 
z-VAD(OMe)-FMK was purchased by BIOMOL, Necrostatin-1 from Enzo Life Sciences. 
PD98059 and UO126 were purchased from CalBiochem, LY294002 from Sigma, 
Triciribine from Selleckem. 
Infliximab and Enbrel were provided by Ospedale Policlinico (Milan). 
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SM83 was synthetised at CISI Institute by Prof. Pierfausto Seneci [Manzoni et al, 2012; 
Lecis et al, 2012]. 
CPT was purchased from Sigma. 
 
 
3.1.2.4 Production of mutated KRas expression vector 
 
The vector pINDUCER20 was kindly provided by Prof. Stephen J. Elledge. These 
vectors as used as vehicles, which enable cDNA induction in mammalian cells 
[Meerbrey et al, 2010]. In our experiments mutant KRas (G13D) was cloned in the 
pINDUCER20 and its expression was induced by Doxocycline. 
 
 
3.2 Methods – Task I 
 
3.2.1 Preparation of cell lysates 
 
Cells were harvested by centrifugation at 4500 rpm for 5 minutes at 4°C. After washing 
once with PBS, lysates were prepared by resuspending cell pellets in 60-100 μl cell lysis 
buffer I or II supplemented with 1 x Complete™ protease inhibitors (Roche Diagnostics) 
and phosphatase inhibitors (cocktail I and II) according to the manufacturer's 
instructions. If lysis is performed in Buffer I, after 30 min incubation on ice, the lysates 
were centrifuged at 13000 rpm for 20 min at 4°C, cleared supernatants were transferred 
to a new tube and frozen at -20 °C. If lysis is performed in Buffer II, lysates were boiled 
at 99°C, sonicated at 30% intensity for 10’’ at RT. Then the lysates were centrifuged at 
13000 rpm for 20 min at RT and cleared supernatants were transferred to a new tube 
and frozen at -20 °C. 
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3.2.2 Determination of protein concentration 
 
To determine the protein concentration of cell lysates, the bicinchonic acid (BCA)-
containing protein assay was applied according to the manufacturer’s instructions 
(QuantumMicro Protein purchased from Euroclone). In a 96-well plate, 2 ul lysate were 
incubated with 148 ul water and BSA was used as standard protein is titrated up to 15  
ug/ul. To 150 ul of final volume, 150 ul BCA solution was added. The plate was then 
placed at 37 °C for 20 minutes, followed by absorption measurement at 485 nm using 
TECAN Ultra Microplate reader (Thermo Labsystems).  
 
 
3.2.3 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Proteins were separated according to size using pre-cast 4-12% Bis-Tris-NuPAGE gels 
(Invitrogen). Cell lysates were mixed with 4x reducing SDS-Sample buffer containing 
10% β-mercaptoethanol (Sigma) and heated for 10 min at 93°C. As molecular weight 
standard, Page Ruler Plus Pre-Stained Protein Ladder (Euroclone) was used. The 
electrophoretic separation was achieved by applying a constant voltage of 80 V for 7 
minutes and subsequently 120 V for 150 minutes. MES buffer was used for the 
separation of proteins smaller than 30 kDa, MOPS buffer was used for the separation of 
all other proteins. 
 
 
3.2.4 Western blot analysis 
 
Cells were treated as indicated and then lysed in Buffer I or II. Proteins were separated 
by SDS-PAGE (NuPAGE) and analysed by western blotting. PVDF membranes 
(Millipore) were incubated with PBS-tween for 5’, blocking buffer for 30’ and then 
incubated overnight with the indicated primary antibodies. 
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3.2.5 Cell viability assay 
 
96-well Optical Bottom Plate, Polymer Base White (Thermo Scientific) were used. At 
Day 1, 10000 cells per well were seeded in 100 ul medium. At day 2, cells were treated 
adding the indicated drug(s) in 10 ul volume per well. At day 3, cell viability was 
determined using the CellTiter Glo assay (Promega) according to the manufacturer’s 
instructions. 
 
 
3.2.6 siRNA-mediated knockdown (reverse protocol) 
 
To achieve transient knockdowns of target proteins, siRNA single sequences were 
purchased from Qiagen. RNAi MAX purchased by Invitrogen was used as transfection 
reagent. Briefly, for 12-well plate (1 well), 3,25 μl RNAi MAX and 200 μl Optimem 
(GIBCO) were mixed and incubated for 5 minutes at RT. Subsequently, 3,25 μl siRNA of 
a 20 μM stock were added, mixed and incubated for further 30 minutes at RT. The 200 
μl transfection mix was placed into one well and 0,15 x 106 cells seeded in 800 uL on top 
of the transfection mix. Cells were incubated for 72 hours for the knockdowns to be 
efficient in all cases. If the KD is followed by treatment with compounds, the treatment is 
scheduled 24 hours after the KD. 
 
 
3.2.7 Ras-GTP pull-down assay 
 
2.5 x 106 cells were seeded into 10 cm dishes. The next day, cells were incubated with 
and without 250 ng/ml of Dox. Cell lysis and Ras-GTP pulldown was performed: Cells 
were then lysed in 500 μl IP-lysis buffer supplemented with a cocktail of protease 
inhibitors. To fully detach lysed cells, they were scratched of the plates using a cell 
scraper and transferred into tubes for 30 minute lysis at 4 °C on a rotator. Afterwards, 
the lysates were centrifuged at 13000 rpm for 30 min and cleared supernatants were 
transferred to a new tube. After protein adjustment of the lysate, Ras-GTP was 
precipitated by using anti-RBD-beads (Sigma) overnight. The following day, beads were 
washed 5 times with IP-lysis buffer and precipitated protein complexes were eluted from 
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the beads via boiling in SDS-Sample buffer for 10 minutes at 80°C. Proteins were 
separated by SDS-PAGE (NuPAGE) and analysed by western blotting. 
 
 
3.3 Material – Task II and III 
 
3.3.1 Cell lines and human samples 
 
Isogenic colorectal cancer cell line DLD-1, DKO4 and HCT116 [Shirasawa et al, 1993] 
were kindly provided by O. Kranenburg, pancreatic cancer cell lines Panc Tu I and 
Colo357 by A. Trauzold. The human lung adenocarcinoma panel of KRAS-mutated and 
WT cell lines (H460, H441, H522, H322, H23 and Calu-1) by J. Downward. A549-luc 
cells were purchased from Caliper Life Science. The murine NSCLC cell lines 802T4, 
394T4 and 482T2 derived from lung tumours of KP mice. DLD-1, DKO4, HCT116, Hkh-2 
cells were cultured in DMEM supplemented with 10% FCS and 2 mM Glutamine, Panc 
Tu I, Colo357, 802T4, 394T4 and 482T2 in RPMI1640 supplemented with 10% FCS, 2 
mM Glutamine and 1 mM sodium pyruvate and the human lung cancer cell line panel 
including A549-luc cells in RPMI1640 supplemented with 10% FCS. All cell lines were 
mycoplasma-free as determined by MycoAlert™ Mycoplasma Detection Kit (LONZA). 
Human biopsies employed for H&E, CDK9 and TTF-1 staining derive from NSCLC 
patients. The UCL Biobank Ethical Commettee approved the employement of human 
samples for that experiment. 
 
 
3.3.2 Reagents 
 
3.3.2.1 Buffers and Solutions 
 
- Blocking Buffer:  
5% milk powder,  
0.05% Tween-20, 
PBS. 
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- Freezing medium (for cells): 
90% FCS (v/v),  
10% DMSO (v/v).  
- Lysis Buffer (cell lysates and IP): 
30 mM Tris-Base (pH 7.4),  
120 mM NaCl,  
2 mM EDTA,  
2 mM KCl,  
10% Glycerol (v/v),  
1% Triton X-100 (v/v) (IP-LB1),  
COMPLETE protease-inhibitor cocktail.  
- MES running buffer: 
50 mM MES,  
50 mM Trizma Base,  
1 mM EDTA.  
- MOPS Running Buffer (pH = 7.7): 
50 mM MOPS,  
50 mM Tris-Base,  
3.5 mM SDS,  
1.0 mM EDTA.  
- PBS (pH = 7.4): 
137 mM NaCl,  
8.1 mM Na2HPO4,  
2.7 mM KCl,  
1.5 mM KH2PO4.  
- PBS/Tween: 
137 mM NaCl  
8.1 mM Na2HPO4  
2.7 mM KCl  
1.5 mM KH2PO4  
0.05% Tween-20, 
PBS (v/v).  
- Stripping Buffer (pH = 2.3) (Western blots): 50 mM Glycin in H2O. 
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- Transfer Buffer (Western blots): 
192 mM Glycin,  
25 mM Tris-Base,  
0.01% EDTA,  
10% Methanol (v/v). 
 
 
3.3.2.2 Antibodies 
 
α-KRAS was purchased from Santa Cruz, α-β-Actin from Sigma, α-Rac1 from Millipore, 
α-TRAIL-R2 from Cell Signaling for knockdown detection and from ProSci for SEC, α-
TRAIL from Alexis and α-TRAIL-R1 from ProSci, α-pAKT and AKT were purchased from 
Cell Signaling and α-PTEN from Santa Cruz; α-RNA-Pol II, α-pSer2 was purchased from 
Convance; α-Caspase-3 and α-cIAP from R&D Systems; α-Caspase-8 (C15) from Enzo; 
α-PARP was purchased from BD Bioscience; α-Caspase-9 from MBL; α-Bid was from or 
Cell Signalling (Rabbit) or R&D Systems (Goat).  
 
 
3.3.2.3 Inhibitors 
 
GDC-0941 was purchased from Selleck Chemicals and z-VAD(OMe)-FMK was 
purchased from Abcam. SNS-032 was purchased from Selleck Chemicals, Dinaciclib 
was purchased by Haoyuan Chemoexpress Co.. 
 
 
3.3.2.4 Recombinant proteins 
 
Recombinant TRAIL was used as an isoleucine zipper-tagged version of the 
extracellular domain of human TRAIL (izTRAIL) and was produced in E. coli, purified as 
described previously [Ganten et al, 2009], izTRAIL was LPS-free after purification as 
tested by Limulus amebocyte lysate (LAL) assay (LONZA). MoTAP-TRAIL was 
produced in E. coli, purified in our laboratory.  
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3.4 Methods – Task II and III 
 
3.4.1 Preparation of cell lysates 
 
Half of the cells were detached and washed for transwell migration as described in 
3.4.10, then were harvested by centrifugation at 45000 rpm for 2 minutes at 4°C. After 
washing once again with PBS, lysates were prepared by resuspending cell pellets in 40 
ul cell lysis buffer supplemented with 1 x Complete™ protease inhibitors (Roche 
Diagnostics) and phosphatase inhibitors (cocktail I and II from Sigma) according to the 
manufacturer's instructions. After 30 min of incubation on ice, the lysates were 
centrifuged at 13000 rpm for 20 min at 4°C, cleared supernatants were transferred to a 
new tube and frozen at -20 °C. 
 
 
3.4.2 Determination of protein concentration 
 
To determine the protein concentration of cell lysates, the bicinchonic acid (BCA)-
containing protein assay was applied according to the manufacturer’s instructions 
(Pierce). 2 ul lysate were incubated with 100 ul BCA solution at 37 °C for 20 minutes, 
followed by absorption measurement at 560 nm using a Multiskan Ascent plate-reader 
(Thermo Labsystems). All sample volumes were adjusted to equal concentrations 
according to differences in absorption.  
 
 
3.4.3 SDS polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Proteins were separated according to size based on the method by Laemmli (Laemmli, 
1970) using pre-cast 4-12% Bis-Tris-NuPAGE gels (Invitrogen). Cell lysates were mixed 
with 4x and immunoprecipitations with 2x reducing SDS-Sample buffer and heated for 
10 min at 80 °C. As a molecular weight standard, SeeBlueTM Plus2 Pre-Stained marker 
(Novex) was used. The electrophoretic separation was achieved by applying a constant 
voltage of 80 V for 7 minutes and subsequently 180 V for 50 minutes. MES buffer was 
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used for the separation of proteins smaller than 30 KDa, MOPS buffer was used for the 
separation of all other proteins. 
 
 
3.4.4 Western blot analysis 
 
Cells were treated as indicated and then lysed in IP-lysis buffer (30 mM Tris-HCl [pH 
7.4], 120 mM NaCl, 2 mM EDTA, 2 mM KCl, 1% Triton X-100, 1× COMPLETE protease-
inhibitor cocktail) at 4°C for 30 min. Proteins were separated by SDS-PAGE (NuPAGE) 
and analysed by western blotting. Membranes were stripped with 50 mM glycine (pH 
2.3) before reprobing with other antibodies. 
 
 
3.4.5 Stripping of western blot membranes 
 
All Western blot membranes had to be incubated with more than one primary antibody. 
Therefore, after successful signal detection, previous antibodies were removed by 
incubating the membranes with stripping buffer at RT for 15 minutes. The low pH of the 
stripping buffer alters protein conformation resulting in release of antibody/antigen-
binding. The membranes were washed 3 times with PBS/Tween, followed by incubation 
in blocking solution and a new round of probing. 
 
 
3.4.6 Cell viability assay 
 
Cell viability was determined using the Cell Titer Glo assay (Promega) according to the 
manufacturer’s instructions. See Paragraph 3.2.5. 
 
 
3.4.7 siRNA-mediated knockdown (reverse protocol) 
 
To achieve transient knockdowns of target proteins, siRNA smart-pools purchased from 
Thermo Scientific or single sequences if indicated were used. Dharmafect was used as 
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transfection reagent. Briefly, per six-well (1 well), 1.5 ul Dharmafect and 200 ul FCS-free 
RPMI were mixed and incubated for 5 minutes at RT. Subsequently, 2.2 ul siRNA of a 
20 uM stock were added, mixed and incubated for further 20 minutes at RT. The 200 ul 
transfection mix was placed into one well of a fresh 6-well plate and 1.5 x 105 cells 
seeded on top of the transfection mix. Cells were incubated for 48 hours for the 
knockdowns to be efficient in all cases. 
 
 
3.4.8 Coomassie staining of protein gels – Task II 
 
Proteins were stained with Coomassie staining solution for visualisation. Firstly, SDS 
had to be rinsed from the gel, by either 15 min washing or brief cooking of the gel in 
deionised H2O. Then, the gel was transferred into the Coomassie staining solution and 
cooked in the microwave to accelerate staining. After sufficient staining, for example 
overnight, the background was reduced by periodic rinsing in deionised H2O. The 
stained gel was scanned for documentation and dried with gel drying solution for long 
term storage. To increase the staining of lowly abundant proteins the gel was rinsed in 
20 % NaCl overnight. 
 
 
3.4.10 Migration assay – Task III 
 
Migration assays were performed using the xCELLigence System (Acea Biosciences, 
Inc.) that uses specially designed microtiter plates containing gold microelectrodes to 
measure electrical impedance of cells adhering to electrodes in real time. Increased 
impedance of background control wells was subtracted from all other values, the 
increase in electrical impedance/migration of control siRNA-transfected/control vector-
infected cells was then defined as 100% migration and relative migration of all other 
transfected samples was calculated as compared to control-transfected cells, 
accordingly. Migration plates (CIM 16) are based on the Boyden chamber principle, the 
lower surface of the filter is covered with microelectrodes measuring cells that have 
migrated through the pores and adhere to the lower surface of the filter in real-time. 
Briefly, the lower chambers of a CIM 16 plate were filled with media containing 2% FCS 
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as chemoattractant, the upper part was assembled and 30 ul of FCS-free medium was 
added to the top wells. The plate was then equilibrated at 5% CO2 and 37°C for 1 h. 
Cells were trypsinized and washed three times in FCS-free medium. Then, 8 x 105 cells 
were resuspended in 1 ml FCS-free medium and 100 ul cell suspension was added to 
each well after a background measurement without cells was performed. Four wells 
without cells (FCS-free medium only) were included as assay background control. Cells 
were left to settle in the top well of the plates at room temperature for 30 minutes and 
then plates were returned to the RTCA-DP xCELLigence system and impedance 
measurements were taken every minute. Cells that had been transfected with siRNA 
were left to migrate for a total of 6h. 
 
 
3.4.11 Invasion assay – Task III 
 
Invasion assays were performed using the xCELLigence System (Acea Biosciences, 
Inc.) that measures cell impedance in real-time (see Migration assay). In this assay, E-
plates were used which do not follow a Boyden chamber principle but are regular wells 
(16-wells, each with the size of a 96-well) that contain gold electrodes at the bottom of 
the well. Wells were coated with 30 ul of 1:10-diluted Matrigel (BD) and left to set in the 
incubator for 1 hour. Importantly, matrigel was diluted in medium containing 10% FCS to 
promote invasion. In the meantime cells were prepared as described for the migration 
assay. Again, before adding washed cells to the well, a background measurement was 
taken. After adding cells, they were left for 30 minutes at room temperature to settle. 
Wells without cells and the non-invasive cell line NIH3T3 were included as controls in 
each experiment. E-plates were then returned to the RTCA-DP xCELLigence system to 
take measurements every minute for a total of 6 h. Cell Index measurements increase 
as a function of cells that have passed through the matrigel and have reached the 
electrodes. Background of wells without cells was subtracted and control transfected 
cells were set to 100% migration and relative migration of TRAIL-R2 knockdown cells 
and NIH3T3 was calculated accordingly. Subsequently, the matrigel layer was removed 
and cells adhering to electrodes were stained by crystal violet and washed with PBS. 
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3.4.12 Size exclusion chromatography (SEC) – Task III 
5 x 106 cells were lysed in 240 µl of IP-lysis buffer (30 mM Tris-HCl [pH 7.4], 120 mM 
NaCl, 2 mM EDTA, 2 mM KCl, 1% Triton X-100, 1X COMPLETE protease-inhibitor 
cocktail, 10 mM MgCl2) at 4°C for 20 minutes. Subsequently, lysates were cleared by 
centrifugation and additional centrifugal spin filtration (0.2 um). At this point lysates were 
either stored at -80°C or fractionated using the Superose™ 6 PC 3.2/30 (GE 
Healthcare). Briefly, the column was equilibrated with 2 column volumes (2x 2,4 ml) of 
running buffer (20 mM HEPES, 120 mM NaCl, 2 mM EDTA, 2 mM KCl, 5% (w/v) 
sucrose, 1% Triton X-100, [pH 7.5]). Lysates were then injected and collected in 50 ul 
fractions. 12 ul of fractions 9-32 were analyzed by western blotting. 
 
 
3.4.13 Re-expression of wild type version of TRAIL-R2 – Task III 
 
A549-luc pLKO.1 and shTRAIL-R2 (targeting the 3’UTR) cells were transfected with 
either pcDNA3.1 or full length TRAIL-R2 (long isoform) inserted into pcDNA3.1 using 
Lipofectamine 2000 (Invitrogen, Paisley, UK) according to the manufacturer’s 
instructions. After 24 h incubation, cells were subjected to migration assays or to SDS-
PAGE and subsequent western blot. 
 
 
3.4.14 Immunohistochemistry & Immunofluorescence – Task II 
 
For preparation of lung tissue sections, mice were sacrificed 3.5 weeks after cell 
injection according to Guidance on Operation of Animals [Scientific Procedures] Act 
1986. From each mouse the upper lobe of the left lung was removed, fixed in 10% 
formalin (Sigma) for one week and then transferred to 70% ethanol. Paraffin embedding, 
preparation of sections and H&E stainings were performed as part of a histological 
staining service at the National Heart & Lung Institute. Sections were de-waxed and 
rehydrated by passing the slides through xylene and descending grades of alcohol then 
rinsed in water. The slides were incubated for 15 minutes with 0.6% hydrogen peroxide 
solution for IHC. Slides were rinsed and immersed in 0.1 M citrate buffer (pH 6.0) and 
microwaved for 15 minutes (750 watts) for antigen retrieval. Slides were then 
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immediately cooled under running water and rinsed in PBS. 100 ul of Protein Block was 
added to each slide for 5 minutes. After rinsing with 0.05% PBS/Tween 20 solution for 5 
minutes, the slides were incubated with 100 ul of the primary antibody at 4oC overnight. 
Paraffin sections of lungs from KP mice were stained for CDK9 (Cell Signaling) at a 
1/100 dilution for IF. Following overnight incubation, slides were washed with 0.05% 
PBS/Tween 20 solution.  The sections were then incubated with secondary antibody for 
30 minutes (IHC) or 1 h (IF) at room temperature and again washed three times. The 
sections were developed using the ABC kit (Vector laboratories) before being 
counterstained by haematoxylin for 2 minutes and rinsed in water for 5 minutes for IHC. 
Slides were then dehydrated in ascending grades of alcohol and cleared in 3 changes of 
xylene (IHC). Finally, the sections were mounted using Di-N-Butyle Phthalate in Xylene 
(DPX) mounting solution and covered with a glass coverslip (IHC) or mounted in DAPI 
(ProLong® Golds antifade reagent with DAPI, Invitrogen) (IF). For negative controls, 
duplicate slides from each case were used. These slides were incubated with 100 μl 
antibody diluent instead of primary antibody/secondary antibody. H&E stainings were 
examined by an experienced pathologist (Mona A. El-Bahrawy) who was blinded to the 
study design. 
CDK9 and TTF-1 for human samples were IHC-stained by UCL Hospital Service. 
 
Histological Quantifications. 
Lung metastasis burden (xenograft) was quantified by counting all nodules within a 
central 50x microscopic field. All histopathological analyses were performed by an 
experienced pathologist (Mona A. El-Bahrawy), who was blinded to the study design. 
 
 
3.4.15 Transformation of competent E.Coli 
 
Competent bacteria previously generated in the laboratory were thawed on ice and 5 ul 
of plasmid DNA (stable knockdown constructs) were added followed by further 
incubation on ice for 30 min. Afterwards, a heat-shock was performed at 42 ºC for 90 
seconds and the bacteria were again incubated on ice for 5 minutes. Subsequently, 200 
ul SOC medium were added and the bacteria suspension was incubated at 37 ºC for 60 
minutes. Finally, bacteria were plated onto previously cast LB agar plates containing the 
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respective antibiotic and incubated overnight at 37 ºC. Single clones were picked the 
next day for further expansion of plasmid containing bacteria. 
 
Isolation of plasmid DNA. 
For the preparation of plasmid DNA, 300 ml overnight bacteria cultures were inoculated 
and harvested the next day by centrifugation at 4500 rpm for 30 minutes. The resulting 
pellets were processed using the E.Z.N.A. Plasmid Maxi kit (OMEGA bio-tek) according 
to the manufacturer’s protocol. 
 
 
3.4.16 Animal Experiment 
 
6 to 12-week old female Fox Chase® SCID Beige Mice (Charles River, Germany) were 
injected with 2 x 106 A549-luc cells via the lateral tail vein. After one week all mice were 
imaged for bioluminescence using the Ivis Spectrum (Caliper Life Science). Photons per 
second (Photon Flux) were quantified using the Ivis Spectrum software. Mice with 
established tumour burden were included in the study and randomized into the treatment 
groups (8 mice per group). Subsequently, mice were treated for 4 consecutive days with 
daily i.p. injections of 600 ug SNS-032 (or 300 ug Dinaciclib) (30 mg/KG) and/or 100 ug 
izTRAIL (or 50 ug in the Dinaciclib experiment) (5 mg/KG) or 200 ul Buffer as control. 
After three weeks tumor burden was quantified by bioluminescence imaging. For 
preparation of lung tissue sections, mice were sacrificed according to Guidance on 
Operation of Animals [Scientific Procedures] Act 1986. Lungs were removed, fixed in 
10% formalin for one week and then transferred to 70% ethanol. Paraffin embedding, 
preparation of sections and H&E stainings were performed as part of a histological 
staining service at the National Heart & Lung Institute. H&E stainings were examined 
and quantified by an experienced pathologist (Mona A. El-Bahrawy) who was blinded to 
the study. Tumor burden was quantified as percentage of tumor tissue in the lung. SCID 
beige mice were maintained in individually ventilated cages (IVCs), received autoclaved 
food, water and bedding according to the institutional guidelines under a UK Home 
Office project license. The required risk assessments were obtained for this study. 
KP mice were from Charles River (USA) and were infected following the protocol 
described by Dupage et al. [DuPage et al, 2009]. That optimisation of that protocol is still 
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ongoing in our lab. AdenoCre for infection was purchased by Gene Transfer Vector 
Code from the University of Iowa. 
 
 
3.4.17 In vivo Bioluminescence imaging 
 
Starting on day 1 after cell injection all mice were imaged weekly for bioluminescence. 1 
gram D-luciferin was purchased from Caliper Life Science and solved in DPBS at a final 
concentration of 30 mg/ml and syringe filtered through 0,2 μm. Subsequently, luciferin 
was aliquoted (700 μl) and frozen at -80 °C. To avoid batch-to-batch variability, all 
luciferin used in this study came from the same batch and was only frozen once. Prior to 
imaging, each mouse was anaesthetised by 4% Isofluorane gas and received 100 μl 
subcutaneous injection of 3 mg luciferin per 20 g mouse. For maintenance of 
anaesthesia, Isofluorane dose was reduced to 1.5%. 10 minutes after luciferin injections 
bioluminescence images were acquired using the Ivis Spectrum at 1 minute exposure 
time (Caliper Life Science). Afterwards, mice recovered from anaesthesia in a 37 °C 
heating chamber. Photons per second were quantified using the Ivis Spectrum software. 
 
 
3.4.18 Statistical analysis – Task II 
 
Data were analysed using GraphPad Prism 5 software (GraphPad Software). Statistical 
significance between groups was determined using unpaired Student’s t-test. A p-value 
of <0.05 was considered significant and indicated with *p<0.05, **p<0.01, *** p<0.005 
and **** p < 0.0001. 
 
 
3.4.19 Statistical analysis – Task III 
 
Data were analyzed using GraphPad Prism 5 software (GraphPad Software). Results 
are expressed as means ± SEM. Statistical significance between groups was 
determined using Student’s t-test and/or one-way analysis of variance (ANOVA), 
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followed by the Bonferroni post-test. A p-value of <0.05 was considered significant and 
indicated with **p<0.01 and ***p<0.001. ns = non-significant. 
 
 
3.5 Purification of recombinant murine TRAIL (iz-
mu-TRAIL) – Task II 
 
The purification of iz-mu-TRAIL was adapted and optimised from the protocol for the 
purification of the human version iz-hu-TRAIL which was established in our laboratory 
based on the protocol published by Ashkenazi in 1999 [Ashkenazi et al, 1999]. After 
bacterial lysis, a two step chromatographic purification was applied, first a 
hydroxyapatite column followed by a Ni-NTA (nickel Nitrilotriacetic acid) column, which is 
usually used to purify His-tagged proteins. Even though iz-mu-TRAIL does not contain 
any affinity tag, it seems to bind to the Ni-NTA resin quite efficiently by an unknown 
mechanism. To remove lipopolysaccharides (LPS) from the protein preparations we 
used the detergent triton-X-114 as described below. 
 
Bacterial lysis: 
10 L of bacterial cultures were used for one purification. Lysis took place on ice in 
phosphate based bacterial lysis buffer (100 ml/1 L bacterial culture). 
 
Lysis buffer: 
- 50 mM potassium phosphate buffer (pH = 7.4), 
- 200 mM NaCl, 
- 100 mM KCl, 
- 10% glycerol, 
- 0,5% triton-X-100, 
 add freshly before lysis: 
- 2 mM DTT, 
- 100 µM AEBSF, 
- 5 µM  E-64,  
- 1 µM Pepstatin.  
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When the pellet was nearly dissolved, 5 U/ml of benzonase and 50 ug/ml lysozyme were 
added. This increases the lysis capacity even though the Rosetta TM(DE3) pLysS strain 
already contains an endogenous lysozyme encoded on the pLysS plasmid. For further 
lysis and DNA shearing, the solution was sonified 5 to 6 times (1 min, duty cycle 30, 
output control 40) on ice. In between, the lysate was stirred on ice for 10 to 15 min. The 
lysate can be stored on -20◦C, but is ideally processed freshly. To pellet still unlysed 
bacteria and cell debris, the solution was first centrifuged at 4,600 rpm for 30 min (4◦C) 
and afterwards at 15,000 rpm for 30min (4◦C), to remove the inclusion bodies. The 
lysate can then be stored overnight on ice until the first step of the purification on the 
next day. Before loading onto the column, the solution was filtered with 0.45 um syringe 
filters to remove potentially precipitated protein. 
 
Hydroxyapatite Purification 
Hydroxyapatite (Ca(PO4)3OH)2 is a special form of calcium phosphate that can be used 
as a matrix for chromatographic purification of proteins. Protein binding is facilitated by 
interac- tions of basic amino acids with Ca2+ and acidic and neutral residues with the 
PO3− groups.  
Elution occurs by increasing the phosphate concentration. Hydroxyapatite (type I) with 
40 um particle size was packed in a 100 ml column volume (CV). To maintain protein 
activity throughout the procedure, purification was performed at 4◦C in the cold room. 
Samples and protein containing fractions were kept on ice. All buffers were degassed, 
0.22 um filtered and cooled to 4◦C before the purification. Reducing reagents like DTT 
(dithiothreitol) and β-ME (β-mercaptoethanol) were added freshly to all buffers to prevent 
disulfide bridge formation during the purification. The maximum pressure during the 
whole purification was not higher then 0.3 MPa on the column. 
The hydroxyapatite column was equilibrated overnight with 5 to 6 CV of Hydroxy-Equili 
bration buffer (50 mM potassium phosphate) with 0.2 - 1 ml/min. The filtered bacterial 
lysate was then loaded onto the column at 3 ml/min and the flow-through collected for 
further analysis. The flow rate was then increased to 5 ml/min for all further steps. To 
reduce protein loss in the application volume, the sample container was rinsed twice with 
50 to 100ml of bacterial lysis buffer, which was also applied to the column. To remove 
unbound proteins, contaminants and inactive target protein, the column was washed 
with 3CV of 200 mM potassium phosphate buffer (Hydroxy-Wash buffer). For elution 
4CV of Hydroxy-Elution buffer (400 mM potassium phosphate) were used and 10 ml 
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fractions collected. To analyse protein content of the fractions, every third or second 
fraction was analysed in an SDS-PAGE. The iz-mu-TRAIL containing fractions (typically 
fraction E8-E25) were stored on ice in the cold room overnight for the Ni-NTA purification 
on the next day. 
 
The following buffers were used during the described procedure. 
 
1. Hydroxyapatite equilibration buffer: 
50 mM Potassiumphosphate pH 7,4,          
100 mM NaCl,    
Vacuum filtration (0.22 µm filters) to degas buffer afterwards add:   
0,02% Tween 20. 
Right before purification add 2 mM β-mercaptoethanol. 
2. Hydroxyapatite wash buffer 1: 
200 mM Potassiumphosphate pH 7,4,          
100 mM NaCl.    
Vacuum filtration (0.22 µm filters) to degas buffer afterwards add:  
0,02% Tween 20, 
0.1% Triton x 114.                                          
Right before purification add 2 mM β-mercaptoethanol. 
3. Hydroxyapatite wash buffer 2: 
200 mM Potassiumphosphate pH 7,4,          
100 mM NaCl.    
Vacuum filtration (0.22 µm filters) to degas buffer afterwards add:    
0,02% Tween 20. 
Right before purification add 2 mM β-mercaptoethanol. 
4. Hydroxyapatite elution buffer: 
400 mM Potassium phosphate pH7,4, 
100 mM NaCl. 
Vacuum filtration (0.22 µm filters) to degas buffer afterwards add: 
0,02% Tween 20. 
Right before purification add 2 mM β-mercaptoethanol. 
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Ni-NTA purification 
In the Ni-NTA purification, protein interactions occur due to complexes of the NTA-matrix 
with Ni2+ ions and histidine (His) residues in proteins. In the case of iz-mu.TRAIL, which 
does not contain a His-tag, internal residues, other amino acids or the tertiary structure, 
usually complexing a zinc ion, could contribute to the binding effect. 
The eluates from the hydroxyapatite column containing the target protein were pooled, 
filtered with a 0.22 um syringe filter and loaded onto the Ni-NTA column (100 ml column 
volume) that had been equilibrated with the respective buffer beforehand (for 3-5 CV). 
The flow rate for this column was always 3 ml/min, as it is not possible to run the Ni-NTA 
column with higher pressures. The flow-through was collected for further analysis. The 
same buffer as the equilibration buffer was used to wash the column with 3 CV. A buffer 
containing a low imidazol concentration eluted the purified protein. 
To check for presence of iz-mu-TRAIL, an SDS-PAGE was carried out with a sample of 
every second fraction. The respective fractions were then pooled and dialysed in two 
steps. To remove the imidazol and other buffer constituents in which the protein is 
unstable, it was dialysed in 5 L maintenance buffer (without arginine) overnight and then 
another 24 h in 3 L maintenance buffer in the presence of 0.5 M arginine. The protein 
could then be sterile filtered and the protein content measured at on optical density (OD) 
of 280 nm wavelength in the Nanodrop photometer. As the extinction coefficient of iz-
mu-TRAIL is close to one, the OD280 directly correlates with the amount of protein. The 
protein was then aliquoted and frozen at -80°C. 
 
The following buffers were used during this purification step. 
 
1.  Ni-NTA equilibration buffer pH= 8: 
50 mM Tris –HCl pH 7,4,  
200 mM NaCl,  
100 mM KCl. 
Vacuum filtration (0.22 µm filters) to degas buffer afterwards add: 
10% Glycerol, 
0,5% Triton x100. 
Prior to use add 2 mM β- Mercaptoethanol. 
2.  Ni-NTA wash buffer: 
50 mM Tris- HCl pH 8, 
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200 mM NaCl, 
100 mM KCl, 
15 mM imidazole.  
Vacuum filtration (0.22 µm filters) to degas buffer afterwards add: 
10% Glycerol, 
0,5% Triton x100, 
0.1% Triton x 114, 
Prior to use add 2 mM β-Mercaptoethanol. 
3.  Ni-NTA elution buffer pH= 8: 
20 mM Tris-HCl pH 8, 
300 mM NaCl, 
170 mM imidazole.  
Vacuum filtration (0.22 µm filters) to degas.   
Prior to use add 2 mM β-Mercaptoethanol. 
4. Maintenance buffer I: 
20 mM Tris-HCl pH 8,   
100 mM NaCl, 
0,005% Tween 20. 
Prior to use add 2 mM β-Mercaptoethanol. 
5. Maintenance buffer II: 
20 mM Tris-HCl pH 8, 
100 mM NaCl, 
0,005% Tween 20, 
0.5 M Arginine. 
Prior to use add 2 mM β-Mercaptoethanol. 
 
Proteins that are produced in bacteria are most likely to be contaminated with endotoxin, 
also called LPS, which is a constituent of the bacterial cell wall. If the recombinant 
protein is intended to be used in vivo, it is indispensable to check and remove traces of 
LPS from these preparations. 
Two different strategies of LPS removal were adopted. Firstly, already purified iz-mu-
TRAIL batches were bound onto the hydroxyapatite column and the LPS removed from 
the preparation with a 0.1% triton-X-114 containing buffer. Secondly, further iz-mu-
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TRAIL batches were purified using additional steps with 0.1% triton-X-114 in the wash 
buffer during both purifications. 
 
LPS removal from protein preparation 
For LPS removal of already purified iz-mu-TRAIL batches, the general protocol of 
hydroxyapatite purification was used. The protein was pooled from the aliquots and 
diluted 1:2 into equilibration buffer to facilitate binding to the column. Then, it was bound 
onto the equilibrated column, and 3 CV of the equilibration buffer containing 0.1% (v/v) 
triton-X- 114 were rinsed over the column at 3 ml/min to increase the contact time. To 
remove the triton-X-114 from the column and the protein again, 3 CV of the equilibration 
buffer without triton-X-114 were run over the column at 4.5 ml/min. Afterwards the 
protein was eluted as usual and dialysed in maintenance buffer with arginine for at least 
24 h. This procedure was repeated when the LPS values (determined by LAL test) were 
still too high. In the usual purification protocol in both purification steps an additional 
washing step with wash buffers containing 0.1% triton-X-114 were added. First 3 CV of 
buffer plus triton-X-114 and then at least 3 CV of buffer without triton-X-114 were applied 
before elution. 
 
Comassie staining 
A typical result of the two-step purification is illustrated in figure 9. To analyse the protein 
content of the different fractions, samples were subjected to SDS-PAGE and the 
proteins were stained with coomassie. The first lane of Figure 9A shows a dilution of the 
bacterial lysate containing several different bacterial proteins. A substantial amount of iz-
mu-TRAIL running at approximately 25 KDa was found in this fraction. During the 
application of the lysate, the flow-through containing only very little of the target protein 
was collected. Then, the potassium phosphate concentration was increased in the 
washing buffer to remove contaminating proteins. In later wash fractions, iz-mu-TRAIL 
was leaking from the column. Yet, activity tests of these fractions showed that this 
protein is mostly inactive and probably not properly folded (data not shown). The protein 
was eluted by increasing potassium phosphate concentration. The fractions containing 
iz-muTRAIL were then collected, pooled and applied on the Ni-NTA column (see curly 
brackets in Figure 9A). The purification success on the first column can be judged by 
comparing the first two lanes of Figure 9B. The target protein was concentrated and the 
contaminating proteins from the crude bacterial extract were removed to a great extend. 
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The Ni-NTA column was then used to further reduce contaminations. As it can be seen 
in figure 10 B, a few contaminants were still present in the relevant elution fractions. The 
fractions containing the purified iz-mu-TRAIL were pooled and subjected to dialysis in an 
appropriate maintenance buffer, containing arginine for stabilisation. 
 
 
 
Figure 9Two-steps purification of iz-mu-TRAIL. (a) Hydroxyapatite purification. (b) 
Ni-NTA purification. 10 ul of different purification fractions were supplemented with 
reducing sample buffer and separated by SDS-PAGE in MES buffer. Samples were: 
bacterial lysate (1:10 diluted in sample buffer), preflow (Pre), flow-through (FT), wash 
fractions (W) and elution fractions (E). The target protein iz-mu-TRAIL at a size of 25 
KDa is marked with an arrow. The curly brackets indicate the fractions pooled for the 
second purification step (application) or for dialysis of the final protein. 
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Activity of iz-mu-TRAIL. 
After the purification, we tested whether the newly produced ligand was active. At that 
moment, we did not have any TRAIL-sensitive murine cancer cell line available. 
Therefore, a TRAIL-resistant hepatocellular cancer cell (HCC) line mutated for NRAS 
and p19 was treated with Dinaciclib and iz-mu-TRAIL. 
 
                 
 
Figure 10Iz-mu-TRAIL is active. HCC NRAS/p19 were pre-incubated with Dinaciclib 
[25nM] and treated with iz-mu-TRAIL at the indicated concentrations. After 24 hours cell 
viability was performed. Dina: Dinaciclib. 
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4   Results 
 
4.1   Smac-Mimetic in combination with 
Camptothecin selectively kills pre-malignant 
epithelial cells mutated for KRAS 
 
Since most cancer cells are resistant to SMs as single agents, SM is commonly 
employed as a sensitiser for either death ligands [Li et al, 2004] or chemotherapeutics 
[Probst et al, 2010]. This is the reason why we aimed to find a drug that, in combination 
with SM, triggers a strong cell death. To this end, in collaboration with the Institute of 
Cancer Research (ICR) in London, we performed an in vitro pharmacological screen to 
test the capability of a new SM, named SM83 and designed by our collaborators of the 
CISI Institute [Cossu et al, 2012, Lecis et al, 2012, Manzoni et al, 2012], to induce cell 
death by targeting IAPs in the presence or absence of a library of 3000 pharmacological 
compounds. Interestingly, the drug which best synergises with SM83 was the 
Topoisomerase I inhibitor Camptothecin (CPT) [Tomicic and Kaina, 2013]. 
Importantly, the ideal cancer drug targets are those essential in tumour cells bearing 
oncogenic mutations and cause synthetic lethality with cancer-specific genetic lesions. 
KRAS is frequently mutated in human cancers and therapies currently available to treat 
patients are not efficient. This led us to search for synthetic lethal interactions between 
drug-combinations and proteins frequently mutated in cancer cells with particular focus 
on aberrant activation of KRAS. For this reason, we tested whether the combination of 
SM83 and CPT could be effective in killing cells bearing oncogenic mutation in KRAS. 
Therefore, we selected hTERT-immortalised human mammary epithelial (hTERT-HME) 
cell lines, which were subjected to targeted introduction via homologous recombination 
(Knock-In technology) of a specific point mutation at one KRAS allele (G13D or D13, 
HME KRasG13D) whereas the other allele was still wild-type (WT or +, HME WT) (see 
Paragraph 3.1.1). Biochemical analysis demonstrated that this insertion strongly 
activated KRAS by permanently switching the corresponding mutated protein into the 
GTP-bound active state [Di Nicolantonio et al, 2008]. 
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Surprisingly, we found that SM83 in combination with 1 uM of CPT profoundly induced 
cell death in HME D13/+ contrarily to the parental ones (Figure 11A). Whereas this cell 
death was blocked by pre-treatment with pan-caspase inhibitor zVAD, the necroptosis 
inhibitor Necrostatin-1 (Nec-1) failed to rescue cell death, thus suggesting that HME 
D13/+ died apoptotically (Figure 11B). In line with these results, HME D13/+ cells treated 
with both SM83 and CPT showed a drastic increase in the cleavage of Poly (ADP-
ribose) polymerase (PARP), caspase-3 and caspase-8 (Figure 11C). SM83 was active in 
depleting cIAP1 and cIAP2 as shown in Figure 11D. 
These results demonstrate that the combination of SM83 with CPT and not the same 
drugs as single agents strongly and selectively kills KRAS-mutated normal cells. 
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Figure 11Combined SM83 and CPT induce apoptosis in KRAS-mutated HME cell 
line. (a) HME +/+ and HME D13/+ cells were treated with DMSO, SM83 and CPT at the 
indicated concentrations. Cell viability was quantified by Cell Titer Glo assay after 24 h. 
One representative of four independent experiments is shown. (b) HME +/+ and HME 
D13/+ cells were preincubated with DMSO, z-VAD [50 uM], Nec-1 [20 uM] for 1 h and 
subsequently stimulated with SM83 [100 nM] and CPT [1 uM]. Cell viability was 
determined after 24 h. (c,d) HME +/+ and HME D13/+ cells were treated with DMSO, 
SM83, CPT at the indicated concentrations for 6 h. Cells were lysed and subjected to 
western blotting. (b, c, d) One representative of two independent experiments is shown. 
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4.1.1 Oncogenic KRAS confers sensitivity to SM83 and CPT 
 
The strong cell death of HME D13/+ is exclusively observed in the concomitant presence 
of three factors: mutated KRAS, SM83 and CPT. Firstly, we aimed to address how much 
the KRAS lesion contributes to SM83/CPT-sensitivity. HME D13/+ were then depleted 
for mutated KRAS and treated with SM83 and CPT. As shown in Figure 12A, knock-
down (KD) of mutated KRAS partially rescued SM83/CPT-induced cell death. However, 
we could not exclude that the amount of KRas protein remained after the KD was 
sufficient to compensate the phenotype as shown in Figure 13B, right panel. To further 
test whether mutated KRAS was indeed responsible for SM83/CPT-induced apoptosis, 
HME and another human mammary epithelial cell line MCF10A were transduced with a 
doxocycline (Dox)-inducible lentivector (pInducer20) encoding for either KRasG13D 
(pInducer20 KRasG13D) or control (pInducer20 MOCK). The map of this expression 
vector is shown in Figure 12B. After 48 hours of induction with Dox [250 ng/ml], HME 
and MCF10A pInducer20 KRasG13D nicely expressed hyperactivated KRAS as shown 
in Figure 12C for HME. Strikingly and in line with the results obtained for HME D13/+ 
cells, KRasG13D-induced-expressing cells (HME and MCF10A) showed high sensitivity 
to the combination of SM83 and CPT (Figure 12D and 12E respectively) while MOCK-
induced-expressing cells were not affected. 
Taken together, these data demonstrate that the presence of mutated KRas markedly 
confers high sensitivity to combined SM83/CPT in our models of pre-malignant cell lines. 
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Figure 12 Mutated KRAS confers sensitivity to SM83 and CPT co-treatment. (a) 
HME +/+ and HME D13/+ were transfected with siRNA targeting KRas for 72 h and 
subsequently treated with SM83 [100 nM] and CPT [1 uM]. Cell viability was determined 
after 24 h. (b) Map of the pInducer20 expressing vector. (c) HME pInd MOCK and HME 
pInd KRasG13D were incubated with Dox [250 ng/ml] for 48 hours and subjected to pull-
down (PD) assay for activated Ras (Ras-GTP). Cells were subjected to western blotting. 
HME D13/+ were used as positive control for activated KRas. (d) HME pInd MOCK and 
HME pInd KRasG13D were pre-incubated with Dox [250 ng/ml] for 48 hours and treated 
with SM83 [100 nM] and CPT [1 uM]. Cell viability was determined after 24 h. (e) 
MCF10A pInd MOCK and MCF10A pInd KRasG13D were pre-incubated with Dox [250 
ng/ml] for 48 hours and treated with SM83 [100 nM] and CPT [0,1 uM]. Cell viability was 
determined after 24 h. (a, c, d, e) One representative of two independent experiments is 
shown. pInd: pInducer20. GST-RBD: Ras Binding Domain bound to a GST resin. 
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4.1.2 KRAS-induced upregulation of Noxa sensitises cells to 
SM83/CPT co-treatment 
 
At this point, we demonstrated that the presence of mutated KRAS provides a 
background, which favours SM83/CPT-induced cell death. However, the molecular 
mechanisms engaged by this oncogenic mutation to enhance apoptosis in pre-malignant 
cells still need to be investigated. So far, several groups reported that either mutated 
RAS or DNA damage inducing agents can upregulate pro-apoptotic and downregulate 
anti-apoptotic proteins belonging to Bcl-2 family. More in details, Seamus Martin’s lab 
published that expression of oncogenic HRAS V12 leads to extensive autophagy by 
increasing the expression of Noxa [Elgendy et al, 2011]. Another group demonstrated 
that oncogenic KRAS sensitises colorectal tumour cells to oxaliplatin and 5-fluorouracil 
by upregulating Noxa [de Bruijn et al, 2010]. In line with this, recent studies conducted in 
melanoma cells revealed that the BH3-mimetic ABT-737, in combination with cytotoxic 
drugs that induce Noxa or repress Mcl-1 protein levels, may be an attractive therapeutic 
strategy [Lucas et al, 2012]. In this last example KRas mutation is not involved, however, 
the reports mentioned above suggest taking into consideration that the balance among 
pro- and anti-apoptotic factors associated to mitochondria might be modulated by 
oncogenic lesions in cancer cells. 
Therefore, we aimed to study whether the presence of KRasG13D in HME cells 
correlated with increased expression of Noxa, thus leading to more sensitisation in the 
presence of SM83 and CPT. In order to answer this question we firstly analysed Noxa 
protein levels in pre-malignant cell lines at basal conditions and, as expected, levels of 
Noxa in HME D13/+ were higher than in HME +/+ as shown in Figure 13A, left panel. In 
line with this finding, either HME or MCF10A pInducer20 KRasG13D, upon Dox 
treatment, expressed mutated KRAS and this was associated with robust upregulation of 
Noxa protein levels already after 48 hours of KRAS-induction (Figure 13A, right panel). 
Both HME +/+ and Dox-treated HME/MCF10A pInducer20 MOCK cells failed to induce 
Noxa expression (Figure 13A, right panel) and survived upon SM83/CPT combination as 
previously shown in Figure 12D and 12E, confirming that the increased expression of 
Noxa and cell death observed under these conditions tightly correlated with the 
presence of mutated KRAS. To address whether the upregulation of NOXA driven by 
mutated KRAS was responsible for SM83/CPT-induced cell death, we knocked-down 
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Noxa in HME D13/+ (KI) and treated them with the combination. As the viability assay in 
Figure 13B, left panel illustrates, the full loss of Noxa (Figure 13B, right panel) nearly 
totally rescued cell death. 
Overall, these data suggest that expression of Noxa is tightly regulated by mutated KRas 
and plays a role in the KRas pathway to promote cell death upon SM83 and CPT 
treatment. 
 
 
 
Figure 13Noxa expression increases in KRAS-mutated HME favouring 
SM83/CPT-induced cell death. (a, left panel) HME +/+ and HME D13/+ were lysed and 
subjected to western blot. (a, right panel) HME/MCF10A pInd MOCK and pInd 
KRasG13D were incubated with Dox [250 ng/ml] for the indicated time [hours] and 
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subjected to western blotting. (b, left panel) HME +/+ and HME D13/+ were transiently 
transfected with siRNA targeting NOXA for 48 h and subsequently treated with SM83 
[100 nM] and CPT [1u M]. Cell viability was determined after 24 h. (b, right panel) HME 
D13/+ were transfected with siRNA targeting KRas and Noxa for 48 h and subsequently 
subjected to western blot analysis to verify the KD efficiency. One representative of two 
independent experiments is shown. 
 
 
4.1.3 KRAS-induced upregulation of Noxa is mediated by MAPK 
signaling axis. 
 
Our evidences support the idea that mutated KRas enhances SM83/CPT-induced cell 
death via markedly upregulation of Noxa. However, which specific effectors within KRas 
pathway are directly involved in controlling expression of Noxa have not been identified 
yet. Notoriously, KRas activates multiple critical effectors such as MEK/ERK, PI3K/AKT, 
NF-kB pathways in order to drive tumour development and maintenance [Montagut and 
Settleman, 2009]. Therefore, we focused on exploring whether KRasG13D-induced 
expression of Noxa required MEK/ERK- and/or PI3K/AKT-signaling and whether these 
intermediate players would, in turn, affect SM83/CPT-induced cell death. First, HME 
D13/+ cell lines and their WT counterparts were pre-treated with two different inhibitors 
of the upstream ERK-activating kinase MEK, PD98059 and UO126 both of which 
approximately fully rescued SM83/CPT-induced cell death (Figure 14A) and, intriguingly, 
reduced KRasG13D-mediated overexpression of Noxa (Figure 14B). Conversely, pre-
treatment with AKT inhibitor Triciribine and PI3K inhibitor LY294002 did not exert any 
evident effect on SM83/CPT-induced cell death (Figure 14A) and did not alter Noxa 
levels (Figure 14B), thus suggesting that PI3K/AKT, the other side of the KRas 
downstream signalling, is not responsible for KRAS-driven sensitivity to SM83 and CPT. 
To further confirm that the effectors ERK1/2 downstream mutated KRas are dispensable 
for Noxa modulation and given that the inhibitors might have possible off-target effects, 
we transiently silenced ERK1 and ERK2 and checked for Noxa protein levels. As clearly 
shown in Figure 14C, Noxa protein levels were, as expected, decreased in the absence 
of KRas. Intriguingly, selective loss of ERK2 itself downregulated Noxa. We then 
wondered whether SM83 and CPT as single agents or in combination would affect 
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ERK1/2 phosphorylation-status, thus influencing KRas-mediated activation of these 
MAPKs. Under basal conditions the amount of phosphorilated-ERK1/2 (pERK1/2) in 
HME D13/+ cell line is higher than in the WT counterpart, but SM83 increased pERK1/2 
only modestly, while CPT either alone or combined with SM83 even decreased, thought 
moderately, pERK1/2.  
In conclusion, we propose a model where downstream oncogenic KRas, the MAPK 
ERK2 is the main responsible for upregulation of Noxa, thus favouring the pro-apoptotic 
response upon treatment with SM83 plus CPT. 
 
 
 
Figure 14MAPK ERK2 is the KRas main effector responsible for Noxa-induction. 
(a) HME +/+ and HME D13/+ cell lines were pre-incubated with the following inhibitors 
PD98059, UO126, Triciribine and LY294002 at the indicated concentrations for 2 hours 
and subsequently treated with SM83 [100 nM] and CPT [1 uM]. Cell viability was 
quantified after 24 h. One representative of three independent experiments is shown. (b) 
HME +/+ and HME D13/+ cell lines were treated with the following inhibitors PD98059, 
UO126, Triciribine and LY294002 at the indicated concentrations for 2 hours and 
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subsequently subjected to western blotting. (c) HME +/+ and HME D13/+ were 
transiently transfected with the indicated siRNAs for 72 hours and subsequently 
subjected to western blotting. (d) HME +/+ and HME D13/+ cells were treated with 
DMSO, SM83, CPT and the combination at the indicated concentrations for 6h. Cells 
were lysed and subjected to western blotting. (b, c, d,) One representative of two 
independent experiments is shown. 
 
 
4.1.4 TNF/TNF-Rs system partially cooperates to SM83/CPT-
induced cell death in KRAS-mutated cells 
 
Beyond the fact that KRas can regulate NF-kB signaling [Montagut and Settleman, 
2009], it is known that SM-mediated downregulation of cIAP1/2 leads to the stabilisation 
of NIK and NF-kB-induced transcription of TNF which, in turn, kills cells in an autocrine 
fashion [Petersen et al, 2007].  
Therefore, we hypothesised that expression of TNF might be induced by SM83 in a cell 
system where the presence of mutated KRAS might already positively impact on 
endogenous/secreted TNF amount and/or on the endogenous TNF-Rs expression at the 
cell surface, thus facilitating cell death upon combined SM83 and CPT. To this end, we 
pre-treated HME WT and HME KRasG13D with Infliximab (IFX), a monoclonal antibody 
targeting human TNF as well as Enbrel, thereby blocking the interaction between TNF 
and its cognate receptors. As a result, both IFX (Figure 15A) and Enbrel (Figure 15B) 
partially rescued SM83/CPT-induced cell death in KRAS-mutated HME.  
Therefore, we can conclude that TNF is one of the mediators of cell death, nevertheless, 
whether KRAS-mutated cells, compared to the WT counterparts are characterised by 
high basal levels of TNF or by high surface expression of TNF-Rs still needs to be 
clarified. 
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Figure 15TNF/TNF-R contribute to SM83/CPT-induced cell death in KRAS-
mutated HME cell line. HME +/+ and HME D13/+ cell lines were pre-incubated with 
either IFX [10 ug/ml] (a) or Enbrel [10 ug/ml] (b) for 1 hour and subsequently treated with 
SM83 [100 nM] and CPT [1 uM]. Cell viability was quantified after 24 h. One 
representative of three independent experiments is shown. 
 
 
4.1.5 Sensitivity to SM83/CPT is KRAS-independent in a panel of 
colorectal cancer cell lines. 
 
We then investigated whether the findings described with SM83 and CPT-treated HME 
KRasG13D are true also for cancer cells carrying the same mutation. 
Therefore, we hypothesised that colorectal cancer cells containing oncogenic KRAS 
would be more sensitive to SM83/CPT than their WT counterparts. For this aim, we 
chose a panel of isogenic colorectal cancer (CRC) cell lines: SW48 and Lim1215 bear 
either KRAS-WT alleles (+/+) or one allele of the two is mutated (D13/+) by KI 
technology; HCT116 and DLD-1 bear either one allele mutated (D13), which can be 
accompanied by the knock-out (KO) of the wild-type resulting in the D13/- genotype or 
one allele wild-type (+) and the other one is null (-) resulting in the +/- genotype. Notably, 
after the treatments, SW48 (Figure 16A), Lim1215 (Figure 16B) and HCT116 (figure 
16C) were sensitive to combined SM83 and CPT independently of the mutational status 
of KRAS. In particular, even at 10 uM CPT the combination with SM83 did not kill more 
than 50% of the cells. Conversely, DLD-1 showed a quite different response from the 
others (Figure 16D): DLD-1 bearing mutated KRAS was more resistant than DLD-1 
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which followed targeted disruption of the D13 (+/-) and, overall, this cell line was 
completely resistant to the combination. 
 
 
 
Figure 16Response to SM83/CPT does not depend on the mutational status of 
KRas in a panel of isogenic CRC cell lines. SW48 +/+ and SW48 D13/+ (a), Lim1215 
+/+ and Lim1215 D13/+ (b), HCT116 +/- and HCT116 D13/- (c) and DLD-1 D13/- and 
DLD-1 +/- (d) cell lines were treated with DMSO and the combination of SM83 and CPT 
at the indicated concentrations. Cell viability was quantified after 24 h. One 
representative of three independent experiments is shown. 
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4.1.6 Noxa levels do not differ on the basis of KRAS mutational 
status in CRC cell lines 
 
We then asked why mutation of KRAS is not associated with sensitivity to SM83 and 
CPT. Since we found that Noxa-mediated cell death in human normal cells was 
KRasG13D dependent, we then hypothesised that colorectal cancer cells bearing 
oncogenic KRas did not upregulate Noxa, thereby resulting in a similar outcome in 
presence of WT and mutated KRAS. As Figure 17 shows, Noxa protein levels were not 
altered by the presence of KRasG13D even in the absence of the WT one (D13/- 
genotype) i.e. HCT116 and DLD-1. 
 
To summarize, in normal immortalized cell lines (HME and MCF10A) the mutation of 
KRAS confers sensitivity to combination therapy, while in colorectal cancer cell lines it 
does not. In conclusion, the sensitivity to treatment observed in colorectal cancer cell 
lines is KRasG13D-independent, while the robust synergism detected in HME and 
MCF10A is KRasG13D-dependent and is triggered by MAPK ERK2-mediated 
upregulation of Noxa. 
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Figure 17Noxa protein levels are not upregulated by the presence of mutated 
KRAS. SW48 +/+ and SW48 D13/+ (a), Lim1215 +/+ and Lim1215 D13/+ (b), HCT116 
+/- and HCT116 D13/- (c), DLD-1 D13/- and DLD-1 +/- (d) cell lines were treated with 
DMSO, SM83, CPT and the combination at the indicated concentrations for 6 h. Cells 
were lysed and subjected to western blotting. One representative of two independent 
experiments is shown. (*) indicates the antibody specificity. 
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4.2   Cyclin Dependent Kinase 9 inhibition 
overcomes TRAIL-resistance in KRAS-mutated 
non-small cell lung cancer 
 
TRAIL can induce apoptosis in many cancer cells without causing toxicity in vivo 
[Ashkenazi et al, 1999, Walczak et al, 1999]. Since most primary human cancers are 
TRAIL-resistant [Todaro et al, 2008], future TRAIL-based therapies will require the 
addition of sensitising agents that remove crucial blocks in the TRAIL apoptosis 
pathway. PI3K are components of signalling pathways which promote tumour growth, 
migration, invasion and metastasis. Consequently, PI3K inhibitors have emerged as a 
novel class of agents currently used in clinical trials as single agents or as potential 
TRAIL-sensitiser candidates. 
Intriguingly, recently data published by Johannes Lemke [Lemke et al, 2014a] show that 
PIK-75, an inhibitor of the p110α isoform of PI3K, is an exceptionally potent TRAIL-
apoptosis sensitiser. Surprisingly, PI3K inhibition is not responsible for this activity. A 
kinome-wide in vitro screen reveals that PIK-75 strongly inhibits a panel of 27 kinases. 
Within this panel, CDK9 has been identified as responsible for TRAIL-resistance of 
cancer cells. Indeed, CDK9 inhibition by SNS-032, a small molecule inhibitor already in 
clinical trials [Conroy et al, 2009], could strongly sensitise tumour cells to TRAIL-induced 
apoptosis. Mechanistically, SNS-032-mediated CDK9 inhibition induced transcriptional 
suppression of cFlip and Mcl-1, thus facilitating cell death at DISC- and mitochondria-
levels as represented in Figure 18. 
There are several CDKs inhibitors currently used in clinical trial. We therefore evaluated 
a novel combinatorial therapy consisting of TRAIL and the clinically used CDK9 inhibitor 
SNS-032. Despite it inhibits CDK2, CDK7 and CDK9 among other CDKs and kinases, its 
inhibitory capacity is about 10-fold selective for CDK9 (the half maximal inhibitory 
concentration IC50 = 4 nM) over the others. Furthermore, this combination is not 
hepatotoxic at the killing concentrations of the co-treatment. 
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Figure 18Proposed model of the molecular mechanisms of CDK9 inhibition-
mediated TRAIL sensitisation. 
 
 
4.2.1 Combination of TRAIL and SNS-032 kills a panel of human 
NSCLC cell lines 
 
As published by Lemke et al., TRAIL and SNS-032 were highly efficient in killing A549, a 
human non-small cell lung cancer cell line. To investigate whether this co-treatment may 
be applicable more broadly, we tested the combination on a panel of TRAIL-resistant 
NSCLC cell lines [Kumar et al, 2012]. Upon 10 ng/ml of TRAIL together with 300 nM of 
SNS-032, all cell lines tested were potently sensitised (Figure 19). 
Therefore, we demonstrate that SNS-032/TRAIL combination can be extended to a 
broad range of KRAS-mutated NSCLC cell lines. 
CDK9i 
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Figure 19Human NSCLC cell lines are sensitive to combined SNS-032 and TRAIL. 
Seven different NSCLC cell lines were pre-incubated with SNS-032 [300 nM] for 1 h and 
subsequently stimulated with izTRAIL (10 ng/ml). Cell viability was quantified after 24 h. 
The graph represents means of three independent experiments ± SEM; individual dots 
represent means of three experiments of one cell line. *** P < 0.0005; Student’s t-test. 
 
 
4.2.2 TRAIL combined with CDK9 inhibition eradicates 
orthotopic lung tumours in vivo 
 
Having demonstrated the efficacy of TRAIL with SNS-032 in vitro, we evaluated whether 
it is active also in vivo. To this end, we induced lung tumours via tail vein injection of 
A549 cells stably expressing luciferase (A549-luc). After seven days, mice were 
randomised to obtain similar amounts of tumour burden in each group and subsequently 
a four-day treatment regime was applied with either vehicle, TRAIL, SNS-032 or the 
combination of SNS-032 and TRAIL (Figure 20A). Whereas TRAIL treatment alone had 
a slight growth inhibitory effect, and SNS-032 only marginally affected lung tumour 
burden, combined treatment with TRAIL and SNS-032 completely eradicated 
established lung tumours in most mice as determined by in vivo bioluminescence 
imaging (Figure 20B). Furthermore, histopathological inspection of lung sections 
confirmed the results obtained by in vivo imaging (Figure 20C). Strikingly and in line with 
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the bioluminescence data, 7 out of 8 mice receiving TRAIL combined with SNS-032 
were histologically tumour-free after the treatment cycle. 
Therefore, the novel treatment strategy of TRAIL and CDK9 inhibition may lead to the 
design of highly powerful and cancer-selective therapeutics. 
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Figure 20TRAIL/SNS-032 co-treatment eradicates orthotopic lung tumours in 
vivo. (a) Experimental treatment schedule is shown. (b) Tumour burden was quantified 
by bioluminescence imaging (Photon Flux) one week after injection of 2x106 A549-Luc 
cells and three weeks after treatment. Dots represent individual mice (n=8 per group) +/- 
SEM. Three representative mice from each group are shown. (c) Paraffin sections of 
lungs from all mice were stained with H&E and subjected to microscopical analysis 
quantifying the percentage of total lung area occupied by tumour tissue. Dots represent 
lungs from individual mice, (n=8 per group) +/- SEM. Representative histological images 
are shown (arrows indicate tumour tissue). * p < 0.05; ** p < 0.01, *** p < 0.0005, 
Student’s t-test. 
 
 
4.2.3 Establishment of autochthonous lung tumours that have a 
tumour supporting microenvironment 
 
The strength of this novel combination has been evaluated in an orthotopic lung tumour. 
However, the injection of a human NSCLC cell line into an immunodeficient mouse does 
not closely resemble human NSCLC dynamics. Therefore, we next focused on analysing 
the efficacy of CDK9 inhibition in combination with TRAIL in an autochthonous mouse 
model where the mouse is genetically engineered to develop NSCLC that mimics the 
genetic and histophatological features of the human disease [Meuwissen and Berns, 
2005]. In principle, autochthonous tumours arise from few somatic cells that, upon Cre-
recombinase delivery, become transformed in their natural location, surrounded by a 
normal tissue microenvironment [Frese and Tuveson, 2007]. As shown in Figure 21, the 
mouse genome is engineered to contain LoxP DNA elements, ‘flox’, that either surround 
exons critical to a tumour suppressor gene or surround a synthetic ‘stop’ element, ’Lox-
Stop-Lox’ (‘LSL’), inserted in front of an oncogene. LoxDNA elements are under the 
control of Cre-recombinase that, once delivered to the appropriate cell type, can turn-off 
tumour suppressor genes or turn-on oncogenes, thus generating the tumour [Frese and 
Tuveson, 2007]. 
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Figure 21Genetically controlled events in a mouse model of lung cancer. [DuPage 
et al, 2009] 
 
Common mutations in NSCLC are activating mutation in KRAS (10-30%) and loss of 
function in p53 (50-70%) [Herbst et al, 2008]. Tyler Jacks’s lab generated an oncogenic 
mutation in KRAS, G12D in the endogenous locus of the gene. Then, a LSL cassette 
was engineered into the first intron of the KRAS gene (K-RasLSL-G12D), thereby preventing 
the expression of the mutant KRAS allele until the stop elements are removed by the 
activity of Cre recombinase [DuPage et al, 2009]. Since the cassette creates a null allele 
and given that KRAS null mice are embrionically lethal, mice can only be heterozygous 
for the K-RasLSL-G12D allele [Johnson et al, 1997]. To more recapitulate the p53 loss of 
function mutations, Tyler Jacks’s lab generated a conditional point mutation version of 
p53, R172H under the control of LSL (p53LSL-R172H) as described for KRas [DuPage et al, 
2009]. 
To summarize, in order to develop NSCLC in mice, Cre recombinase needed to be 
virally delivered to the lungs, thus sporadically allowing the cells to express mutant K-
Ras and p53 alleles. To this end, mice had to inhale adenoviruses engineered to 
express Cre (Ad-Cre) either by intranasal (IN) instillation (Figure 22) or intratracheal (IT) 
intubation as described in details by Tyler Jacks [DuPage et al, 2009]. 
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Figure 22Intranasal infection technique. [DuPage et al, 2009] 
 
For our study, we decided to employ the K-RasLSL-G12D/+ (K) and p53LSL-R172H/+ (P), KP 
conditional mouse model of NSCLC where the IN delivery method was chosen to 
introduce Ad-Cre according to the Tyler Jacks’s method. The first experiment aimed to 
understand how many weeks after Cre recombinase infections were necessary to 
assure the development of the tumour. Mice were then sacrificed at 8, 12 and 16 weeks 
after Cre infection. Therefore, based on the amount of tumour burden detected by the 
histology, we set out that 12 weeks might be the mouse-age to start the treatment with 
either vehicle, TRAIL, CDK9 inhibitor or the combination. Yet, the optimisation of the 
protocol of infection and the treatment schedule are still ongoing. 
 
 
 
Figure 23Experimental schedule of Ad-Cre-mediated growth of NSCLC in KP 
mice. Mice were IN-infected with Ad-Cre. 8-, 12- and 16-weeks-old mice were sacrificed 
and paraffin sections of lungs from all mice were stained with H&E. The top left panel 
shows the genotype of mice used in this study. 
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Murine tumours derived from the KP mouse model were supposed to be treated with a 
recombinant murine form of izTRAIL (iz-mu-TRAIL). Therefore, a highly active form of 
murine TRAIL was generated and from here it is named izTRAIL. 
Interestingly, a database search revealed that the extracellular domain of murine TRAIL 
is only a few amino acids longer than its human homologue. The cloning of iz-mu-TRAIL 
was already performed in our lab. However, purification of iz-mu-TRAIL was essential to 
produce a high amount of the ligand to perform both in vitro and in vivo experiments. 
Purification method is described in details in Matherial & Methods chapter, Paragraph 
3.5.  
 
 
4.2.4 Dinaciclib-mediated CDK9-inhibition combined with TRAIL 
kills murine NSCLC cell lines while SNS-032 does not 
 
So far, in vitro and in vivo experiments were performed by using SNS-032 as CDK9 
inhibitor. Since this molecule is able to specifically downregulate the human form of 
CDK9, we could not employ SNS-032 to test this combination either in murine NSCLC 
cell lines or in the new established autochthonous mouse model. Therefore, we chose to 
employ another CDK9 inhibitor, Dinaciclib. 
Dinaciclib (MK-7965, formerly SCH7277965) is a novel, potent, small-molecule inhibitor 
of CDK1, CDK2, CDK5 and CDK9 with IC50 values in the 1 nM to 4 nM range, and 
inhibits CDK4, CDK6, and CDK7 at IC50 values from 60 nM to 100 nM  range [Parry et 
al, 2010, Paruch et al, 2010]. A first-in-human phase I dose escalation study of Dinaciclib 
shows that its initial bioactivity and the observed disease stabilization support further 
evaluation as a treatment option for patients with advanced solid malignancies 
[Nemunaitis et al, 2013]. Importantly, it has been reported that Dinaciclib has direct anti-
leukemia cytotoxicity, but effects are of short duration, suggesting that it needs to be 
combined with chemotherapy or other novel agents [Gojo et al, 2013]. In line with this 
findings, it has been recently conducted a phase II randomised clinical study where 
Dinaciclib does not exert any antitumour activity as monotherapy in patients with 
advanced NSCLC [Stephenson et al, 2014]. 
We therefore proposed to evaluate the anticancer activity of Dinaciclib in combination 
with TRAIL in our model of NSCLC. We firstly compared the effect of Dinaciclib to SNS-
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032 on the inhibition of murine CDK9. To this end, 802T4, a murine NSCLC cell line 
derived from KP mouse model, was treated with either Dinaciclib or SNS-032. Strikingly, 
western blot analysis for Ser2 Phosphorilation of RNA Pol II revealed that 25 nM of 
Dinaciclib were sufficient to completely inhibit murine CDK9 within 6 hours while SNS-
032 did not have any effects (Figure 24A). To investigate whether this novel CDK9 
inhibitor was efficient in synergising with TRAIL, we treated 802T4 cell line with the 
combination and immediately after 24 hours, 100 ng/ml of iz-mu-TRAIL almost 
completely killed these cells in combination with 100 nM Dinaciclib (Figure 24B). As 
expected and in line with the western blot data showed in Figure 24A, 802T4 were 
resistant even at 500 nM of SNS-032 in combination with TRAIL. 
Hence, we demonstrate that Dinaciclib is active in inhibiting murine CDK9 and sensitises 
murine NSCLC cell lines to TRAIL-induced cell death. Accordingly, Dinaciclib can be 
considered as a preferential CDK9 inhibitor to be employed in our next experiments. 
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Figure 24Dinaciclib inhibits murine CDK9 and sensitises 802T4 to TRAIL-induced 
cell death.  (a) 802T4 cells were treated with SNS-032 or Dinaciclib at the indicated 
concentrations for 6 h. Cells were lysed and subjected to western blotting. (b) 802T4 
cells were pre-incubated with Dinaciclib [100 nM] for 1h and subsequently stimulated 
with izTRAIL at the indicated concentrations. Cell viability was quantified after 24 h. (c) 
802T4 cells were pre-incubated with SNS-032 [500 nM] for 1 h and subsequently 
stimulated with izTRAIL at the indicated concentrations. Cell viability was quantified after 
24 h. One representative of three independent experiments is shown. 
  
84 
 
4.2.5 Dinaciclib sensitises human NSCLC to TRAIL-induced 
apoptosis in vitro 
 
Despite Dinaciclib was employable in the autochthonous mouse model, its effects on 
inhibiting human CDK9 and on killing human NSCLC cell lines in combination with iz-hu-
TRAIL needed to be tested. For this reason, A549 were treated with increasing doses of 
Dinaciclib and 25 nM concentration was enough to prevent Ser2 phosphorilation of RNA 
Pol II after 6 hours, while SNS-032 needed 10-fold more to do so (Figure 25A). Notably, 
25 nM Dinaciclib was sufficient to kill A549 in combination with 10 ng/ml of TRAIL as 
shown in Figure 25B while it was previously shown by Lemke et al. that these cells 
needed 300 nM of SNS-032 to obtain the same effect. Furthermore, we demonstrated 
that A549 died apoptotically upon Dinaciclib and TRAIL co-treatment; in fact, cleaved-
caspases together with cleaved-PARP and tBid are detectable only when TRAIL was 
added to Dinaciclib (Figure 25C). Moreover, this novel CDK9 inhibitor combined with 
TRAIL was also active in killing a panel of human NSCLC cell lines as well as SNS-032 
as shown below (Figure 25D). 
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Figure 25Dinaciclib inhibits human CDK9 and sensitises A549 cells to TRAIL-
induced apoptosis in vitro. (a) A549 cells were treated with SNS-032 or Dinaciclib at 
the indicated concentrations for 6 h. Cells were lysed and subjected to western blotting. 
(b) A549 cells were pre-incubated with SNS-032 for 1 h and subsequently stimulated 
with izTRAIL at the indicated concentrations. Cell viability was quantified after 24 h. (c) 
A549 cells were pre-incubated with Dinaciclib [100 nM] for 1 h and subsequently 
stimulated with izTRAIL [100 ng/ml] for the indicated time points. Cells were lysed and 
subjected to western blotting. (d) Six different NSCLC cell lines were pre-incubated with 
SNS-032 [100 nM] for 1 h and subsequently stimulated with izTRAIL (10 ng/ml). Cell 
viability was quantified after 24 h. The graph represents means of three independent 
experiments ± SEM; individual dots represent means of three experiments of one cell 
line. **** P < 0.0001; Student’s t-test. (*) indicates the cleaved form. One representative 
of three independent experiments is shown. 
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4.2.6 TRAIL combined with Dinaciclib eradicates orthotopic lung 
tumours in vivo 
 
Finally, to evaluate the effect of Dinaciclib and TRAIL in an orthotopic xenograft in vivo, 
lung tumours were induced via tail vein injection of A549-luc. The experiment was 
carried out as shown in Figure 20A. Photon flux images and the hystopathological 
analysis showed that TRAIL alone already had an effect on tumour regression while 
Dinaciclib alone did not (Figure 26). However, in mice treated with the combination there 
was no sign of tumour. 
Therefore, Dinaciclib in combination with TRAIL was effective even towards human 
NSCLC in vivo. 
 
                                   
 
Figure 26 Combination of Dinaciclib and TRAIL eradicates orthotopic lung 
tumours in vivo. Tumor burden was quantified by bioluminescence imaging (Photon 
Flux) one week after injection of 2x106 A549-Luc cells and three weeks after treatment. 
Dots represent individual mice (n=8 per group) +/- SEM. Three representative mice from 
each group are shown. ** p < 0.01; *** p < 0.0005, Student’s t-test. 
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4.2.7 Not all murine NSCLC cell lines are sensitive to combined 
TRAIL and Dinaciclib 
 
We next examined whether TRAIL in combination with Dinaciclib was active in killing 
several murine NSCLC cell lines as 802T4. We then treated two murine NSCLC cell 
lines 394T4 and 482T1, together with 802T4 with Dinaciclib at 100 nM and an escalation 
dose of izTRAIL up to 1 ug/ml. After 24 hours, whereas 802T4 cells were, as expected, 
strongly sensitive to Dinaciclib and TRAIL (Figure 27A) confirming the results shown in 
Figure 24B, 394T4 were slightly sensitive only at high doses of TRAIL (Figure 27B) and 
482T1 were resistant even at 1 ug/ml of TRAIL (Figure 27C). 
This finding indicates that Dinaciclib/TRAIL co-treatment may not be efficient in killing all 
murine NSCLC cell lines, thus anticipating that the employment of this combination in an 
autochtonous mouse models may need the addition of a sensitising agent(s). 
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Figure 27Treatment with both TRAIL and Dinaciclib does not have high cytotoxic 
activity in 394T4 and 482T4 cell lines. (a) 802T4, (b) 394T4, (c) 482T1 cell lines were 
pre-incubated with Dinaciclib [100 nM] for 1 h and subsequently stimulated with iz-mu-
TRAIL at the indicated concentrations. Cell viability was quantified after 24 h. One 
representative of three independent experiments is shown. 
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Therefore, we evaluated the possibility to add a further agent in order to overcome the 
resistance to Dinaciclib and TRAIL engaged by some NSCLC cell lines. Since SMs are 
known to be potent TRAIL sensitisers [Li et al, 2004], we pre-treated 394T4 (Figure 28A) 
and 482T1 (Figure 28B) with SM83 at 100 nM and then with izTRAIL. We also included 
802T4 (Figure 28C) even though they are already sensitive to the combination to check 
whether SM83 can further sensitise to TRAIL/Dinaciclib co-treatment. The results 
obtained from this experiment showed that SM83 did not further enhance TRAIL-induced 
apoptosis. 
 
 
 
Figure 28SM83 does not synergise with TRAIL. (a) 394T4 (b) and 482T4 (c) 802T4 
cell lines were pre-incubated with Dinaciclib [100 nM] for 1 h and subsequently 
stimulated with SM83 [100 nM] and izTRAIL at the indicated concentrations. Cell viability 
was quantified after 24 h. One representative of three independent experiments is 
shown. 
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4.2.8 CDK9 is overexpressed in NSCLC 
 
SNS-032- or Dinaciclib-mediated CDK9 inhibition represents our proposed strategy to 
overcome TRAIL resistance in NSCLC. We then asked whether this protein might be 
overexpressed selectively in NSCLC thus providing a strong rationale of targeting CDK9 
in the treatment of this tumour. 
Therefore, we performed immunofluorescence for CDK9 on the lungs of 16-weeks-old 
mice from the KP model together with hematoxylin and eosin to identify tumour areas. 
As shown in Figure 29A, tumours delimited by the white line were CDK9 positive. In line 
with these in vivo data, tumour biopsies from NSCLC patients overexpressed CDK9, 
thus supporting the idea that CDK9 might be considered as a biomarker in clinic in order 
to study this newly Dinaciclib-based targeted therapeutic strategy. To address whether 
CDK9 positivity in the human samples is tumour-specific, the biopsies were stained also 
for TTF-1, a human marker for lung adenocarcinoma by immunohistochemistry (IHC) as 
shown in Figure 29B. High positivity for CDK9 is exclusively related to TTF-1 positive 
areas, thus suggesting that combined TRAIL/CDK9 inhibition treatment could be 
combined to TRAIL-based therapy. 
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Figure 29CDK9 is overexpressed in murine and human NSCLC. (a) Paraffin 
sections of lungs from 16-weeks-old mice were stained with H&E and with CDK9 by 
immunofluorescence. The white line defines the area of the tumour. (b) Biopsies from 
three representative NSCLC patients were stained for H&E, CDK9 and TTF-1. 
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4.3   Endogenous TRAIL/TRAIL-R2 complex 
promotes metastasis progression in KRAS-
mutated cancers via Rac-1/PI3K signaling axis 
 
TRAIL can selectively kill tumour cells in vivo [Ashkenazi et al, 1999, Walczak et al, 
1999]. These findings have initiated the development of TRAIL and other TRAIL-R 
agonists for clinical application as novel cancer therapeutics [Lemke et al, 2014b]. More 
recent studies have however revealed that many tumour cell lines and, importantly, the 
majority of primary tumours are resistant to TRAIL-induced apoptosis [Koschny et al, 
2007, Todaro et al, 2008]. Hence, besides inducing apoptosis, exogenous TRAIL has 
also been shown to activate non-apoptotic signaling. These findings highlight potential 
risks of a TRAIL-based therapy as a single agent for patients with TRAIL-resistant and/or 
KRAS-mutated cancers. Furthermore, cancer cells usually do not down-regulate TRAIL-
R suggesting a biological role of this receptor favouring cancer progression In 
accordance to this hypothesis, many cancers even upregulate TRAIL-Rs, and therefore 
we hypothesised the existence of a yet unknown cancer-beneficial role of the 
endogenous TRAIL/TRAIL-R system. TRAIL-Rs and TRAIL are often highly expressed 
in renal, breast, metastatic head and neck, NSCLC and PDAC with the latter almost 
always harboring oncogenic KRAS mutations [Elrod et al, 2010, Ganten et al, 2009, 
Macher-Goeppinger et al, 2009, Sanlioglu et al, 2007a, Sanlioglu et al, 2007b]. 
 
Within Silvia von Karstedt’s PhD project, preliminary data from an experimental lung 
metastasis model in vivo show that depleting TRAIL-R2 or blocking TRAIL by TRAIL-R2-
Fc reduces lung metastasis. However, proliferation, cell death, vascularization and 
anoikis are not affected. Furthermore, immunosuppressed mice transplanted with human 
pancreatic cancer cells depleted for TRAIL-R2 develop fewer or no liver metastasis, 
whilst primary tumour growth is not influenced, suggesting that a pro-metastatic process 
is prevented by disabling the endogenous TRAIL/TRAIL-R2 system (von Karstedt et al, 
submitted). 
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4.3.1 Endogenous TRAIL-R2 drives cell autonomous migration 
and invasion in KRAS-mutated tumour cell lines 
 
It has been previously published that treatment with TRAIL can induce migration in 
KRAS-mutated but not KRAS-wild type (WT) colorectal cancer cell lines [Hoogwater et 
al, 2010]. Therefore, we hypothesised that TRAIL/TRAIL-R2 control KRAS-mutated cells 
migration. To address this point, we performed migration assays in isogenic colon 
carcinoma cell lines with mutated or WT KRAS [Shirasawa et al, 1993], in the presence 
or absence of endogenous TRAIL-R2. As expected, KRAS-mutated cells showed 
increased migration capacity relative to their KRAS-WT counterparts (Figure 30A). 
Strikingly, KD of TRAIL-R2 abrogated the entire enhanced migratory capacity of mutated 
KRAS cells. To test whether TRAIL-R2 was responsible for the induction of migration in 
KRAS-mutated cells, we reconstituted A549 shTRAIL-R2 cells with TRAIL-R2 
expression. Indeed, reconstitution of TRAIL-R2 expression led to rescued migration to 
normal levels (Figure 30B). Migration and invasion are two fundamental steps for cancer 
metastasis formation. Therefore, we next tested whether absence of endogenous 
TRAIL-R2 affects also invasion. Indeed, TRAIL-R2-KD blunted invasion to nearly the 
same low level exhibited by the non-invasive cell line NIH3T3 in DLD-1 (colon), Colo357 
(pancreas) and A549 (lung) cells, representing the three most common cancer types 
with KRAS mutations (Figure 30C and Figure 30D, representative images of cells that 
have passed through a matrigel layer). 
Thus, endogenous TRAIL-R2 drives cell-autonomous migration and invasion in KRAS-
mutated cells irrespective of tissue of origin. 
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Figure 30TRAIL-R2 drives migration and invasion of KRAS-mutated cancer cells. 
(a, left panel) Isogenic KRAS-mutated (DLD-1) and KRAS-WT (DKO4) cells were 
transfected with the siRNA targeting KRAS and TRAIL-R2 for 48 h and subsequently 
subjected to migration assays. Migration was normalised to control transfected DKO4 
cells. (a, right panel) Representative western blot is shown. (b, left panel) A549-luc 
pLKO.1 and shTRAIL-R2 were transiently transfected with either vector (pcDNA3.1) or 
with a TRAIL-R2 overexpression construct (pcTRAIL-R2) for 24 hours and subsequently 
subjected to migration assays. (b, right panel) Representative western blots are shown. 
(c) KRAS-mutated A549-luc, DLD-1 and Colo357 cells were transfected with the siRNA 
targeting TRAIL-R2 for 48 hours and subjected to invasion assays. (d) Matrigel layers 
were removed and cells that had passed through and adhered to the electrodes were 
stained by crystal violet. Representative images are shown.  
All figures represent means of three independent experiments +/- SEM, individual dots 
represent means of three experiments of one cell line. * p < 0.05 and *** p < 0.0001 
(Student’s t-test (a and b) or ANOVA (c)). 
 
95 
 
4.3.2 TRAIL and TRAIL-R2 form an endogenous non-apoptotic 
complex 
 
Since TRAIL/TRAIL-R2 was responsible for enhanced migration of KRAS-mutated cells, 
we investigated whether this effect is caused by the formation of an endogenous 
TRAIL/TRAIL-R2 complex. Interestingly, when subjecting lysates of KRAS-mutated cells 
at basal condition to Size Exclusion Chromatography (SEC) we found that in all cell lines 
tested a subfraction of endogenous TRAIL-R2 could be detected in high molecular 
weight fractions along with endogenous TRAIL (Figure 31A). Moreover, siRNA-mediated 
KD of TRAIL led to a shift of TRAIL-R2 from high molecular weight fractions to the size 
range of trimerised TRAIL-R2 (Figure 31B). 
Thus, we could conclude that endogenous cancer-cell-expressed TRAIL and TRAIL-R2 
can bind to each other and the resulting native complex may be responsible for the 
enhanced migration in KRAS-mutated cell lines. 
 
 
Figure 31Endogenous TRAIL and TRAIL-R2 constitute a native complex. (a) 
Native lysates of the indicated cell lines were fractionated by SEC. Fractions 9-32 were 
then subjected to western blotting. (b) Panc Tu I cells were transfected with siRNAs for 
48 hours as indicated and subjected to lysis, SEC fractionation and western blotting as 
above. Representative western blots from two independent experiments are shown. 
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4.3.3 Endogenous TRAIL/TRAIL-R2 complex drives Rac-1/PI3K-
mediated migration 
 
The study of the mechanisms controlled by TRAIL/TRAIL-R2 revealed that constitutive 
activation of Rac-1 was reduced by TRAIL-R2-KD. Moreover, silencing of Rac-1 reduced 
migration to a similar extent as TRAIL-R2-KD, yet no additional reduction was achieved 
by co-suppression of TRAIL-R2 and Rac-1, implying that endogenous TRAIL/TRAIL-R2 
and Rac-1 acted in the same pathway. Based on these results, it was concluded that 
KRAS-mutated cells employ constitutive endogenous TRAIL/TRAIL-R2 signaling to 
activate Rac-1 for migration (data not shown).   
Rac-1 activation has been described to be mediated either in a PI3K-dependent 
[Nimnual et al, 1998] or -independent manner [Lambert et al, 2002]. Therefore, we first 
tested whether the cell lines used, with particular focus on A549, required constitutive 
PI3K activity for migration. To do so, we employed the pan-PI3K inhibitor GDC-0941. 
Interestingly, PI3K inhibition suppressed basal migration and, importantly, when we 
suppressed Phosphatase and tensin homolog (PTEN), which counteracts PI3K activity 
reducing the pool of PIP3 [Ali et al, 1999], cells increased migration in a PI3K activity-
dependent manner (Figure 32A). Based on these results, we next hypothesised whether 
basal PI3K activity might be dependent on TRAIL-R2 and Rac-1. Firstly, we observed a 
marked reduction of constitutive phosphorylation of AKT when TRAIL-R2 expression 
was suppressed in A549 (Figure 32B), Panc Tu I and DLD-1 (data not shown) cells, 
thereby proving that PI3K activity is modulated by TRAIL-R2 at basal conditions. 
Secondly, Rac1-KD also suppressed basal AKT phosphorylation to a similar extent to 
TRAIL-R2-KD (Figure 32B). In line with these findings, PI3K-dependent migration 
induced by PTEN-KD was also entirely reversed by either TRAIL-R2- or Rac-1- KD in 
A549 (Figure 32C), Panc Tu I and DLD-1 cells (data not shown). So far, we 
demonstrated that the constitutive phosphorylation of AKT is affected by TRAIL-R2 and 
with less extend by Rac-1 in three KRAS-mutated cell lines representing non-small cell 
lung cancer (NSCLC), colorectal cancer (CRC) and pancreatic ductal adenocarcinoma 
(PDAC), thus showing that endogenous TRAIL-R2 and Rac-1 enables PI3K activation 
which is required for migration of KRAS-mutated cancer cells. However, since cancer 
cells are normally exposed to pro-survival signals in the microenvironment, we still 
needed to clarify whether AKT phosphorylation induced by exogenous stimuli could be 
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affected by the presence of TRAIL-R2 and Rac-1. Interestingly, we observed that A549, 
Panc Tu I and DLD-1, after one hour of stimulation with serum, showed increased levels 
of phosphorylated AKT that were then diminished by the absence of TRAIL-R2 (Figure 
32D). Since Rac-1-KD was not efficient, we could not verify whether Rac-1 really 
modulated the phosphorylation of AKT upon external stimuli.  
We therefore propose a model in which KRAS-mutated cancer cells, TRAIL-R2 and Rac-
1 are upstream of PI3K activity in a cell-autonomous migration pathway triggered by 
endogenous TRAIL/TRAIL-R2. 
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Figure 32 Endogenous TRAIL-R2 promotes activation of a pro-migratory 
Rac1/PI3K signaling axis. (a, left panel) A549-luc cells were transfected with PTEN-
targeting siRNAs and subsequently subjected to migration assays in the presence or 
absence of GDC-0941 [1 uM]. (a, right panel) A representative western blot is shown. (b) 
A549-luc and PancTu cells were transfected with the indicated siRNAs for 48 hours and 
subjected to western blot. (c) A549-luc cells were transfected as indicated in panel b and 
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subjected to migration assays. (d) A549, PancTu and DLD-1 were transfected with 
TRAIL-R2-targeting siRNA, subsequently stimulated with FCS [2%] for the indicated time 
points and subjected to western blot. One representative of three independent 
experiments is shown. (a, b, c) Values are means +/- SEM of three independent 
experiments. ** p < 0.01 and *** p < 0.0001 (ANOVA). 
 
These results place both TRAIL-R2 and Rac-1 upstream of PI3K activity in the cell-
autonomous migration pathway triggered by endogenous TRAIL/TRAIL-R2. Thus, we 
propose a model in which endogenous TRAIL/TRAIL-R2 promote a Rac1/PI3K signaling 
axis which drives migration, invasion and metastasis of KRAS-mutated cancers (Figure 
33). 
 
                                           
 
Figure 33 Proposed model of invasion/migration/metastasis signalling mediated 
by endogenous TRAIL/TRAIL-R2.  
 
 
Herein, we have demonstrated that in KRAS-mutated cancer cells TRAIL and TRAIL-R2 
constitute an endogenous complex that can promote migration by activating the 
downstream non-apoptotic effectors Rac-1 and PI3K. Therefore, targeting TRAIL-R2 
and/or non-apoptotic effectors might represent a strategy to convert the pro-migratory 
pathway into a pro-apoptotic outcome upon treatment with exogenous TRAIL. 
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5   Discussion 
 
Task I - Smac-Mimetic in combination with Camptothecin selectively kill pre-malignant 
human epithelial cells mutated for KRAS. 
 
Here we newly show that SM83 in combination with CPT induces apoptosis in human 
normal cells mutated for KRAS. Mechanistically, oncogenic KRAS leads to MAPK ERK2-
mediated upregulation of Noxa, thus enhancing, together with SM83, CPT-induced 
apoptosis.  
Since most cancer cells are resistant to SM as single agent, SM is commonly employed 
as a sensitiser for either death ligands [Li et al, 2004] or chemotherapeutics [Probst et al, 
2010]. Hence, we aimed to find a drug that, in combination with SM, would strongly 
trigger cell death. Among potential chemotherapeutics identified from the screening at 
ICR, Camptothecin emerged as the top candidate. CPT is the inhibitor of the nuclear 
Topoisomerase I (TOP1) and exerts its activity causing DNA double strand breaks, 
thereby triggering p53-dependent apoptosis [Tomicic et al, 2010]. Two derivates are 
currently approved for clinical treatment: Topotecan, mainly employed for second line 
therapy of small cell lung cancer (SCLC) and ovarian cancer and Irinotecan for 
colorectal cancer [Venditto and Simanek, 2010]. Despite the high initial response rates, 
the majority of patients relapse early to these conventional chemotherapies [Hamilton et 
al, 2014]. Of note, the fact that SM has been reported to synergise with DNA damage 
inducers such as Cisplatin, 5-Fluorouracil, Etoposide and analogs of camptothecin 
[Foster et al, 2009, Greer et al, 2011, Servida et al, 2011] strongly supported the result 
from our screening. 
Moreover, the killing potency of SM83 and CPT was even increased in the context of 
KRas knocked-in mutations in normal human cell lines. Indeed, when inducing 
KRasG13D expression in cells, which normally owed the WT-KRas, the KRas lesion 
triggered a robust apoptosis event upon combined SM83 and CPT treatment. 
Mechanistically, we identify that SM83/CPT-mediated cell death of pre-malignant KRAS-
mutated cells is executed by activation of a MAPK signaling axis; in particular ERK2 
upregulates Noxa and renders the cells more prone to apoptosis. Importantly and in line 
with our hypothesis, it has been published that mutations of the other Ras family 
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member HRAS plays a role in inducing autophagic cell death via Noxa upregulation 
[Elgendy et al, 2011]. Furthermore, it has been shown that transient overexpression of 
mutated KRAS positively regulates Noxa via ERK1/2 signalling, thereby sensitising to 
platinum-based chemotherapy [Sheridan et al, 2010]. Importantly, we show that 
treatment with MEKK inhibitors prevents SM83/CPT-induced apoptosis, in contrast with 
the conventional therapeutic approaches based on the employment of MEKK inhibitors 
as anti-cancer drugs [Hata et al, 2014]. Intriguingly, as shown in Figure 14, whereas 
depletion of ERK2 downregulates Noxa, depletion of ERK1 does not affect Noxa in 
KRAS-mutated HME cells, suggesting that ERK1 and ERK2 play dual roles in regulating 
Noxa levels, with ERK2 ultimately favouring KRasD13-induce apoptosis upon 
SM83/CPT co-treatment. Our findings suggest that the MAPK ERK2-mediated 
upregulation of Noxa renders the cells more prone to pro-apoptotic stimuli. Therefore, 
ERK2 inhibition would protect HME KRasG13D cells from combined SM83/CPT 
treatment. This opens a scenario in which ERK1 and ERK2 play different and even 
opposite functions, in line with what previously observed by others, describing a a 
mutual regulation between the two molecules downstream KRas signalling [Guegan et 
al, 2013]. Nevertheless, whether ERK2 displays a pro-apoptotic function in KRas 
signaling pathway is still to be proven.  
Studying the molecular mechanisms responsible for SM83/CPT-induced cell death, we 
investigated the role played by each component of this triad SM-CPT-KRasG13D. 
However, whereas CPT intervention is exerted by inducing intrinsic apoptosis and 
mutated KRAS by upregulating Noxa, in our hands SM83 manly consists in inhibiting 
XIAP in order to release caspases. Of note, SM-depletion of cIAP1 and cIAP2 leads to 
the transcription of TNF, which can then kill cells in an autocrine manner [Petersen et al, 
2007]. With our work, we demonstrated that TNF blocking by either Infliximab or Enbrel, 
KRAS-mutated cells survive to SM83/CPT combination. This suggests that cells engage 
other parallel responses to our treatment besides KRas-induced upregulation of Noxa. 
Whether cell death is caused by (i) high basal levels of TNF or (ii) hyperproduction of 
TNF or (iii) by high surface levels of TNF-Rs is still not clarified. Moreover, we still have 
not investigated whether KRAS-mutated cells (and not the WT cells) express basal high 
level of TNF or TNF-Rs that confer more susceptibility to the combinatorial treatment. 
The comprehension of these points would completely explain the molecular mechanisms 
responsible for synthetic lethal interaction between combined SM83/CPT and oncogenic 
KRAS. 
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Of note, synthetic lethality can selectively kill cancer cells while sparing normal cells. A 
therapeutic treatment based on synthetic lethality would thus be in theory extremely not 
toxic. As mutational activation of KRAS occurs in approximately 30% of human cancers 
in general [Bos, 1989, Malumbres and Barbacid, 2003] and 50% of colorectal 
adenocarcinoma [Grady and Markowitz, 2002], targeting KRas activation with the 
proposed combined SM83 and CPT treatment would be a potential new approach for 
these recalcitrant tumours. Therefore, we tested this combination using a panel of 
isogenic colorectal cancer cell lines bearing oncogenic and wild type KRas. First, since 
cancer cells engage several pro-survival pathways to escape apoptosis, it is surprising 
that they are as sensitive as KRAS-mutated HME cells to SM83 and CPT. In fact, cell 
death detected through cell viability assays was about 30% less than the premalignant 
cells. Furthermore, there were no differences in terms of cell death between KRas 
G13D- and WT- cancer cells, meaning that the observed sensitivity was independent of 
the KRAS mutational status. When we checked for Noxa levels in WT and mutated 
KRas colorectal cancer cells, they were comparable between mutated and WT isogenic 
pairs. Therefore, we can speculate several hypotheses: (i) KRAS-mediated upregulation 
of Noxa is antagonised by simultaneous upregulation of anti-apoptotic factors such as 
members of the Bcl-2 family or (ii) MAPKs, responsible for upmodulation of NOXA, are 
blocked by PI3K/AKT axis known to be markedly activated in cancer cells. Another 
possible explanation relies on (iii) the final equilibrium between death and survival, 
meaning that, in both KRAS-mutated and WT cancer cells, aberrant pro-survival signals 
deriving from mutation in PI3K or EGFR counterbalance the pro-apoptotic stimuli 
promoted by mutated KRAS. This would mean that activating mutations of oncogenes 
like KRAS are accompanied by the development of other mutations in transformed cells 
and for example HCT116 and DLD-1 cells bearing PI3KCA mutations seem to support 
this idea. Accordingly, we can consider that the introduction of mutations in immortalized 
human cells of epithelial origin (HME, MCF10A) is not sufficient to confer transforming 
properties and these cells are therefore sensitised to treatment, having no “protecting” 
mutations in other pathways. 
Taken together our results show pre-clinical evidence of synthetic lethal interaction 
among SM83, CPT and constitutive hyperactivation of KRAS in pre-malignant epithelial 
cells. This interaction relies on the effects at different levels: mutated KRAS upregulates 
Noxa via MAPK ERK2; SM83 prevents caspases blockage by inhibiting XIAP and, 
depleting cIAPs, enhances TNF-mediated cell death. Thus, specific KRAS mutations 
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and SM83 greatly offer a death-prone scenario in which pre-malignant cells efficiently 
die via CPT-mediated triggering of the mitochondrial apoptotic pathway. Although in the 
colorectal cancer setting the combination of SM83 and CPT is not highly efficient, we 
may employ this co-treatment as a ‘scaffold’ combination, which can be sensitised by a 
further agent. Alternatively, SM83/CPT can represent itself a sensitising combination to 
treat KRAS-mutated cells resistant to conventional therapies such as 
MEKK/PI3K/mTORC inhibitors. 
 
 
Task II – CDK9 inhibition overcomes TRAIL-resistance in KRAS-mutated NSCLC. 
 
Preliminary data show that the p110α-inhibitor PIK-75 potently sensitises to TRAIL-
induced apoptosis. Surprisingly PI3K inhibition is not responsible for this effect. A 
kinome-wide screen reveals that PIK-75 exerts off-target effects on a panel of 27 
kinases in addition to p110α. Further investigations show that the main target inhibited 
by PIK-75 and responsible for TRAIL sensitisation is CDK9. Intriguingly, analysis of the 
molecular mechanisms at the basis of this potent synergism showed that CDK9 blocks 
the DISC and the mitochondria acting on cFLIP and Mcl-1. In fact, SNS-032-mediated 
CDK9 inhibition leads to concomitant downregulation of cFLIP and Mcl-1, thereby 
facilitating DISC- and mitochondria-mediated apoptosis [Lemke et al, 2014a].  
Here, we demonstrate that selective inhibition of CDK9 via SNS-032, an inhibitor 
targeting CDK9 preferentially among other cell cycle CDKs [Conroy et al, 2009], 
synergises with TRAIL not only in A549, the human NSCLC cell line selected to perform 
the experiment, but also in an panel of human NSCLC cell lines. Therefore, the strong 
killing effect of this combination can be extended to a broad range of KRAS-mutated 
NSCLC cell lines. Importantly, our results show that CDK9 inhibition in combination with 
TRAIL cannot kill primary human hepatocytes (PHH) [Lemke et al, 2014a]. Notably, the 
concentration of SNS-032 sufficient for effective sensitisation of cancer cells to TRAIL-
induced apoptosis is easily reached and sustained in the plasma of patients [Tong et al, 
2010]. Moreover, we provide in vivo evidence of the potency of this novel treatment 
strategy. In fact, a four-day treatment with SNS-032 and TRAIL combination totally 
eradicates established lung tumours. However, the xenograft model used lacks a 
complete murine tumour microenvironment as SCID beige mice, for instance, lack 
activated T and mature Natural Killer (NK) cells, two major cell types described to 
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express TRAIL [Mirandola et al, 2004, Takeda et al, 2005]. In order to address whether 
exogenous TRAIL and paracrine microenvironment-associated factors are required to 
eradicate the tumour, we employed an autochthonous mouse model of NSCLC, named 
the KP conditional mouse model [DuPage et al, 2009, Hingorani et al, 2005]. Since SNS-
032 is not able to inhibit murine CDK9 and, as a consequence, it does not synergise with 
TRAIL to trigger apoptosis in murine NSCLC cell lines, we chose another potent CDK9 
inhibitor, Dinaciclib, already employed in clinical trials [Nemunaitis et al, 2013, 
Stephenson et al, 2014]. We demonstrated that it is active by inhibiting not only human 
but also murine CDK9. However, the IC50 of Dinaciclib towards CDK9 is similar to other 
CDKs [Parry et al, 2010, Paruch et al, 2010], a fact that has to be considered for the in 
vivo experiment. The effects of Dinaciclib in mice might be caused by the inhibition of 
other CDKs. Yet, to prove that Dinaciclib effect is caused selectively by CDK9 inhibition, 
we proposed another approach, i.e. the injection of BALB/c mice with murine NSCLC 
cell line inducible knocked-down for murine CDK9. The depletion of CDK9 will then be 
induced once the tumour is established simultaneously to TRAIL treatment. Moreover, 
the fact that Dinaciclib targets also other CDKs might in part explain the reason why we 
found that even at very low concentrations it synergises with TRAIL in killing a panel of 
human NSCLC cell lines. On the contratry, SNS-032 needs 6-fold more concentration to 
provoke the same killing effect. However, when we tested Dinaciclib and TRAIL co-
treatment in two further murine NSCLC cell lines derived from the KP mice, they were 
only partially sensitive, thus suggesting that the combination in not potent enough to 
induce apoptosis. Therefore, we tried to add to the combination our developed SM83 
[Lecis et al, 2012, Manzoni et al, 2012], which is known to synergise with TRAIL (data 
not shown), without success. We speculate that these cells can either engage anti-
apoptotic factors or be intrinsically resistant due to the presence of additional oncogenic 
mutations helping to escape cell death. Hence, it would be reasonable to include other 
types of TRAIL sensitisers such as ABT-263 [Tse et al, 2008], ABT-199 [Touzeau et al, 
2014] belonging to BH3-mimetic, Bortezomib [Lecis et al, 2010], chemotherapeutic 
agents like Cisplatin [Xu et al, 2011, Yin et al, 2011] in order to overcome this resistance 
also in vivo. In this study, we also prove that CDK9 is overexpressed in NSCLC. In 
particular, both lung tumours from 16-week old mice and human lung tumours biopsies 
show high expression of CDK9 as compared to the normal lung tissue surrounding the 
tumour nodules. In human samples, the positivity for CDK9 is specific for lung tumour 
areas as the co-staining for TTF-1, which selectively marks lung adenocarcinoma 
105 
 
demonstrates. Hence, detection of CDK9 overexpression makes this protein a candidate 
marker for NSCLC, which might then be responsive to our proposed combinatorial 
therapy. 
In conclusion, we herein propose a newly targeted therapeutic strategy that may 
overcome TRAIL resistance in a cancer-selective manner. However, further preclinical 
and ultimately clinical studies using TRAIL and CDK9 inhibitor could be considered for 
the treatment of NSCLC. 
 
 
Task III – The Endogenous TRAIL/TRAIL-R2 complex promotes metastasis progression 
in KRAS-mutated cancers via Rac-1/PI3K signaling axis. 
 
In this task, we show that endogenous TRAIL and TRAIL-R2-mediated signaling is 
required to promote migration, invasion and metastasis via activation of the Rac-1/PI3K 
signaling axis in KRAS-mutated cancer. This oncogenic mutation represents a key 
feature of pancreatic, colorectal and lung cancers [Bos, 1989], tumours mostly highly 
aggressive. Furthermore, we provide genetic in vivo evidence that mouse TRAIL-R 
(mTRAIL-R) is a key driver of cancer progression and metastasis in an autochtonous 
mouse model of lung cancer and two autochtonous mouse models of pancreatic cancer 
(data not shown). Moreover, high TRAIL-R2 expression correlates with shortened 
metastasis-free survival in KRAS-mutated colorectal cancer patients, thus supporting the 
idea that TRAIL-R2, endogenously expressed by KRAS-mutated cancer cells is 
responsible for metastatisation (Von Karstedt et al., submitted). Since metastasis is the 
main reason for cancer related deaths [Hanahan and Weinberg, 2011], from a 
therapeutic point of view, our finding indicates both TRAIL and TRAIL-R2 as potential 
targets in clinic. At the same time, treatment with recombinant TRAIL has been 
commonly shown to selectively kill tumour cells in vivo without causing toxicity [Walczak 
et al, 1999], thus beginning the development of TRAIL and other TRAIL-R agonists for 
clinical application as novel cancer therapeutics [Lemke et al, 2014b]. Therefore, our 
study, which suggests a tumour-promoting role of endogenous TRAIL/TRAIL-R2 seems 
to be in contrast with the standard concept which supports an anti-tumour activity of 
TRAIL and TRAIL-R agonists. Nonetheless, if the tumour is sensitive to TRAIL-induced 
cell death, a therapy based on TRAIL or TRAIL-R agonists would be reasonable in order 
to eradicate the tumour. Otherwise, when cancer cells physiologically employ 
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TRAIL/TRAIL-R2 to invade, migrate and form metastasis as demonstrated by our 
experiments, endogenous TRAIL/TRAIL-R2 system and even paracrine TRAIL stimuli by 
the tumour microenvironment should be antagonized by a designed therapeutic strategy. 
Mechanistically, we identify that TRAIL-R2-mediated cell-autochtonous migration of 
KRAS-mutated cancer cells is independent of the canonical cell death-inducing 
machinery. The non-apoptotic role of TRAIL/TRAIL-R has already been described [Azijli 
et al, 2012]. However, we enlighten a correlation between PI3K and Rac-1 effectors 
downstream TRAIL-R2 which create a circuit governing migration and invasion of cancer 
cells. Hence, it would be object of interest to delineate the precise molecular 
mechanisms that directly or indirectly connect these effectors in order to orchestrate the 
events that determine the aggressiveness of KRAS-mutated tumours. Interestingly and 
in line with the model we propose, a recent publication has demonstrated the selective 
requirement of KRAS/PI3K activation in pancreatic cancer [Eser et al, 2013] and 
tumours from KP mice were shown to harbor elevated Rac-1 activity [Johnsson et al, 
2014] highlighting once more the importance of targeting this pathway. Although further 
investigations are needed to explore this pathway more in depth, we give new insights in 
the non-canonical TRAIL/TRAIL-R system as promoter of cancer progression, invasion 
and metastasis in KRAS-mutated cancers. Therefore, we provide potential cancer-
therapy targets that might be clinically considered in the treatment of these recalcitrant 
tumours. 
 
 
In conclusion, the whole thesis is focused on colorectal, lung and pancreatic cancers, 
which are all characterised by the presence of the oncogenic KRAS lesion. Task I and 
Task II propose two different approaches to kill KRAS-mutated colorectal and lung 
cancer cell lines respectively. These targeted therapeutic strategies rely on apoptosis 
induction triggered by either a genotoxic stress (CPT) or a death ligand (TRAIL). 
Whereas the first task is mainly a mechanistic study, which tries to explain the synthetic 
lethal interaction between SM, CPT and mutated KRAS in a context of pre-malignancy, 
the second task provides a combination based on inhibiting CDK9 to enhance TRAIL-
induced apoptosis in an already transformed cell (NSCLC). Although several 
combinatorial approaches have been entered clinical trials so far, patients relapse early 
as KRAS-mutated cancers are known for their high capacity to metastatise. Task III 
indeed explain why, mechanistically, KRAS-mutated cancers are aggressive: they 
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physiologically employ endogenous TRAIL/TRAIL-R2 system together with downstream 
effectors PI3K and Rac-1 to migrate, invade and, as a final result, metastatise. 
Therefore, this thesis propose two complementary frontlines to completely eradicate 
KRAS-mutated cancers: on one side, the aim is killing tumour cells by the employment 
of targeted drug combinations, on the other side, the purpose is to block the endogenous 
migratory/invasion capacity of the cancer cell, thereby preventing metastatisation, which 
still remains the main cause of cancer-related death. 
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6   Appendix 
 
6.1 Abbreviations 
 
A Alanine 
Ad-Cre Adenovirus engeneered to express Cre 
ATP Adenosin-triphosphate 
Bak Bcl-2 homologous antagonist/killer 
Bax Bcl-2–associated X protein 
Bcl 2 B-cell lymphoma 2 
Bcl-xL B-cell lymphoma-extra large 
Bid BH3 interacting-domain death agonist 
Bim Bcl-2-like protein 11 
CARD Caspase recruitment domain 
CCA Cholangiocarcinoma 
CDK Cyclin-dependent kinase 
cFLIP Cellular FLICE-Inhibitory Protein 
cIAP Cellular inhibitor of apoptosis protein 
CPT Camptothecin 
CRC Colorectal cancer 
CUL-3 Cullin-3 
CYLD Cylindromatosis 
Da Dalton 
DD Death Domain 
DISC Death inducing signaling complex 
DMEM Dulbecco’s modified Eagle’s medium 
DUB Deubiquitinase 
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EGF Epithelial Growth Factor 
EGFR Epithelial Growth Factor receptor 
ER Endoplasmic reticulum 
ERK Extracellular signal related kinase 
FACS Fluorescence-Associated Cell Sorting  
FADD Fas associated death domain 
FBS Fetal Bovine Serum 
FCS Fetal calf serum 
GAP GTPase-Activating Protein 
GATA2 GATA binding protein 2 
GEF GTP-Exchanging Protein 
Grb2 Growth-factor-receptor-bound protein 2 
GTP Guanosine-triphosphate 
H Histidine 
HBS Hepes buffered saline 
HME Human mammary epithelial cell line 
HOIL-1 Haeme-oxidized IRP2 ubiquitin ligase 1 
HOIP HOIL-1-interacting protein 
HRP Horseradish-peroxidase 
hTERT Human telomerase reverse transcriptase 
HVR Hyper variable region 
I Isoleucine 
IAP Inhibitor of apoptosis protein 
IF Immunofluorescence 
IFN Interferon 
IKK Inhibitor of kappaB kinase 
IKK IκB Inhibitor of kappaB 
IL Interleukin 
IN Intranasal instillation 
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IT Intratracheal inalation 
KP K-Ras
LSL-G12D/+ and p53LSL-R172H/+ mouse model 
KRas Kirsten rat sarcoma viral oncogene homologue 
L Lysine 
LPS Lipopolysaccharide 
LT Lymphotoxin 
LUBAC Linear ubiquitin chain assembly complex 
MAPK Mitogen-activated protein kinase 
Mcl-1 Myeloid leukemia cell differentiation protein 
mTOR mammalian target of rapamycin 
mTRAIL-R murine TRAIL-R 
NEAA Non-essential amino acid 
NEMO NF-κB essential modulator 
NF-kB Nuclear factor kappaB 
NK Natural Killer 
Noxa ‘damage’ in latin 
NSCLC non-small cell lung cancer 
OPG Osteoprotegerin 
OTULIN OTU deubiquitinase with linear linkage specificity 
P Proline 
P-TEFb Positive transcriptional elongation factor b 
PAGE Polyacrylamid gel electrophoresis 
PARP Poly ADP ribose polymerase 
PBS Phosphate buffered saline 
PDAC Pancreatic Ductal Adenocarcinoma 
PI3K Phosphoinositide 3-kinase 
PUMA p53 upregulated modulator of apoptosis 
RANK Receptor activator of NF-κB 
RANKL Receptor activator of NF-κB Ligand 
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RIP Receptor interacting protein 
RIP 3 Receptor interacting protein 3 
RIPK1 Receptor interacting protein kinase 1 
RNA-Pol II RNA-Polymerase II 
RNAi RNA interference 
ROCK Rho-associated protein kinase 
RTK Receptor tyrosine kinases 
S Serine 
SEM Standard Error Mean 
SHARPIN SHANK-associated RH-domain-interacting protein 
siRNA Small interfering RNA 
SM SMAC-mimetic 
Smac/DIABLO Second mitochondria-derived activator of caspase/ Direct IAP-
binding protein with low isoelectric point 
Sos Son of Sevenless 
Src Schmidt-Ruppin A-2 viral oncogene homolog 
TAB TAK1 binding protein 
TAK TGF-β-activated kinase 1 
tBid truncated Bid 
Thr Threonine 
TLR Toll-like receptor 
TNF Tumor Necrosis Factor 
TNF-SF Tumour necrosis factor-superfamily 
TNF-SF-R Tumour necrosis factor receptor-superfamily receptor 
TR Tyroid hormaone receptor 
TRADD TNF-R1-associated death domain 
TRAF TNF-receptor associated factor 
TRAIL Tumor necrosis factor-related apoptosis-inducing ligand 
Tyr Tyrosine 
V Valine 
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Wnt Wingless proto-oncogene 
WT wild-type 
XIAP X-linked inhibitor of apoptosis protein 
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The apoptotic process of programmed cell death is dysfunc-
tional in its regulation in a variety of human pathologies, among
which cancer,1–3 inﬂammation4,5 and neurodegeneration,6,7 where
it has become the focus of extensive pharmaceutical research.
Pathways leading to apoptosis include the extrinsic or death recep-
tor-dependent path8,9 and the intrinsic or mitochondrial path,8,10
both caspase-dependent; and some caspase-independent mecha-
nisms, involving other proteases as apoptosis executioners.11
In a complex scenario, hitting more than one putative signiﬁ-
cant target with a lead should maximize the chances of therapeutic
success. Thus, we focused on targeting molecular entities involved
in several apoptotic pathways, rather than extremely targeted
agents. Such polypharmacology12 approach is precedented in
target classes such as kinases13 and GPCRs.14
The family of Inhibitor of Apoptosis Proteins (IAPs)15,16 is char-
acterized by the presence of one or more Baculovirus IAP Repeat
(BIR) domains. Since the discovery of the ﬁrst viral iap gene and
its linkage with apoptosis,17 IAPs were considered putative targetsll rights reserved.
: +39 0250314075.
eci).for pro-apoptotic drugs in oncology.18 The initial assumption of a
common anti-apoptotic mechanism for the whole IAP target family
through interference with caspase-dependent pathways19,20 has
been proven wrong, or at least only partially correct for other IAP
proteins,21,22 but their interest as oncology targets related to apop-
tosis has not been seriously challenged.23
The most caspase-connected IAP is the X-Inhibitor of Apoptosis
Protein24,25 (XIAP). XIAP is capable of binding caspase 9 (the initia-
tor caspase) and both caspases 3 and 7 (the executioner caspases).26
XIAP binding prevents activation of caspases and, consequently,
prevents cells from entering apoptosis.
A protein released from mitochondria, the Second Mitochon-
dria-derived Activator of Caspases (Smac)27/Direct IAP Binding
protein with LOw pI (DIABLO)28 binds XIAP as a dimer29 on the
same binding sites of caspase 9 (BIR3 domain).30–32 Smac interferes
also with the XIAP binding site of caspases 3 and 7 (linker-BIR2 do-
main),33 promoting both the extrinsic and intrinsic apoptosis
paths. The delicate balance of this binding equilibrium is altered
in various diseases; for example, several tumor cell lines show
overexpression of XIAP and, consequently, a caspase-dependent
resistance to enter apoptosis.34,35 Thus, XIAP inhibition via Smac
mimetics’ binding is considered a validated mechanism for
intervention in cancer therapy.36–38
6688 L. Manzoni et al. / Bioorg. Med. Chem. 20 (2012) 6687–6708Smac binding to other human IAP family members such as
cIAP139 and cIAP240 through their BIR domains is also proven,
although not related to their NF-jB activation-related anti-apopto-
tic properties.41–43 Thus, Smac mimetics may modulate the
pathological action of any IAP oncology target,44–46 although the
complex network of IAP-dependent interactions still needs to be
fully elucidated to understand any drawback for the use of Smac
mimetics in therapy.47
Several authors have shown how monomeric Smac mimetics/
IAP inhibitors such as 1a (Fig. 1, top left), inspired by the Smac
N-terminal AVPI sequence and built on aza-containing bicycloal-
kane carboxylate scaffolds, bind XIAP, cIAP1 and cIAP2 on their
BIR domains with sub-micromolar potency, induce rapid cIAP1
degradation, and affect apoptosis in tumor cells when given in
combination with cytotoxic agents.48 The same authors reported
diazabicyclic scaffolds as potent, orally active pan-IAP antago-
nists.49 Among them, 2a (AT406, Fig. 1, bottom left) is in clinical
development for the treatment of solid and hematological tu-
mors.50 Recently, another orally active clinical candidate 3a
(GDC-0152, Fig. 1, top right) was fully described.51
We have reported a structure-driven approach to potent, mono-
meric Smac mimetics/IAP inhibitors of general formula 4 (Fig. 1,
middle), where introduction of a 4-substitution on the 1-aza-2-
oxobicyclo[5.3.0]decane scaffold established novel molecular
interactions with the binding linker-BIR2 and/or BIR3 sites.52,53
Our early lead 4a52 (Fig. 1, bottom right) showed good in vitro—
cell-free and cellular—potency. The optimized lead 4b54 (Fig. 1,
bottom right) showed a signiﬁcant improvement in solubility and
penetration through biological membranes.
Dimeric Smac mimetics/IAP inhibitors such as 5–7 (Fig. 2) were
also presented as bifunctional ligands able to simultaneously bind
toBIR2andBIR3domainsofXIAP, and to inducerapid cIAP1andcIAP2
degradation.55–57 Their structure includes two AVPI-related pepti-
domimetics connected through one (5,7) or two (6) linkers of varying
length, rigidity and lipophilicity. The observed cytotoxic effects on se-
lected cell lines55 and signiﬁcant activity in animal models57 sug-
gested a downstream developability for such ‘non drug-like’ dimers.
Here we report novel, dimeric Smac mimetics/IAP inhibitors
8–10 (Fig. 3)which take advantageof their characteristic 4-substitu-
tion to exploit three connection strategies. Labeling as ‘head’ the
4-substituent and ‘tail’ the C-terminus amide of the 1-aza-2-oxobi-
cyclo[5.3.0]decane scaffold (Fig. 3), we have designed, synthesized
and biologically characterized several head–head (8) and tail–tailheteroatom
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Figure 1. Monomeric Smac mhomodimers (9), together with unprecedented heterodimeric
head–tail compounds (10, Fig. 3).We aimed to introduce symmetri-
cal and unsymmetrical substitution patterns on the two linker-con-
nectedmonomer units, and to assess a few synthetic strategies fully
compatible with a wide variety of functional groups. We reasoned
that, if fully achieved, such goals should have allowed to understand
the inﬂuence of structural modiﬁcations on in vitro and in vivo efﬁ-
cacy of dimeric Smac mimetics/IAP inhibitors 8–10, and to select at
least one suitable candidate for preclinical evaluation.
The rational design and the chemical synthesis of dimeric Smac
mimetics/IAP inhibitors 8–10 is presented and discussed in this pa-
per. Their structural and biological characterization, including
NMR and X-ray studies, cell-free, cellular and in vivo efﬁcacy test-
ing on selected compounds, are reported in the following paper.58
2. Synthesis
2.1. Rationale
Some of us recently reported52,59 an innovative synthesis strat-
egy to access monomeric compounds of general formula 4, which
differ from known structures 1 for the additional 4-substitution
on the 1-aza-2-oxobicyclo[5.3.0]decane scaffold (Fig. 1). Having se-
cured synthetic access to such structures, and having established a
preliminary SAR on the 4-position, we decided to study how two
such structures could be connected, through a suitable linker at-
tached onto a chemically modiﬁable functional group, to take
advantage of a simultaneous interaction with two BIR domains,
as previously reported by others.55,57
As to the connecting chemical function between the monomer
unit and the linker, it has to be both chemically replaceable-modi-
ﬁable, and compatible with preserving BIR-binding properties even
after substantial structural modiﬁcations. Two such groups were
known at the time whenwe designed our dimer assembly strategy:
the C-terminus amide portion, used in several papers as an anchor
point for dimer synthesis,55,57 and the 4-substitution, which was
proven by us to tolerate the introduction of various functional
groups, including bulky substituents.52 We named the latter com-
pounds as head–head dimers 8, while the former were labelled as
tail–tail compounds 9.
We reasoned that, in order to reach both binding sites in two
BIR domains of a given IAP protein, the two monomeric AVPI
mimetics would need to adopt speciﬁc—and possibly rather,
,
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L. Manzoni et al. / Bioorg. Med. Chem. 20 (2012) 6687–6708 6689constrained—conformations. A graphically effective pictorial anal-
ogy of head–head, head–tail and tail–tail dimers is reported in
Figure 4. It is likely that, to assume a relative orientation of both
monomers in a given dimer 8 or 9 which would allow to bind
simultaneously to two BIR targets, either one or both of the linked
monomers should move away from their minimum energy state.
It’s also reasonable that their capability to reach such dimer bind-
ing conformation would be different, due to the constraints in-
duced in dimer regions by a tail-tail or a head-head connection.
We then reasoned that, if synthetically feasible, head-tail heterodi-
mers 10 would also provide useful information in terms of binding
modes, and obviously of dimers’ structural requirements to
maximize their pro-apoptotic effects (Fig. 4).
The linker unit, connecting two AVPI mimetics, is also going to
inﬂuence the bi-functional binding potential of dimeric Smacmimetics. We selected several linking backbones, taking also
advantage of reported efforts by other groups,60 with the aim to ex-
plore how, inter alia, their length, ﬂexibility and lipophilicity would
inﬂuence the dimer activity. Some preferred linker structures are
depicted in Figure 5.
2.2. Key monomers
Six monomeric intermediates were selected as synthetic gate-
ways to our dimers. Their structure is shown in Figure 6, while
their synthesis was previously reported.52
Namely, compound 4c corresponds to the product of step ii,
Scheme 1, Ref. 52; compound 4d corresponds to the product of
step iv, Scheme 1, Ref. 52; compounds 4e,f and 4g,h correspond,
respectively, to compounds 8a,b and 9a,b, Scheme 1 in Ref. 52.
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Nine head–head homodimers 8 were synthesized. A diphe-
nylmethylamide was the tail for all compounds 8, while three of
them contained (S)-ethylglycine and six contained N-methyl(S)-
ethylglycine (AA, Fig. 3).
Amine 4gwas reacted with two alkynyl carboxylic acids (step a,
Scheme 1) to provide high yields of 4-alkynyl amides 11a,b. The
amides were reacted with azide 4e in a Cu-catalyzed click chemis-
try reaction (step b, Scheme 1) to provide good yields of N-Boc-pro-
tected dimers 12a,b. Acidic deprotection with methanolic HCl (step
c) provided high yields of head–head dimers 8a,b as bishydrochlo-
rides (Scheme 1). The unoptimized overall yields for 8a and 8b
were, respectively, 38% and 42%.
Alkynylamide 11b was oxidatively dimerized55 in moderate
yields (step a, Scheme 2) using copper (II) acetate, and the resulting
symmetrical N-Boc-protected dimer 12c was deprotected (step b)
to provide quantitative yields of head–head dimer 8c as a dihydro-
chloride (Scheme 2). The unoptimized overall yield for 8c was 36%.N-Methylamine 4h was reacted with three biscarboxylates
(step a, Scheme 3) to provide good yields of N-Boc-protected di-
mers 12d–f. Acidic deprotection with TFA (step b) provided good
to excellent yields of head–head dimers 8d–f as bistriﬂuoroace-
tates (Scheme 3). The unoptimized overall yields for 8d, 8e and
8f were, respectively, 44%, 53% and 39%.
N-Methylamine 4hwas also reacted with an alkynyl heptanoate
(step a, Scheme 4) to provide N-methyl, 4-alkynyl amide 11c in
excellent yield. This was oxidatively dimerized55 in excellent yields
(step b) using copper (II) acetate, and the resulting symmetrical N-
Boc-protected dimer 12gwas deprotected (step c) to provide mod-
erate yields of head–head dimer 8g as a dihydrochloride (Scheme
4). The unoptimized overall yield for 8g was 30%.
The amide 11c was also reacted with a known bis-azide61 in a
Cu-catalyzed click chemistry reaction (step a, Scheme 5) to provide
moderate yields of the N-Boc-protected dimer 12h. Acidic depro-
tection with TFA (step b) provided quantitative yields of the
head–head dimer 8h as a bistriﬂuoroacetate (Scheme 5). The unop-
timized overall yield for 8h was 29%.
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a   n = 0
b   n = 2
.HCl
a, DCC, DMAP, CH2Cl2, 0°C to rt, 1 hr; b, 2d, Cu(OAc)2, Na ascorbate, t-BuOH:water 1:1, rt, 18 hrs;
c, 3N HCl in MeOH, rt, 18 hrs. 
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L. Manzoni et al. / Bioorg. Med. Chem. 20 (2012) 6687–6708 6691Finally, N-methylamine 4hwas reacted with N-Cbz beta alanine
(step a, Scheme 6) to provide N-methyl amide 11d in quantitative
yield. The amide was hydrogenolytically deprotected (step b) and
reacted with diethyl squarate (step c) to give the symmetrical,N-Boc-protected dimer 12i in excellent yield. Acidic deprotection
with TFA (step d) provided excellent yields of the head–head dimer
8i as a bistriﬂuoroacetate (Scheme 6). The unoptimized overall
yield for 8i was 75%.
.TFA
.TFA
a
8d - 64%
8e - 95%
8f  - 75%
12d - 68%
12e - 56%
12f  - 52%
d   link = (CH2)6
e   link = (OCH2CH2)2O
f    link = (OCH2CH2)3O
a, EDC, HOBt, DIPEA, CH2Cl2, rt, 2 hrs; b, TFA, CH2Cl2, rt, 4 hrs. 
b
b
4h 
BOC
BOC
LINK
COOHHOOC LINK
LINK
N
O
N
H
N
O O
N
HN
H
OO
N
H
N
N
H
O
N
OO
N
H
O
N
H
N
N
H
O
N
H
O
N
H
O
N
H
N
N
H
O O N
H N
H
O
O
+
Scheme 3. Synthesis of head–head dimers 8d–f.
4h
b
.TFA
a
c
8g - 41%
.TFA
12g - 84%
a, 6-heptynoic acid, EDC, HOBt, DIPEA, CH2Cl2, rt, 4 hrs; b, Cu(OAc)2, CH3CN, reflux, 0.5 hrs;
c, TFA, CH2Cl2, rt, 4 hrs. 
11c - 92%
BOC
BOC
( )3
( )3
( )3
( )3
BOC
( )3
N
O
N
H
N
O O
N
HN
H
O
N
H
N
N
H
O
N
O
N
H
O
O
O
O
N
H
N
N
H
O
N
H
O
N
H
O
N
H
N
N
H
O
N
H
O
N
H
O
N
O
N
H
N
OO
N
H N
H
O
Scheme 4. Synthesis of head–head dimer 8g.
6692 L. Manzoni et al. / Bioorg. Med. Chem. 20 (2012) 6687–67082.4. Tail–tail homodimers 9
Seven tail–tail homodimers 9 were synthesized. N-methyl(S)-
ethylglycine was present in all compounds 9 (AA, Fig. 3), while
three different 4-substitutions (–CH2OH in ﬁve compounds, -
CH2NHCH2Ph and elongated –CH2CH2NH2 in one compound) were
introduced.
Carboxylic acid 4d was reacted with an optically active alkynyl
amine (step a, Scheme 7) to provide C-terminus-alkynyl amide 13ain good yield. The amide was reacted with a known bis-azide58 in a
Cu-catalyzed click chemistry reaction (step b) to provide the
N-Boc-protected dimer 14a in good yield. Acidic deprotection with
TFA (step c) provided tail–tail dimer 9a as bistriﬂuoroacetate in
good yield (Scheme 7). The unoptimized overall yield for 9a was
29%.
A set of four tail–tail dimers 9b–e was prepared by reaction of
the same carboxylic acid 4d with four bis-amine linkers 17a–d.
Such bis-amines were prepared from bis-amines 15a–d62 by
db,c
.TFA .TFA
8i - 83%
a, N-CBz beta-alanine, EDC, HOBt, DIPEA, CH2Cl2, rt, 2 hrs; b, Pd/C, H2, continuous flow, 10 bar, 40°C; c, diethyl 
squarate, TEA, EtOH, DMAP, rt, 18 hrs; d,TFA, CH2Cl2, rt, 4 hrs. 
a
12i - 92%
11d - quant. 
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a, Cu(OAc)2, Na ascorbate, t-BuOH:water 1:1, rt, 18 hrs;
b, TFA, CH2Cl2, rt, 4 hrs. 
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L. Manzoni et al. / Bioorg. Med. Chem. 20 (2012) 6687–6708 6693condensation with (S)-phenylglycine (step a, Scheme 8) to give
N-Boc protected compounds 16a–d in excellent yields. Desired
bis-amine linkers 17a–d were obtained by TFA deprotection (step
b) in quantitative yields (Scheme 8).
Carboxylic acid 4d was reacted with four bis-amine linkers
17a–d (step a, Scheme 9) to give, with good to excellent yields,
N-Boc protected dimers 14b–e. Acidic deprotection with TFA (step
b) provided tail–tail dimers 9b–e as bistriﬂuoroacetates in good to
excellent yields (Scheme 9). The unoptimized overall yields for9b–e, starting from 4d and 17a–d, were, respectively, 53%, 73%,
31% and 56%.
N-Boc protected dimer 14a was decorated on its 4-substitution
to provide tail–tail dimer 9f (Scheme 10). Namely, 14a was mesy-
lated and reacted with sodium azide (steps a, b) to give azide 14f in
good yield. The azide was reduced in a Staudinger reaction (step c)
to give the amine 14g in quantitative yield, and the amine was
N-alkylated in a reductive amination protocol (step d) to provide
the N-protected, benzylated dimer 14h in moderate yields. Acidic
.TFA
.TFA
a b
13a - 67%
14a - 74%b
c
a, EDC, HOBt, DIPEA, dry CH2Cl2, rt, 2 hrs; b, Cu(OAc)2, Na ascorbate, tBuOH:water 1:1, rt, 18 hrs; 
c,TFA, CH2Cl2, rt, 4 hrs. 
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6694 L. Manzoni et al. / Bioorg. Med. Chem. 20 (2012) 6687–6708deprotection with TFA (step e) provided tail–tail dimer 9f as a
tetratriﬂuoroacetate in good yield (Scheme 10). The unoptimized
overall yield for 9f from 14a was 24%.
Finally, 4-hydroxymethyl methyl ester 4c was N-Boc protected,
mesylated and reacted with a tetraalkyl ammonium cyanide (steps
a–c, Scheme 11) to provide the cyano compound 13b in good yield.
After N-deprotection and condensation with N-protected and
methylated (S)-ethylglycine (steps d,e) to yield 13c, the cyano
group was reduced, and the resulting amine was protected with
Boc in a one-pot reaction protocol (steps f,a) to give the N-Boc
protected, elongated amine 13d in moderate yield. After quantita-tive basic hydrolysis of the methyl ester (step g), the acid 13e was
reacted with previously described bis-amine 17b (step h) to give
tetra N-Boc protected dimer 14i in good yields. Acidic deprotection
with TFA (step i) provided elongated tail–tail dimer 9g as a tetratri-
ﬂuoroacetate in good yield (Scheme 11). The unoptimized overall
yield for 9g was 12%.
2.5. Head–tail heterodimers 10
Three head–tail heterodimers 10 were synthesized together
with a hybrid heterodimeric structure. N-Methyl(S)-ethylglycine
9b - 58%, 9c - 97%,
9d - 69%, 9e - 91%
.TFA .TFA
a
14b - 97%, 14c - 80%, 
14d - 51%, 14e - 74%
b
a, 17a-d, HOBt, HBTU, collidine, dry DMF, 0° to rt, 2 hrs; b, TFA, CH2Cl2, rt, 4 hrs. 
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a, MsCl, TEA, dry CH2Cl2, 0° to rt, 2 hrs; b, NaN3, dry DMF, 100° C, 0.5hrs; c, Me3P, dry CH2Cl2, rt, 
2 hrs; d, PhCHO, NaBH(OAc)3, dry CH2Cl2, rt, 18 hrs; e, TFA, CH2Cl2, rt, 4 hrs. 
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id,e
13e - quant., R=H
h
13d - 44%, R=Me13c - 67%
g
.TFA
.TFA
9g - 80%
a-c
.TFA
f,a
.TFA
14i - 77%
13b - 63%
a, Boc2O, TEA, CH2Cl2, rt, 2 hrs; b, MsCl, TEA,  CH2Cl2, rt, 2 hrs; c, nBu4N+CN-, DMF, microwave, 
80°C, 1.5 hrs; d, 3N HCl in MeOH, rt, 18 hrs; e, N-Boc,N-Me-(S)-2aminobutanoic acid, EDC, 
HOBt, DIPEA, dry CH2Cl2, rt, 2 hrs; f, Ni Raney, EtOH, continuous flow, 60 bar, 60°C, 6 hrs; 
g, 2N LiOH, 1,4-dioxane:water, 0°C to rt, 1 hr; h, 17b, HOBt, HBTU, collidine, dry DMF, rt, 
18 hrs; i, TFA, CH2Cl2, rt, 4 hrs. 
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tail were conserved in the three heterodimers, while the hybrid
structure connected the head of a 1-aza-2-oxobicyclo[5.3.0]decane
scaffold-based AVPI mimetic with a structurally different, known55
monomeric unit.
Four key tail-linker monomeric intermediates 18a–d were pre-
pared as shown in Scheme 12. Commercially available azidoamine
15ewasﬁrst reactedwith (S)-phenylglycine (stepa) to give interme-
diate 16e in good yield, then N-deprotected (step b). Coupling with
4d (step c) provided the linker-bearing monomeric azide 18a in
excellent yield. After catalytic hydrogenation (step d) of the same
azide toprovidequantitatively the linker-bearingmonomeric amine
18b, the same amine was either coupled with 4-pentynyl-butanoic
acid (step e) to give the linker-bearing monomeric alkyne 18cwith
excellent yield, or with diglycolic anhydride (step f) to give the
linker-bearing monomeric carboxylate 18d (Scheme 12).
Linker-bearing monomeric azide 18a was coupled in a click
chemistry reaction with 4-alkynyl amide 11e (step b, Scheme
13), this last prepared from 4h (step a), to provide in good yield
the N-protected head–tail heterodimer 19a. Acidic deprotection
with TFA (step c) provided head–tail heterodimer 10a as a bistri-
ﬂuoroacetate in excellent yield (Scheme 13). The unoptimized
overall yield for 10a was 55% from 18a.
Linker-bearing alkyne 18c was coupled in a click chemistry
reaction with azide 4f (step a, Scheme 14) to provide in very good
yield the N-protected head–tail heterodimer 19b. Acidic deprotec-
tion with TFA (step b) provided head–tail heterodimer 10b as a bis-
triﬂuoroacetate in excellent yield (Scheme 14). The unoptimized
overall yield for 10b was 69% from 18c.Linker-bearing carboxylate 18d was coupled with amine 4h
(step a, Scheme 15) to provide in very good yield the N-protected
head–tail heterodimer 19c. Acidic deprotection with TFA (step b)
provided head–tail heterodimer 10c as a bistriﬂuoroacetate in
excellent yield (Scheme 15). The unoptimized overall yield for
10c was 59% from 18d.
Finally, a heterodimer containing two linker-connected AVPI
mimetics based on different scaffolds was prepared as in Scheme
16. Namely, azide 4e was coupled in a click chemistry reaction
with N-protected alkyne-containing Smac mimetic 20a55 (step a)
to give N-Boc, N-Fmoc protected heterodimer 19d in good yield.
Sequential deprotection in basic (step b) and acidic (step c) condi-
tions produced the hybrid heterodimer 10d in excellent yield. The
unoptimized overall yield for 10d was 51%.
3. Conclusions
The chemical feasibility of head head-8, tail tail-9 and head tail-
10 dimers based on 4-substituted 1-aza-2-oxobicyclo[5.3.0]decane
scaffolds was successfully proven through the synthesis of 20 com-
pounds, bearing various 4-substitutions. The monomer units in
each dimer were connected through linkers with varying length,
lipophilicity and ﬂexibility.
Extensive details regarding the biological activity of each pre-
pared dimer, and the structural characterization of selected homo-
dimers using NMR, X-ray crystallography and gel ﬁltration are
provided in the following paper.58 Their activity proﬁling will drive
our future synthetic efforts towards the more prospective homo-
and heterodimers. Such efforts will be reported in due time.
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4 hrs; c, 4d, HOBt, HBTU, collidine, dry DMF, 0° to rt, 2 hrs; d, H2, Pd/C, continuous flow, 
10 bar, 35°C; e, 4-pentynoic acid, DCC, DMAP, dry CH2Cl2, 0° to rt, 4 hrs; f, diglycolic 
anhydride, pyridine, dry DMF, rt, 4 hrs.
16e - 74%
15e
BOC
N3
BOC
N3
BOC
N3
BOC
BOC
HOOC
NH2O
O
O
N
H
O
N
H
N
HO
N
H
N
O
O
O
O
O
O
N
H
N
H
N
O
N
H
N
O
HO
O
O
N
H
O
O
O
O
NH
O
O
O
NH2
N
O
N
H
N
O
N
H
N
H
O
O
O
NH
O
O
O
HO
N
O
N
H
N
HO
N
H
N
H
O
O
O
NH
O
O
O
O
O
Scheme 12. Synthesis of tail-linker monomeric intermediates 18a–d.
L. Manzoni et al. / Bioorg. Med. Chem. 20 (2012) 6687–6708 66974. Experimental part
4.1. General methods
1H NMR spectra were recorded on a Bruker Avance instrument
in CDCl3, CD3OD or D2O as solvent at 400 or 600 MHz. 13C NMR
spectra were recorded in CDCl3, CD3OD or D2O as solvent at 100
or 125 MHz. Coupling constants are given in Hertz, Hz, and are
rounded to the nearest 0.1 Hz.
Puriﬁcationswere carried out either by ﬂash chromatography on
silica gel (particle size 60 lm, 230–400 mesh), Kieselgel, or by
Biotage™ ﬂash chromatography [Biotage columns Si-12-M (150 
12 mm; silica gel (40–63 lm), ﬂow rate 12 mL/min); Si-25-M
(150  25 mm; silica gel (40–63 lm), ﬂow rate 25 mL/min)], or by
Biotage™ C18 reverse phase chromatography [Biotage column
C18HS (150  25 mm; KP-C18-HS (35–70 lm), ﬂow rate 25 mL/
min)]. Final products were puriﬁed by C18 reverse phase semi-pre-
parative HPLC using either a Waters X-Terra RP18 OBD column
(19 mm  10.0 cm, 5 lm) or a Supelco Ascentis C18 column
(21.2 mm  15.0 cm, 5 lm).
LC–MS data were collected with an Agilent 1100 HPLC con-
nected to a Bruker Esquire 3000+ ion trap mass spectrometer
through an ES interface.
Optical rotations ½aD20 were measured in cells of 1 dm path-
length and 1 mL capacity with a Perkin Elmer 241 polarimeter.Solvents were distilled and dried according to standard proce-
dures, and reactions requiring anhydrous conditions were per-
formed under nitrogen or argon. Solvents for the reactions were
used directly from the bottle if not differently speciﬁed.
Standard dimers 355 and 557 were prepared according to the
published procedure.
4.2. Head–head dimer 8a—Scheme 1
4.2.1. Compound 11a
A solution of DCC (20.6 mg, 0.10 mmol) and DMAP (2.4 mg,
0.02 mmol) in dry CH2Cl2 (10 mL) was added dropwise to a stirred
solution of compound 4g (59.2 mg, 0.10 mmol) and propiolic acid
(6.2 lL, 0.10 mmol) in dry CH2Cl2 (10 mL) at 0 C. After the addition,
the reaction mixture was warmed to room temperature over a per-
iod of 1 h. After reaction completion, the reaction mixture was ﬁl-
tered, and the ﬁltrate was washed with diethyl ether (2  10 mL).
The combined organic phase was concentrated under reduced pres-
sure, and the crude product was puriﬁed by Biotage™ﬂash chroma-
tography, eluant conditions: 1% ofMeOHand99%of CH2Cl2 to 10%of
MeOH and 90% of CH2Cl2. Yield 85% (55 mg, MW 644.32,
0.085 mmol) of pure 11a. Analytical characterization: ½aD20 81.4
(c 0.75, MeOH); 1H NMR (400 MHz, CDCl3): d: 7.91 (d, J = 8.8 Hz,
1H), 7.50–7.10 (m, 11H), 6.24 (d, J = 8.4 Hz, 1H), 5.00 (d, J = 6.4 Hz,
1H), 4.75 (d, J = 7.2 Hz, 1H), 4.64 (t, J = 9.2 Hz, 1H), 4.20 (dd,
a11e - 93%
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a, 4.pentynoic acid, EDC, HOBt, DIPEA, CH2Cl2, rt, 
4 hrs; b, 18a, Cu(OAc)2, Na ascorbate, 
tBuOH:water 1:1, rt, 18 hrs; c, TFA, CH2Cl2, rt, 4 hrs.
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6698 L. Manzoni et al. / Bioorg. Med. Chem. 20 (2012) 6687–6708J = 10.8, 7.2 Hz, 1H), 4.06 (m, 2H), 3.85 (q, J = 8.4 Hz, 1H), 2.95 (s, 1H),
2.45 (m, 1H), 2.28 (m, 1H), 2.0–1.55 (m, 7H), 1.47 (s, 9H), 1.35–1.10
(m, 2H), 0.97 (t, J = 7.6 Hz, 3H); 13C NMR (100 MHz, CDCl3): d: 172.4,171.3, 169.5, 155.5, 152.2, 142.1, 141.1, 128.7, 127.3, 80.2, 74.6, 68.0,
61.0, 58.7, 56.8, 53.0, 39.1, 34.2, 33.3, 31.3, 28.3, 25.6, 10.4.
4.2.2. Compound 12a
A 0.9 M water solution of sodium ascorbate (45 lL, 0.4 mmol)
and a 0.3 M water solution of Cu(OAc)2 (65 lL, 0.02 mmol) were
sequentially added to a stirred solution of compounds 4e
(61.8 mg, 0.10 mmol) and 11a (64.4 mg, 0.10 mmol) in a 1:1 mix-
ture of H2O/tBuOH (300 lL). The reaction mixture was stirred over-
night at room temperature, and then the solvent was removed
under reduced pressure. Finally, the residue was puriﬁed by Bio-
tage™ ﬂash chromatography, eluant conditions: 1% of MeOH and
99% of CH2Cl2 to 10% of MeOH and 90% of CH2Cl2. Yield 47%
(59 mg, MW 1261.54, 0.047 mmol) of pure 11a. Analytical charac-
terization: ½aD20 64.3 (c 0.51, CHCl3); 1H NMR (400 MHz, CDCl3): d:
7.82 (d, J = 14.0, 1H), 7.73 (d, J = 8.4 Hz, 1H), 7.32–7.00 (m, 24H),
6.12 (t, J = 8 Hz, 2H), 5.07 (d, J = 5.6 Hz, 1H), 4.91 (d, J = 11.2 Hz,
1H), 4.64 (t, J = 6.4 Hz, 2H), 4.55 (m, 3H), 4.14 (t, J = 11.6 Hz, 1H),
3.98 (m, 2H), 3.73 (m, 3H), 3.14 (d, J = 12.0 Hz, 1H), 2.34 (m, 2H),
2.16 (m, 2H), 2.0–1.40 (m, 16H), 1.31 (s, 18H), 1.19 (s, 2H), 0.90
(m, 6H); 13C NMR (100 MHz, CDCl3): d: 173.1, 171.7, 170.6,
169.4, 169.2, 160.4, 142.1, 141.8, 141.0, 128.8, 128.7, 127.7,
127.5, 127.4, 127.2, 127.1, 61.3, 61.1, 58.8, 56.8, 56.7, 54.0, 53.7,
40.7, 40.6, 40.2, 34.4, 33.8, 33.3, 33.2, 31.4, 25.7, 25.5, 25.4, 10.3.
4.2.3. Compound 8a
A 3 N solution of HCl in MeOH (0.5 mL) was added to a stirred
solution of compound 12a (7.6 mg, 0.006 mmol) in MeOH (2 mL).
The reaction mixture was left stirring at room temperature
overnight and then concentrated under reduced pressure. The
.TFA
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b
a
19c - 67%
a,18d, HOBt, HBTU, collidine, dry DMF, 0° to rt, 18 hrs; b, TFA, CH2Cl2, rt, 4 hrs. 
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L. Manzoni et al. / Bioorg. Med. Chem. 20 (2012) 6687–6708 6699residue did not require any further puriﬁcation, and was lyophi-
lized. Yield 92% (6 mg, MW 1134.22, 0.0055 mmol) of pure 8a.
Analytical characterization: ½aD20 39.1 ( c 0.23, H2O); 1H NMR
(400 MHz, D2O): d: 8.35 (s, 1H), 7.32–7.18 (m, 20H), 5.97 (m,
2H), 4.61 (m, 3H), 4.48 (m, 2H), 4.35 (m, 1H), 3.9 (m, 4H), 3.5020a 
b,c
10d - 90%
19d - 57%
a, Cu(OAc)2, Na ascorbate, t-BuOH:water 1:1, rt, 18
c, 3N HCl in MeOH, rt, 18 hrs. 
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Scheme 16. Synthesis of(dd, J = 13.6, 8.4 Hz, 1H), 3.28 (dd, J = 12.8, 8.4 Hz,1H), 2.25–1.35
(m, 22H), 0.95 (m, 6H); 13C NMR (100 MHz, D2O): d: 172.7, 170.5,
169.8, 169.7, 161.9, 142.2, 141.0, 140.9, 129.0, 128.9, 127.8,
127.4, 127.1, 61.9, 58.6, 58.4, 57.6, 54.5, 54.4, 54.3, 41.0, 38.6,
38.1, 32.4, 32.3, 27.8, 24.4, 8.5, 8.4. ESI-MS: m/z 1061.5
[M+H]+1083.6 [M+Na]+, 531.3 [M+2H]2+.
4.3. Head–head dimer 8b—Scheme 1
The head–head dimer 8b was prepared similarly to 8a. The de-
tailed synthetic protocol leading to its synthesis, and its full syn-
thetic characterization are reported in the Supplementary data.
4.4. Head–head dimer 8c—Scheme 2
4.4.1. Compound 12c
A stirred suspension of compound 11b (67.2 mg, 0.10 mmol)
and Cu(OAc)2 (127.1 mg, 0.70 mmol) in acetonitrile (20 mL) was
reﬂuxed for 30 min After reaction completion, the solvent was re-
moved under reduced pressure, the residue was dissolved in
CH2Cl2 and Cu(II) salts were removed by ﬁltering over a short
pad of silica gel eluting with 9/1 CH2Cl2/MeOH. Finally, the crude
products was puriﬁed by Biotage™ ﬂash chromatography, eluant
conditions: 1% of MeOH and 99% of CH2Cl2 to 10% of MeOH and
90% of CH2Cl2. Yield 36% (48 mg, MW 1341.67, 0.036 mmol) of
pure 12c. Analytical characterization: ½aD20 69.3 (c 0.96, CHCl3);
1H NMR (400 MHz, CDCl3): d: 7.90 (d, J = 6.8 Hz, 2H), 7.36–7.16
(m, 25H), 6.22 (d, J = 8.0 Hz, 1H), 5.05 (bd, J = 6.4 Hz, 2H), 4.72 (d,
J = 8.0 Hz, 2H), 4.49 (t, J = 9.6 Hz, 2H), 3.98 (dd, J = 13.6, 7.6 Hz,
2H), 3.81 (dd, J = 17.6, 8.8, 2H), 3.58 (m, 2H), 3.01 (m, 1H), 2.58
(m, 4H), 2.40 (m, 6H), 2.25 (m, 2H), 1.95–1.55 (m, 16H), 1.45 (s,
18H), 1.30–1.10 (m, 2H), 1.00 (t, J = 7.6 Hz, 6H); 13C NMR13C
NMR (100 MHz, CDCl3): d: 173.6, 171.7, 170.8, 169.4, 141.2,
140.8, 128.6, 127.5, 127.4, 127.2, 80.5, 66.0, 61.2, 58.9, 57.0, 56.8,b,c
a
 hrs; b, piperidine, DMF, rt, 0.5 hrs;
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6700 L. Manzoni et al. / Bioorg. Med. Chem. 20 (2012) 6687–670854.0, 41.3, 40.0, 35.3, 34.5, 33.2, 28.3, 25.7, 25.2, 15.9, 10.3. ESI-MS:
m/z 1342.9 [M+H]+, 1363.9 [M+Na]+.
4.4.2. Compound 8c
A 3 N solution of HCl in MeOH (0.5 mL) was added to a stirred
solution of compound 12c (18.5 mg, 0.014 mmol) in MeOH
(2 mL). The reaction mixture was left stirring at room temperature
overnight and then concentrated under reduced pressure. The res-
idue did not require any further puriﬁcation, and was lyophilized.
Quantitative yield (17 mg, MW 1214.35, 0.014 mmol) of pure 8c.
Analytical characterization: ½aD20 43.1 ( c 0.90, H2O); 1H NMR
(400 MHz, D2O): d: 7.35–7.20 (m, 20H), 5.95 (s, 2H), 4.56 (d,
J = 10.4 Hz, 2H), 4.50 (dd, J = 7.6, 4.8 Hz, 2H), 3.98 (m, 4H), 3.23
(dd, J = 13.6, 3.2 Hz, 2H), 3.06 (m, 2H), 2.45–2.30 (m, 4H), 2.25–
1.40 (m, 26H), 0.97 (t, J = 7.2 Hz, 6H); 13C NMR (100 MHz, D2O):
d: 174.3, 172.4, 170.4, 169.6, 141.1, 140.9, 129.0, 128.9, 127.9,
127.8, 127.4, 127.0, 65.8, 61.7, 58.4, 57.7, 54.5, 54.4, 40.7, 37.6,
34.3, 32.6, 30.7, 27.8, 24.4, 15.5, 8.5. ESI-MS: m/z 1163.3
[M+Na]+, 571.1 [M+2H]2+.
4.5. Head–head dimer 8d—Scheme 3
4.5.1. Compound 12d
EDCHCl (23 mg, 0.12 mmol), HOBt (16.2 mg, 0.12 mmol) and
DIPEA (69.7 lL, 0.40 mmol) were sequentially added to a stirred
solution of 1,10-decanedioic acid (9.7 mg, 0.048 mmol) in dry
CH2Cl2 (2 mL) at room temperature. The reaction mixture was left
stirring for 15 min and then added to a stirred solution of 4h
(60.6 mg, 0.10 mmol) in dry CH2Cl2 (2 mL). The reaction mixture
was stirred at room temperature overnight and then, after reaction
completion, the solvent was removed under reduced pressure. The
crude product was diluted with EtOAc (20 mL) and washed with a
saturated solution of ammonium chloride (3  20 mL), saturated
solution of sodium bicarbonate (3  20 mL) and brine (1  20
mL). The organic layer was dried over Na2SO4, and then the solvent
removed under reduced pressure. The residue was puriﬁed by Bio-
tage™ ﬂash chromatography, eluant conditions: 1% of MeOH and
99% of CH2Cl2 to 10% of MeOH and 90% of CH2Cl2. Yield 68%
(48 mg, MW 1376.71, 0.034 mmol) of pure 12d. Analytical charac-
terization: ½aD20 96 (c 1.34, CHCl3); 1H NMR (400 MHz, CDCl3):
d: 7.82 (bs, 2H), 7.30–7.05 (m, 22H), 6.07 (m, 2H), 6.14 (d,
J = 8.0 Hz, 2H), 4.66 (d, J = 7.2 Hz, 2H), 4,38 (m, 4H), 3.68 (m, 2H),
3.54 (m, 2H), 2.77 (m, 8H), 2.35 (m, 2H), 2.15 (m, 2H), 2.10 (m,
4H), 1.95–1.45 (m, 22H), 1.40 (s, 18H), 1.30–1.15 (m, 10H), 1.05
(m, 2H), 0.85 (m, 6H); 13C NMR (100 MHz, CDCl3): d: 173.6,
172.8, 171.8, 169.3, 142.2, 128.6, 127.4, 127.3, 127.2, 61.1, 60.5,
58.9, 56.8, 53.7, 40.0, 37.0, 34.5, 33.2, 29.4, 28.3, 25.8, 25.5, 21.5,
10.7. ESI-MS: m/z 1377.4 [M+H]+, 589.2 [M+2H]2+.
4.5.2. Compound 8d
TFA (450 lL, 5.0 mmol) was added to a stirred solution of com-
pound 12d (37.8 mg, 0.028 mmol) in CH2Cl2 (2 mL). The reaction
mixture was left stirring at room temperature overnight and then
concentrated under reduced pressure. The residue was puriﬁed by
chromatography on a C18 reverse phase semi-preparative hplc col-
umn, eluant conditions: from 70% of H2O (0.2% TFA) and 30% of
CH3CN (0.2% TFA) to 30% of H2O (0.2% TFA) and 70% of CH3CN
(0.2% TFA), ﬂow rate 12 mL/min, 20 min runs. Yield 64% (25.3 mg,
MW 1405.59, 0.018 mmol) of pure 8d. Analytical characterization:
½aD20 61 (c 1.06, CH3OH); 1H NMR (400 MHz, D2O): d: 8.80 (m, 2H),
7.40–7.20 (m, 20H), 6.14 (s, 2H), 4.67 (m, 4H), 4.00 (m, 2H), 3.87
(bs, 2H), 3.44 (d, J = 13.6 Hz, 2H), 3.01 (t, J = 10 Hz, 2H), 2.70 (s,
6H), 2.85–2.70 (m, 6H), 2.70–1.75 (m, 16H), 1.70–1.55 (m, 8H),
1.32 (s, 8H), 1.05 (d, J = 7.0 Hz, 6H); 13C NMR (100 MHz, D2O): d:
175.1, 171.6, 169.6, 167.5, 141.7, 141.5, 128.3, 128.1, 127.2,
127.1, 126.9, 62.6, 61.5, 58.2, 57.0, 54.3, 40.9, 38.2, 35.7, 32.7,31.7, 31.0, 30.0, 28.9, 27.5, 25.6, 23.3, 8.0. ESI-MS: m/z 1177.6
[M+H]+, 589.2 [M+2H]2+.
4.6. Head–head dimers 8e,f—Scheme 3
The head–head dimers 8e and 8f were prepared similarly to 8d.
The detailed synthetic protocols leading to their synthesis, and
their full synthetic characterization are reported in the Supplemen-
tary data.
4.7. Head–head dimer 8g—Scheme 4
4.7.1. Compound 11c
EDCHCl (23 mg, 0.12 mmol), HOBt (16.2 mg, 0.12 mmol) and
DIPEA (69.7 lL, 0.40 mmol) were sequentially added to a stirred
solution of 6-heptynoic acid (15.2 lL, 0.12 mmol) in CH2Cl2
(2 mL) at room temperature. The reaction mixture was left stirring
for 15 min and then added to a stirred solution of 4h (60.6 mg,
0.10 mmol) in dry CH2Cl2 (2 mL). The reaction mixture was stirred
at room temperature overnight and then, after reaction completion,
the solvent was removed under reduced pressure. The crude prod-
uct was diluted with EtOAc (20 mL) and washed with a saturated
solution of ammonium chloride (3  20 mL), saturated solution of
sodium bicarbonate (3  20 mL) and brine (1  20 mL). The organic
layer was dried over Na2SO4, and then the solvent removed under
reduced pressure. The residue was puriﬁed by Biotage™ ﬂash chro-
matography, eluant conditions: from 50% of EtOAc and 50% of
Petroleum ether to 100% of EtOAc. Yield 92% (65 mg, MW 713.42,
0.092 mmol) of pure 11c. Analytical characterization: ½aD20 75 (c
0.90, CHCl3); 1H NMR (400 MHz, CDCl3): d: 7.92 (bs, 1H), 7.40–
7.15 (m, 11H), 6.23 (d, J = 8.4 Hz, 1H), 4.75 (d, J = 7.6 Hz, 1H),
4.46 (m, 2H), 3.77 (m, 1H), 3.60 (m, 1H), 2.88 (s, 6H), 2.85 (m,
1H), 2.47 (m, 1H), 2.23 (m, 4H), 2.00–1.55 (m, 14H), 1.50 (s, 9H),
1.45–1.05 (m, 2H), 0.94 (m, 1H); 13C NMR (100 MHz, CDCl3): d:
173.1, 172.9, 171.7, 169.3, 142.1, 128.5, 127.5, 127.4, 127.3,
127.2, 68.4, 61.1, 58.9, 56.8, 53.8, 40.0, 36.2, 34.5, 33.2, 28.4,
28.1, 25.5, 24.8, 21.6, 18.2, 10.8. ESI-MS: m/z 714.2 [M+H]+.
4.7.2. Compound 12g
A stirred suspension of compound 11c (71.4 mg, 0.10 mmol)
and Cu(OAc)2 (127.1 mg, 0.70 mmol) in acetonitrile (20 mL) was
reﬂuxed for 30 min. After reaction completion, the solvent was re-
moved under reduced pressure. The crude product was diluted
with EtOAc (20 mL) and washed with a saturated solution of
amonium chloride (3  10 mL) and brine (1  10 mL). Finally, the
crude product was puriﬁed by Biotage™ ﬂash chromatography,
eluant conditions: 1% of MeOH and 99% of CH2Cl2 to 10% of MeOH
and 90% of CH2Cl2. Yield 84% (60 mg, MW 1425.83, 0.042 mmol) of
pure 12g. Analytical characterization: ½aD20 85 (c 1.1, CHCl3); 1H
NMR (400 MHz, CDCl3): d: 7.83 (bs, 2H), 7.35–7.05 (m, 22H), 6.80
(m, 2H), 6.14 (m, 2H), 4.65 (bs, 2H), 4.37 (m, 4H), 3.68 (m, 2H),
3.52 (m, 2H), 2.78 (s, 6H), 2.66 (m, 2H), 2.36 (m, 2H), 2.25–2.10
(m, 10H), 1.95–1.45 (m, 22H), 1.40 (s, 18H), 1.35–1.00 (m, 4H),
0.87 (bs, 6H); 13C NMR (100 MHz, CDCl3): d: 172.9, 171.7, 169.3,
142.1, 128.6, 127.5, 127.4, 127.3, 65.6, 61.1, 60.6, 58.9, 56.8, 53.7,
41.1, 40.0, 36.2, 34.5, 33.2, 31.8, 28.3, 28.0, 25.5, 24.9, 21.6, 19.0,
10.8. ESI-MS: m/z 1426.6 [M+H]+, 613.2 [M+2H]2+.
4.7.3. Compound 8g
TFA (450 lL, 5.0 mmol) was added to a stirred solution of com-
pound 12g (94.1 mg, 0.066 mmol) in CH2Cl2 (2 mL). The reaction
mixture was left stirring at room temperature overnight and then
concentrated under reduced pressure. The residue was puriﬁed by
chromatography on a C18 reverse phase semi-preparative hplc col-
umn, eluant conditions: from 70% of H2O (0.2% TFA) and 30% of
CH3CN (0.2% TFA) to 30% of H2O (0.2% TFA) and 70% of CH3CN
(0.2% TFA), ﬂow rate 12 mL/min, 20 min runs. Yield 41% (39 mg,
L. Manzoni et al. / Bioorg. Med. Chem. 20 (2012) 6687–6708 6701MW 1453.64, 0.027 mmol) of pure 8g. Analytical characterization:
½aD20 84 (c 1.16, CH3OH); 1H NMR (400 MHz, D2O): d: 8.80 (m,
2H), 7.40–7.20 (m, 20H), 6.14 (s, 2H), 4.67 (m, 4H), 4.02 (bs, 2H),
3.87 (bs, 2H), 3.44 (d, J = 13.2 Hz, 2H), 3.07 (t, J = 11.2 Hz, 2H),
2.72 (s, 6H), 2.40–2.20 (m, 10H), 2.20–180 (m, 16H), 1.75–1.60
(m, 8H), 1.60–1.45 (m, 4H), 1.05 (d, J = 7.1 Hz, 6H); 13C NMR
(100 MHz, D2O): d: 174.6, 171.6, 169.6, 167.5, 141.7, 141.5,
128.3, 128.1, 127.3, 127.2, 127.0, 126.9, 76.3, 65.4, 62.6, 61.6,
58.3, 57.0, 54.3, 40.9, 38.3, 35.1, 32.7, 31.7, 31.0, 30.2, 27.7, 27.5,
24.8, 23.2, 18.1, 7.8. ESI-MS: m/z 1226.0 [M+H]+, 613.7 [M+2H]2+.
4.8. Head–head dimer 8h—Scheme 5
4.8.1. Compound 12h
A 0.9 M aqueous solution of sodium ascorbate (61 lL,
0.055 mmol) and a 0.3 M aqueous solution of Cu(OAc)2 (83 lL,
0.025 mmol) were sequentially added to a stirred solution of com-
pound 11c (0.10 mmol) and 1,4-(40-azidobutyl)benzene61 (13.6 mg,
0.05 mmol) in a 1:1 mixture of H2O/tBuOH (300 lL). The reaction
mixture was stirred overnight at room temperature and then the
solvent was removed under reduced pressure. The crude product
wasdilutedwithEtOAc (20 mL)andwashedwitha saturated solution
of amonium chloride (3  20mL) and brine (1 20mL). The residue
was puriﬁed by Biotage™ ﬂash chromatography, eluant conditions:
1% of MeOH and 99% of CH2Cl2 to 10% of MeOH and 90% of CH2Cl2.
Yield 32% (27 mg, MW 1700.21, 0.016 mmol) of pure 12h. Analytical
characterization: ½aD20 84 (c 1.16, CHCl3); 1H NMR (400 MHz,
CDCl3): d: 7.84 (bs, 2H), 7.37 (bs, 2H), 7.35–7.15 (m, 22H), 7.09
(d, J = 6.8 Hz, 2H), 6.98 (s, 4H), 6.13 (d, J = 7.6 Hz, 2H), 4.65 (d,
J = 6.8 Hz, 2H), 4.48 (m, 4H), 4.20 (m, 4H), 3.70 (m, 2H), 3.46 (m,
2H), 2.78 (s, 6H), 2.75 (m, 2H), 2.65 (s, 4H), 2.53 (t, J = 6.4 Hz,
4H), 2.34 (m, 2H), 2.17 (m, 6H), 1.95–1.50 (m, 28H), 1.40 (s,
18H), 1.39 (m, 2H), 1.05 (m, 2H), 0.85 (bs, 6H); 13C NMR
(100 MHz, CDCl3): d: 174.9, 173.0, 171.8, 169.4, 150.0, 140.5,
139.0, 1.38.0, 138.6, 128.4, 127.5, 127.3, 120.6, 80.5, 61.2, 60.6,
59.0, 56.9, 53.8, 50.0, 41.3, 40.1, 36.3, 34.8, 34.4, 33.2, 31.8, 30.5,
29.8, 28.9, 28.3, 25.6, 25.3, 21.7, 20.7, 10.8. ESI-MS: m/z 1699.6
[M+H]+, 850.8 [M+2H]2+.
4.8.2. Compound 8h
TFA (450 lL, 5.0 mmol) was added to a stirred solution of com-
pound12h (21.2 mg,0.013 mmol) inCH2Cl2 (2 mL).The reactionmix-
ture was left stirring at room temperature overnight and then
concentrated under reduced pressure. The residue was puriﬁed by
chromatography on a C18 reverse phase semi-preparative hplc col-
umn, eluant conditions: from70%ofH2O (0.2%TFA)and30%ofCH3CN
(0.2% TFA) to 30%ofH2O (0.2%TFA) and70%of CH3CN(0.2%TFA), ﬂow
rate 12 mL/min, 20 min runs. Yield 92% (24 mg, MW 1728.01,
0.011 mmol) of pure 8h. Analytical characterization: ½a20D 99 (c
1.16, CH3OH); 1H NMR (400 MHz, D2O): d: 8.80 (m, 2H), 7.76 (s,
2H), 7.40–7.15 (m, 20H), 7.06 (s, 4H), 6.14 (s, 2H), 4.66 (m, 4H),
4.37 (t, J = 6.4 Hz, 4H), 4.00 (m, 2H), 3.87 (m, 2H), 3.44 (d,
J = 13.2 Hz, 2H), 3.05 (t, J = 11.6 Hz, 2H), 2–74–2.68 (m, 10H),
2.59 (t, J = 6.8 Hz, 4H), 2.26 (m, 6H), 2.15–1.75 (m, 21H), 1.70–
1.50 (m, 17H), 1.06 (t, J = 7.2 Hz, 6H); 13C NMR (100 MHz, D2O):
d: 174.7, 171.6, 169.6, 167.5, 147.1, 141.7, 141.6, 139.2, 128.3,
128.1, 127.3, 127.1, 126.9, 122.2, 62.6, 61.6, 58.3, 57.1, 54.3, 50.0,
41.0, 38.3, 35.3, 34.2, 32.7, 31.7, 31.0, 30.2, 29.3, 28.5, 28.0, 27.6,
25.0, 24.3, 23.2, 7.8. ESI-MS: m/z 1500.2 [M+H]+, 751.2 [M+2H]2+.4.9. Head–head dimer 8i—Scheme 6
4.9.1. Compound 11d
EDCHCl (23 mg, 0.12 mmol), HOBt (16.2 mg, 0.12 mmol) and
DIPEA (69.7 lL, 0.40 mmol) were sequentially added to a stirredsolution of Cbz-b-Ala-OH (26.8 mg, 0.12 mmol) in CH2Cl2 (2 mL)
at room temperature. The reaction mixture was left stirring for
15 min and then added to a stirred solution of 4h (60.6 mg,
0.10 mmol) in dry CH2Cl2 (2 mL). The reaction mixture was stirred
at room temperature overnight and then, after reaction comple-
tion, the solvent was removed under reduced pressure. The crude
product was diluted with EtOAc (20 mL) and washed with a satu-
rated solution of ammonium chloride (3  20 mL), saturated solu-
tion of sodium bicarbonate (3  20 mL) and brine (1  20 mL). The
organic layer was dried over Na2SO4, and then the solvent removed
under reduced pressure. The residue was puriﬁed by Biotage™
ﬂash chromatography, eluant conditions: from 50% of EtOAc and
50% of Petroleum ether to 100% of EtOAc. Yield 99% (80 mg, MW
811.00, 0.099 mmol) of pure 11d. Analytical characterization:
½aD20 118 (c 1.14, CHCl3); 1H NMR (400 MHz, CDCl3): d: 7.80 (d,
J = 8.0 Hz, 2H), 7.30–7.15 (m, 14H), 7.10 (d, J = 7.6 Hz, 2H), 6.13
(d, J = 8.8 Hz, 2H), 5.02 (t, J = 12.0 Hz, 2H), 4.63 (d, J = 7.6 Hz, 1H),
4.31 (m, 2H), 3.62 (m, 1H), 3.40 (m, 3H), 2.75 (m, 3H), 2.35 (m,
3H), 2.12 (m, 1H), 1.90–1.50 (m, 8H), 1.39 (s, 9H), 1.35 (m, 1H),
1.05 (m, 1H), 0.85 (t , J = 6.8 Hz, 3H); 13C NMR (100 MHz, CDCl3):
d:.173.0, 171.6, 169.3, 156.4, 136.7, 128.7, 128.6, 128.4, 128.0,
127.4, 127.3, 127.2, 80.4, 66.5, 61.1, 60.8, 58.8, 56.8, 53.8, 41.3,
40.1, 37.3, 35.9, 34.5, 33.1, 32.0, 30.1, 28.4, 25.5, 21.8, 10.8. ESI-
MS: m/z 811.6 [M+H]+.
4.9.2. Compound 12i
A solution of compound 11d (67.6 mg, 0.1 mmol) in EtOH/H2O
9:1 (10 mL) was Cbz-deprotected by continuous ﬂow hydrogena-
tion using the H-Cube™ system. The hydrogenation was performed
using a Pd/C catalyst cartridge column (CatCart™). The reactor
pressure and temperature were ﬁxed at 10 bar and 40 C, and a
ﬂow rate of 0.8 ml/min was set. After reaction completion, the sol-
vent was removed under reduced pressure.
The crude hydrogenation product was dissolved in EtOH (1 mL),
and then diethyl squarate (7.1 lL, 0.048 mmol), Et3N (55.8 lL,
0.4 mmol) and a catalytic amount of DMAP (1.2 mg, 0.01 mmol)
were sequentially added at room temperature. The reaction mix-
ture was left stirring overnight at room temperature. After reaction
completion, the solvent was removed under reduced pressure, the
crude product was diluted with EtOAc (20 mL) and washed with
water (3  20 mL). The organic layer was dried over Na2SO4, and
then the solvent was removed under reduced pressure. Finally,
the crude product was puriﬁed by Biotage™ ﬂash chromatography,
eluant conditions: 1% of MeOH and 99% of CH2Cl2 to 10% of MeOH
and 90% of CH2Cl2. Yield 92% (63 mg, MW 1431.75, 0.044 mmol) of
pure 12i. Analytical characterization: ½aD20 88 (c 1.60, CHCl3); 1H
NMR (400 MHz, CDCl3): d: 7.76 (d, J = 8.4 Hz, 2H), 7.30–7.10 (m,
22H), 6.13 (d, J = 8.8 Hz, 2H), 4.63 (d, J = 7.2 Hz, 2H), 4.35 (m, 4H),
3.75 (m, 5H), 3.25 (bs, 2H), 2.95 (bs, 2H), 2.73 (s, 6H), 2.42 (bs,
4H), 2.30 (m, 2H), 2.18 (m, 2H), 1.95–1.60 (m, 14H), 1.50 (m,
2H), 1.40 (s, 18H), 1.20 (m, 2H), 0.84 (t, J = 6.8 Hz, 6H); 13C NMR
(100 MHz, CDCl3): d: 171.4, 169.6, 142.1, 141.2, 128.7, 127.4,
127.2, 61.2, 58.8, 56.8, 53.8, 41.5, 40.8, 39.9, 36.9, 34.0, 33.1,
31.8, 30.7, 25.8, 21.6, 10.5. ESI-MS: m/z 1432.0 [M+H]+.
4.9.3. Compound 8i
TFA (450 lL, 5.0 mmol) was added to a stirred solution of com-
pound 12i (41.5 mg, 0.029 mmol) in CH2Cl2 (2 mL). The reaction
mixture was left stirring at room temperature overnight and then
concentrated under reduced pressure. The residue was puriﬁed by
chromatography on a C18 reverse phase semi-preparative hplc col-
umn, eluant conditions: from 70% of H2O (0.2% TFA) and 30% of
CH3CN (0.2% TFA) to 30% of H2O (0.2% TFA) and 70% of CH3CN
(0.2% TFA), ﬂow rate 12 mL/min, 20 min runs. Yield 83% (35 mg,
MW 1459.56, 0.024 mmol) of pure 8i. Analytical characterization:
½aD20 113 (c 1.20, CH3OH); 1H NMR (400 MHz, D2O): d:
6702 L. Manzoni et al. / Bioorg. Med. Chem. 20 (2012) 6687–67087.35–7.25 (m, 20H), 6.00 (s, 2H), 4.57 (d, J = 10.0 Hz, 2H), 4.48 (dd,
J = 7.6, 5.2 Hz, 2H), 3.95 (m, 2H), 3.88 (dd, J = 7.2, 5.2 Hz, 2H), 3.71
(m, 4H), 3.30 (dd, J = 13.6, 3.6 Hz, 2H), 2.99 (dd, J = 13.6, 9.6 Hz,
2H), 2.64 (s, 6H), 2.44 (m, 4H), 2.20–2.05 (m, 4H), 1.95–1.85 (m,
8H), 1.80–1.60 (m, 6H), 1.50–1.35 (m, 4H), 0.94 (t, J = 7.2 Hz, 6H);
13C NMR (100 MHz, D2O): d: 181.7, 172.9, 172.0, 169.9, 168.4,
167.9, 141.3, 141.0, 128.8, 127.6, 127.5, 127.3, 127.0, 62.7, 61.6,
58.2, 57.4, 54.5, 40.7, 37.5, 37.0, 32.4, 31.6, 30.7, 27.7, 23.4, 8.3.
ESI-MS: m/z 1231.9 [M+H]+, 616.5 [M+2H]2+.4.10. Tail–tail dimer 9a—Scheme 7
4.10.1. Compound 13a
EDCHCl (69 mg, 0.36 mmol), HOBt (48.6 mg, 0.36 mmol) andDI-
PEA (209 lL, 1.20 mmol) were sequentially added to a stirred solu-
tion of 4d (132.5 mg, 0.3 mmol) in CH2Cl2 (10 mL) at room
temperature. The reaction mixture was left stirring for 15 min and
then added to a stirred solution of (S)-3-amino-3-phenylprop-1-
yne (13.1 mg, 0.10 mmol) in dry CH2Cl2 (10 mL). The reaction
mixture was stirred at room temperature overnight and then, after
reaction completion, the solvent was removed under reduced pres-
sure. The crudeproductwas dilutedwith EtOAc (20 mL) andwashed
with a saturated solution of ammonium chloride (3  20 mL), satu-
rated solution of sodium bicarbonate (3  20 mL) and brine
(1  20 mL). The organic layer was dried over Na2SO4, and then
the solvent was removed under reduced pressure. The residue was
puriﬁed by Biotage™ ﬂash chromatography, eluant conditions:
50% of EtOAc and 50% of Petroleum ether to 100% of EtOAc. Yield
67% (112 mg, MW 554.69, 0.201 mmol) of pure 13a. Analytical
characterization: ½aD20 116 (c 1.5, CHCl3); 1H NMR (400 MHz,
CDCl3): d: 7.65 (d, J = 7.6 Hz, 1H), 7.36 (m, 3H), 7.20 (m, 3H), 5.87
(d, J = 6.8 Hz, 1H), 4.61 (d, J = 6.0 Hz, 1H), 4.42–4.30 (m, 2H), 3.67
(m, 1H), 3.47 (d, J = 11.6 Hz, 1H), 3.14 (d, J = 12.0, 1H), 2.78 (s,
3H), 2.42 (s, 1H), 2.36 (m, 1H), 2.18 (m, 1H), 2.00–1.70 (m, 4H),
1.70–1.55 (m, 3H), 1.44 (s, 9H), 0.97 (m, 1H), 0.84 (m, 4H); 13C
NMR (100 MHz, CDCl3): d: 171.7, 138.9, 128.9, 126.8, 73.0, 64.1,
60.8, 60.2, 58.7, 53.6, 44.4, 41.5, 34.6, 33.2, 31.0, 30.0, 28.4, 25.4,
21.4, 10.6. ESI-MS: m/z 555.4 [M+H]+, 577.3 [M+Na]+.4.10.2. Compound 14a
A 0.9 Mwater solution of sodium ascorbate (61 lL, 0.055 mmol)
and a 0.3 M water solution of Cu(OAc)2 (83 lL, 0.025 mmol) were
sequentially added to a stirred solution of compound 13a (61 mg,
0.11 mmol) and 1,4-(40-azidobutyl)benzene61 (13.6 mg,
0.05 mmol) in a 1:1 mixture of H2O/tBuOH (300 lL). The reaction
mixture was stirred overnight at room temperature and then the
solvent was removed under reduced pressure. The crude product
was diluted with EtOAc (20 mL) and washed with a saturated solu-
tion of ammonium chloride (3  20 mL) and brine (1  20 mL). The
organic layer was dried over Na2SO4, and then the solvent was re-
moved under reduced pressure. Finally, the residue was puriﬁed by
Biotage™ ﬂash chromatography, eluant conditions: 1% of MeOH
and 99% of CH2Cl2 to 10% of MeOH and 90% of CH2Cl2. Yield 74%
(51 mg, MW 1381.74, 0.037 mmol) of pure 14a. Analytical charac-
terization: ½aD20 83 (c 1.15, CHCl3); 1H NMR (400 MHz, CDCl3): d:
7.94 (m, 2H), 7.42 (m, 2H), 7.30–7.10 (m, 12H), 6.96 (s, 4H), 6.20 (d,
J = 6.4 Hz, 2H), 4.64 (bs, 2H), 4.38 (m, 4H), 4.23 (bs, 4H), 3.70 (m,
2H), 3.53 (d, J = 12.0 Hz, 2H), 3.21 (d, J = 12.0 Hz, 2H), 2.79 (s,
6H), 2.53 (bs, 4H), 2.27 (m, 2H), 2.16 (m, 2H), 2.05–1.60 (m,
18H), 1.56 (m, 4H), 1.42 (s, 18H), 1.14 (m, 4H), 0.84 (bs, 6H); 13C
NMR (100 MHz, CDCl3): d: 173.0, 171.5, 169.6, 140.9, 139.0,
128.6, 128.4, 127.7, 127.1, 121.4, 80.0, 64.3, 61.2, 60.2, 58.8, 53.8,
50.2, 50.0, 41.6, 34.7, 34.5, 33.1, 31.1, 29.7, 28.4, 28.2, 26.0, 21.5,
10.7. ESI-MS: m/z 1382.1 [M+H]+, 691.7 [M+2H]2+.4.10.3. Compound 9a
TFA (450 lL, 5.0 mmol) was added to a stirred solution of com-
pound 14a (30.4 mg, 0.022 mmol) in CH2Cl2 (2 mL). The reaction
mixture was left stirring at room temperature overnight and then
concentrated under reduced pressure. The residue was puriﬁed by
chromatography on a C18 reverse phase semi-preparative hplc col-
umn, eluant conditions: from 90% of H2O (0.2% TFA) and 10% of
MeOH/iPrOH 6:4 (0.2% TFA) to 100% of MeOH/iPrOH 6:4 (0.2%
TFA), ﬂow rate 12 ml/min, 20 min runs. Yield 59% (18 mg, MW
1409.54, 0.013 mmol) of pure 9a. Analytical characterization:
½aD20 110 (c 0.41, CH3OH); 1H NMR (400 MHz, D2O): d: 7.53 (s,
2H), 7.20–7.05 (m, 10H), 6.59 (s, 4H), 6.10 (s, 2H), 4.57 (d,
J = 9.2 Hz, 2H), 4.38 (bs, 2H), 3.96 (bs, 4H), 3.81 (m, 4H), 3–49
(bs, 4H), 2.62 (s, 6H), 2.08 (bs, 4H), 2.00–1.80 (m, 10H), 1.75–
1.55 (m, 8H), 1.50–1.35 (m, 8H), 1.08 (bs, 4H), 0.88 (d, J = 7.2 Hz,
6H); 13C NMR (100 MHz, D2O): d: 172.3, 170.7, 168.0, 147.9,
139.4, 139.1, 128.8, 128.2, 128.0, 127.0, 123.0, 63.1, 62.7, 61.6,
58.5, 54.3, 50.0, 49.9, 39.0, 32.3, 31.5, 29.4, 28.9, 27.7, 27.5, 23.4,
8.3. ESI-MS: m/z 1181.9 [M+H]+, 1204.2 [M+Na]+, 591.8 [M+2H]2+.
4.11. Tail–tail dimer 9b—Schemes 8 and 9
4.11.1. Compound 16a
HOBt (104 mg, 0.77 mmol), HBTU (292 mg, 0.77 mmol) and
Sym-collidine (169.1 lL, 1.28 mmol) were sequentially added to
a stirred solution of commercially available 15a (46.2 mg,
0.32 mmol) and N-Boc-(S)-2-Phenylglycine (200.9 mg, 0.80 mmol)
in dry DMF (2 mL) at 0 C. The reaction mixture was left stirring
for 2 h and then, after reaction completion, the mixture was di-
luted with EtOAc (20 mL) and washed with a saturated solution
of ammonium chloride (3  20 mL), saturated solution of sodium
bicarbonate (3  20 mL) and brine (1  20 mL. The organic layers
were dried over Na2SO4, and then the solvent was removed under
reduced pressure. The residue was puriﬁed by Biotage™ ﬂash chro-
matography, eluant conditions: from 1% of MeOH and 99% of
CH2Cl2 to 10% of MeOH and 90% of CH2Cl2. Yield 94% (183 mg,
MW 610.80, 0.30 mmol) of pure 16a. Analytical characterization:
1H NMR (400 MHz, CDCl3):d: 7.38–7.25 (m, 10H), 5.76 (m, 2H),
5.25 (m, 2H), 3.32 (bs, 1H), 3.23 (m, 2H), 3.13 (bs, 1H), 1.57 (s,
4H), 1.42 (m, 18H), 1.21 (d, J = 11.2 Hz, 6H); 13C NMR (100 MHz,
CDCl3): d: 129.0, 128.9, 128.3, 127.2, 39.7, 39.7, 29.2, 28.8, 28.3,
26.4. ESI-MS: m/z 611.4 [M+H]+.
4.11.2. Compound 17a
TFA (450 lL, 5.0 mmol) was added to a stirred solution of com-
pound 16a (165 mg, 0.27 mmol) in CH2Cl2 (3 mL). The reaction
mixture was left stirring at room temperature and then concen-
trated under reduced pressure to give a crude residue which was
used without puriﬁcation. Quantitative yield (172.4 mg, MW
638.56, 0.27 mmol) of 17a.
4.11.3. Compound 14b
HOBt (32.4 mg, 0.24 mmol), HBTU (91 mg, 0.24 mmol) and
Sym-collidine (52.9 lL, 0.4 mmol) were sequentially added to a
stirred solution of 4d (110.4 mg, 0.25 mmol) and 17a (63.9 mg,
0.10 mmol) in dry DMF (2 mL) at 0 C. The reaction mixture was
left stirring for 2 h and then, after reaction completion, the mixture
was diluted with EtOAc (20 mL) and washed with a saturated solu-
tion of ammonium chloride (3  20 mL), saturated solution of so-
dium bicarbonate (3  20 mL) and brine (1  20 mL). The organic
layers were dried over Na2SO4, and then the solvent was removed
under reduced pressure. The residue was puriﬁed by Biotage™
ﬂash chromatography, eluant conditions: 1% of MeOH and 99% of
CH2Cl2 to 10% of MeOH and 90% of CH2Cl2. Yield 97% (122 mg,
MW 1257.59, 0.094 mmol) of pure 14b. Analytical characteriza-
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(d, J = 8 Hz, 2H), 8.17 (t, J = 5.6 Hz, 2H), 7.86 (bs, 2H), 7.40–7.25 (m,
10H), 5.36 (d, J = 8 Hz, 2H), 4.61 (dd, J = 7.2, 4 Hz, 2H), 4.48–4.36
(m, 4H), 3.89 (m, 2H), 3.45 (bs, 2H), 3.25 (m, 2H), 3.00 (m, 4H),
2.70 (s, 6H), 2.16 (m, 2H), 2.14 (m, 2H), 2.00–1.75 (m, 8H), 1.70–
1.45 (m, 10H), 1.40 (s, 18H), 1.35 (m, 4H), 1.15 (s, 8H), 0.80 (bs,
6H); 13C NMR (100 MHz, CDCl3): d: 171.2, 170.3, 169.9, 139.4,
128.6, 127.8, 127.5, 79.5, 63.1, 61.1, 58.0, 56.8, 53.9, 41.0, 39.0,
33.2, 32.8, 30.2, 29.3, 29.0, 28.5, 28.1, 26.6, 11.2 . ESI-MS: m/z
1257.9 [M+H]+.
4.11.4. Compound 9b
TFA (450 lL, 5.0 mmol) was added to a stirred solution of com-
pound 14b (93.1 mg, 0.074 mmol) in CH2Cl2 (2 mL). The reaction
mixture was left stirring at room temperature overnight and then
concentrated under reduced pressure. The residue was puriﬁed by
chromatography on a C18 reverse phase semi-preparative hplc col-
umn, eluant conditions: from 70% of H2O (0.2% TFA) and 30% of
CH3CN (0.2% TFA) to 30% of H2O (0.2% TFA) and 70% of CH3CN
(0.2% TFA), ﬂow rate 12 ml/min, 20 min runs. Yield 58% (55 mg,
MW 1285.35, 0.043 mmol) of pure 9b. Analytical characterization:
½aD20 94 (c 1.44, CH3OH); 1H NMR (400 MHz, D2O): d: 7.41 (m,
10H), 5.29 (s, 2H), 4.70 (m, 2H), 4.53 (dd, J = 8.0, 4.4 Hz, 2H), 4.05
(m, 2H), 3.88 (dd, J = 7.2, 5.2 Hz, 2H), 3.61 (m, 2H), 3.25 (m, 2H),
3.05 (m, 2H), 2.68 (s, 6H), 2.25 (m, 2H), 2.15 (m, 2H), 2.05 (m,
4H), 1.95 (m, 6H), 1.85 (m, 3H), 1.75 (m, 4H), 1.60 (m, 2H), 1.35
(m, 4H), 1.012(bs, 8H), 0.96 (t, J = 8.0 Hz, 6H); 13C NMR
(100 MHz, D2O): d: 173.2, 171.6, 171.2, 168.3, 136.1, 129.2, 129.0,
127.3, 63.2, 62.8, 61.8, 58.8, 58.2, 54.5, 39.3, 39.0, 32.4, 31.5,
31.4, 29.5, 28.1, 27.8, 25.6, 23.4, 8.2. ESI-MS: m/z 1057.9 [M+H]+.
4.12. Tail–tail dimers 9c–e—Schemes 8 and 9
The tail–tail dimers 9c, 9d and 9ewere prepared similarly to 9b.
The detailed synthetic protocols leading to their synthesis, and
their full synthetic characterization are reported in the Supplemen-
tary data.
4.13. Tail–tail dimer 9f—Scheme 10
4.13.1. Compound 14f
Dry TEA (83.6 lL, 0.6 mmol) and MsCl (46.4 lL, 0.6 mmol) were
sequentially added to a stirred solution of compound 14a
(0.1 mmol) in dry CH2Cl2 (4 mL) under argon at 0 C. The reaction
mixture was stirred at room temperature for 2 h. After reaction
completion, the resulting mixture was diluted with CH2Cl2
(20 mL) and washed with a saturated solution of ammonium chlo-
ride (3  20 mL). The combined organic layers were dried over
Na2SO4, and then the solvent was removed under reduced pressure.
The crude mesylate was dissolved in dry DMF (10 mL) under ar-
gon at room temperature, and then NaN3 (130 mg, 2 mmol) was
added. The reaction mixture was heated at 100 C for 30 min, while
being irradiated in a microwave reactor. After reaction completion
most of the DMF was removed under reduced pressure, the crude
was diluted with EtOAc (20 mL) and washed with water
(3  20 mL). The organic layer was dried over Na2SO4, and then
the solvent was removed under reduced pressure. Finally, the
crude product was puriﬁed by Biotage™ ﬂash chromatography.
eluant conditions: 1% of MeOH and 99% of CH2Cl2 to 10% of MeOH
and 90% of CH2Cl2. Yield 58% (83 mg, MW 1431.77, 0.058 mmol) of
pure 14f. Analytical characterization: ½aD20 105 (c 1.31, CHCl3); 1H
NMR (400 MHz, CDCl3): d: 8.03 (m, 2H), 7.40–7.20 (m, 12H), 7.05
(m, 6H), 6.29 (d, J = 7.6 Hz, 2H), 4.71 (d, J = 6.4 Hz, 2H), 4.58 (m,
2H), 4.49 (m, 2H), 4.33 (bs, 4H), 3.83 (m, 2H), 3.42 (bd,
J = 11.6 Hz, 2H), 3.16 (t, J = 12.8 Hz, 2H), 2.86 (s, 6H), 2.62 (m,
4H), 2.36 (m, 2H), 2.23 (m, 2H), 2.05–2.60 (m, 22H), 1.55 (bs,20H), 1.22 (m, 2H), 0.85 (bs, 6H) ; 13C NMR (100 MHz, CDCl3): d:
171.5, 171.0, 169.6, 140.7, 139.0, 128.7, 128.4, 127.9, 127.1,
121.6, 61.0, 59.0, 58.7, 53.6, 53.2, 50.3, 50.0, 34.7, 34.1, 33.3, 32.1,
29.7, 28.4, 28.2, 26.0, 21.4, 10.6. ESI-MS: m/z 1433.1 [M+H]+,
666.7 [M+2H]2+.
4.13.2. Compound 14g
A 1 N solution of (CH3)3P in toluene (105 lL, 0.105 mmol) was
added dropwise to a stirred solution of compound 14f (50.1 mg,
0.035 mmol) in dry CH2Cl2 (10 mL) under argon at room tempera-
ture. After 2 h, a 1 N HCl aqueous solution (10 mL) was added to
the reaction mixture, and stirring at room temperature was contin-
ued for further 20 min. After reaction completion, the reaction
mixture was neutralized with sodium bicarbonate and extracted
with CH2Cl2 (3  20 mL). The organic layers were combined and
dried over Na2SO4, and the solvent was removed under reduced
pressure. The crude product did not require any further puriﬁca-
tion, and was characterized as such. Yield 99% (48 mg, MW
1379.77, 0.035 mmol) of pure 14g. Analytical characterization:
½aD20 120 (c 0.48, CHCl3); 1H NMR (400 MHz, CDCl3): d: 8.35 (m,
4H), 7.88 (m, 2H), 7.35–7.15 (m, 12H), 6.93 (m, 4H), 6.14 (d,
J = 6.4 Hz, 2H), 4.62 (bs, 2H), 4.40 (m, 4H), 4.24 (bs, 4H), 3.70 (m,
2H), 3.00–2.65 (m, 10H), 2.52 (bs, 4H), 2.30–2.05 (m, 4H), 2.00–
1.55 (m, 20H), 1.54 (m, 4H), 1.39 (s, 18H), 1.19 (m, 4H), 0.84 (bs,
6H); 13C NMR (100 MHz, CDCl3): d: 173.2, 171.7, 169.2, 141.9,
139.3, 129.6, 128.2, 127.5, 127.4, 122.4, 81.0, 64.5, 61.4, 60.1,
58.8, 53.8, 50.2, 50.0, 41.6, 35.7, 33.5, 33.1, 31.5, 29.7, 28.4, 28.2,
26.0, 21.5, 10.4. ESI-MS: m/z 1380.1 [M+H]+, 691.2 [M+2H]2+.
4.13.3. Compound 14h
NaBH(OAc)3 (16.5 mg, 0.078 mmol) was added to a stirred solu-
tion of compound 14g (41.4 mg, 0.03 mmol) and benzaldehyde
(5.5 lL, 0.054 mmol) in dry CH2Cl2 (5 mL). The reaction mixture
was stirred overnight at room temperature, and then the solvent
was removed under reduced pressure. Finally, the crude product
was puriﬁed by Biotage™ ﬂash chromatography, eluant condi-
tions: 1% of MeOH and 99% of CH2Cl2 to 10% of MeOH and 90% of
CH2Cl2. Yield 45% (21 mg, MW 1560.32, 0.0135 mmol) of pure
14h. Analytical characterization: ½aD20 150 (c 0.70, CHCl3); 1H
NMR (400 MHz, CDCl3): d: 8.25 (bs, 2H), 8.03 (m, 2H), 7.40–7.24
(m, 20H), 7.18 (m, 2H), 7.05 (s, 4H), 6.28 (d, J = 7.6 Hz, 2H), 4,73
(bs, 2H), 4.49 (m, 4H), 4.30 (s, 4H), 3.95–3.75 (m, 6H), 2.95–2.75
(m, 6H), 2.70–2.50 (m, 8H), 2.35 (m, 2H), 2.23 (m, 2H), 2.25–1.55
(m, 22H), 1.49 (m, 20H), 1.24 (m, 2H), 0.93 (bs, 6H); 13C NMR
(100 MHz, CDCl3): d: 169.9, 147.8, 141.0, 139.1, 128.8, 128.6,
127.6, 127.2, 127.0, 121.5, 61.0, 58.4, 50.2, 50.0, 38.1, 34.7, 33.3,
33.2, 29.7, 28.5, 28.2, 26.0, 22.1, 10.6. ESI-MS: m/z 1561.4
[M+H]+, 781.0 [M+2H]2+.
4.13.4. Compound 9f
TFA (90 lL, 1.0 mmol) was added to a stirred solution of com-
pound 14h (20.3 mg, 0.013 mmol) in CH2Cl2 (2 mL). The reaction
mixture was left stirring at room temperature overnight and then
concentrated under reduced pressure. The residue was puriﬁed by
chromatography on a C18 reverse phase semi-preparative hplc col-
umn, eluant conditions: from 90% of H2O (0.2% TFA) and 10% of
MeOH/iPrOH 6:4 (0.2% TFA) to 100% of MeOH/iPrOH 6:4 (0.2%
TFA), ﬂow rate 12 ml/min, 20 min runs. Yield 92% (19 mg, MW
1587.83, 0.012 mmol) of pure 9f. Analytical characterization:
½aD20 121 (c 0.95, CH3OH); 1H NMR (400 MHz, D2O): d: 7.52 (s,
2H), 7.35 (s, 10H), 7.25–7.05 (m, 10H), 6.64 (s, 4H), 6.06 (s, 2H),
4.56 (d, J = 9.2 Hz, 2H), 4.37 (bs, 2H), 4.14 (s, 4H), 4.045 (bs, 4H),
3.89 (bs, 2H), 3.76 (bs, 2H), 3.03 (d, J = 12.0 Hz, 2H), 2.95 (t,
J = 11.2 Hz, 2H), 2.49 (s, 6H), 2.15 (bs, 4H), 2.12–1.90 (m, 8H),
1.90–1.70 (m, 8H), 1.70–1.65 (m, 2H), 1.50 (bs, 8H), 1.13 (bs, 4H),
0.84 (t, J = 7.2 Hz, 6H); 13C NMR (100 MHz, D2O): d: 172.5, 168.9,
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128.1, 127.0, 132.2, 62.5, 61.7, 58.0, 54.1, 51.4, 50.2, 50.1, 47.8,
35.2, 33.7, 32.2, 31.5, 29.7, 28.7, 28.4, 27.9, 27.4, 23.4, 8.1. ESI-
MS: m/z 1360.0 [M+H]+, 680.6 [M+2H]2+.
4.14. Tail–tail dimer 9g—Scheme 11
4.14.1. Compound 13b
Dry TEA (223 lL, 1.6 mmol) and Boc2O (349.2 mg, 1.6 mmol)
were sequentially added to a stirred solution of compound 4c
(205 mg, 0.8 mmol) in dry CH2Cl2 (4 mL). The reaction mixture was
stirred at room temperature andmonitoredby LC–MS.After reaction
completion, the solutionwasdilutedwithCH2Cl2 (5 mL) andwashed
oncewith5%citric acidandsaturatedNaHCO3. Theorganic layerwas
dried over Na2SO4 and evaporated under reduced pressure. The
crude product was used as such in the next reaction step.
Dry TEA (335 lL, 2.4 mmol) and MsCl (92.9 lL, 1.2 mmol) were
sequentially added to a stirred solution of crude alcohol (270 mg,
0.78 mmol) in dry CH2Cl2 (4 mL) under argon at 0 C. The reaction
mixture was stirred at room temperature overnight. After reaction
completion, the resulting mixture was diluted with CH2Cl2 (20 mL)
and washed with a saturated ammonium chloride solution
(2  20 mL). The organic layer was dried over Na2SO4, and then
the solvent was removed under reduced pressure.
The crude product was dissolved in dry DMF (10 mL) and trea-
ted with Bu4N+CN- (322.2 mg, 1.2 mmol). The reaction mixture was
heated at 80 C for 90 min in a microwave reactor. After reaction
completion most of the DMF was removed under reduced pressure,
the crude was diluted with EtOAc (20 mL) and washed with water
(3  20 mL). The organic layer was dried over Na2SO4, and then the
solvent was removed under reduced pressure. The crude product
was puriﬁed by Biotage™ ﬂash chromatography, eluant condi-
tions: from 1% of MeOH and 99% of CH2Cl2 to 10% of MeOH and
90% of CH2Cl2. Yield 63% (245 mg, MW 365.0, 0.493 mmol) of pure
13b. Analytical characterization: 1H NMR (400 MHz, CDCl3): d:
5.83 (d, J = 6.8 Hz, 1H), 4.61 (dd, J = 8.0, 4.4 Hz, 1H), 4.25 (t,
J = 9.6 Hz, 1H); 3.92 (dd, J = 14.8, 7.6 Hz, 1H), 3.77 (s, 3H), 2.76
(dd, J = 15.2, 4.4 Hz, 1H), 2.42–2.25 (m, 3H), 2.15–1.65 (m, 7H),
1.45 (s, 9H); 13C NMR (100 MHz, CDCl3): d: 172.2, 169.5, 118.9,
80.2, 60.4, 58.7, 56.2, 52.4, 37.7, 34.0, 33.3, 32.8, 28.3, 27.7,20.9.
ESI-MS: m/z 753.4 [2 M+Na]+.
4.14.2. Compound 13c
Compound 13b (0.49 mmol) was dissolved in 3 N methanolic
HCl solution (3 mL). The resulting mixture was stirred at room
temperature overnight, and then evaporated under reduced pres-
sure. The crude product was re-dissolved in CH2Cl2 (20 mL) and
washed once with a saturated solution of NaHCO3. The organic
layer was dried over Na2SO4, ﬁltered and the solvent was removed
under reduced pressure. The crude product was used as such in the
next reaction step.
Dry DIPEA (341.4 lL, 1.96 mmol) was added to a solution of N-
Boc, N-Me-(S)-ethylglycine (134.7 mg, 0.62 mmol), EDCHCl
(115 mg, 0.6 mmol) and HOBt (73.3 mg, 0.6 mmol) in dry CH2Cl2
(3 mL) at room temperature under a nitrogen atmosphere. The
solution was stirred for 10 min before adding a solution of the
crude amine (180 mg, 0.49 mmol) in CH2Cl2 (2 mL). The reaction
mixture was stirred at room temperature and monitored by LC–
MS. After reaction completion, the solution was diluted with
CH2Cl2 (20 mL) and washed once with 5% citric acid and saturated
NaHCO3. The organic layer was dried over Na2SO4 and evaporated
under reduced pressure. The crude product was puriﬁed by ﬂash
chromatography, eluant conditions: from 1% of MeOH and 99% of
CH2Cl2 to 10% of MeOH and 90% of CH2Cl2. Yield 67% (152 mg,
MW 464.57, 0.327 mmol) of pure 13c. Analytical characterization:
1H NMR (400 MHz, CDCl3): d: 7.14 (d, J = 7.2 Hz, 1H); 4.62 (dd,J = 7.6, 4.0, 1H), 4.56 (t, J = 9.6 Hz, 1H), 4.38 (bs, 1H), 3.97 (dd,
J = 14.8, 7.2 Hz, 1H), 3.78 (s, 3H), 2.87 (s, 3H), 2.65 (bd, 1H), 2.45–
2.28 (m, 3H), 2.20–1.70 (m, 9H), 1.50 (s, 9H), 0.92 (t, J = 7.6 Hz,
3H); 13C NMR (100 MHz, CDCl3): d: 172.3, 169.0, 60.4, 58.6, 54.4,
52.5, 37.5, 33.9, 33.4, 32.7, 28.4, 27.7, 21.6, 20.8, 10.7. ESI-MS:
m/z 465.5 [M+H]+.
4.14.3. Compound 13d
A solution of nitrile 13c (0.31 mmol) in EtOH (4 mL), and the
was ﬂowed through a Raney Nickel catalyst cartridge (hydrogen
pressure 60 bar, temperature 60 C, ﬂow rate 0.5 mL/min) in a con-
tinuous ﬂow hydrogenation H-Cube™ system. After reaction com-
pletion, the solvent was removed under reduced pressure and the
crude was used as such in the next reaction step.
Dry TEA (86.4 lL, 0.62 mmol) and Boc2O (135.3 mg, 0.62 mmol)
were sequentially added to a stirred solution of the crude amine in
dry CH2Cl2 (3 mL). The reaction mixture was stirred at room tem-
perature and monitored by LC–MS. After reaction completion, the
solution was diluted with CH2Cl2 (5 mL) and washed once with
5% citric acid and saturated NaHCO3. The organic layer was dried
over Na2SO4 and evaporated under reduced pressure. The crude
product was puriﬁed by ﬂash chromatography, eluant conditions:
from 10% of EtOAc and 90% of petroleum ether to 100% of EtOAc.
Yield 44% (78 mg, MW 568.60, 0.137 mmol) of pure 13d. Analytical
characterization: 1H NMR (400 MHz, CDCl3): d: 6.88 (d, J = 4.8 Hz,
1H), 4.57 (m, 2H), 4.41 (dd, J = 9.2, 6.0 Hz, 1H), 4.94 (bd,
J = 8.4 Hz, 1H), 3.75 (s, 3H), 3.06 (bs, 2H), 2.84 (s, 3H), 2.25 (m,
1H), 2.20–2.03 (m, 3H), 2.0–1.85 (m, 2H), 1.80–1.55 (m, 6H), 1.49
(s, 9H), 1.43 (s, 9H), 1.28 (t, J = 7.2 Hz, 1H), 0.91 (t, J = 7.2 Hz, 3H);
13C NMR (100 MHz, CDCl3): d: 172.5, 170.7, 155.9, 79.0, 60.2,
58.5, 55.0, 52.3, 38.4, 37.2, 33.5, 32.8, 32.3, 28.4, 27.8, 21.7, 21.0,
14.2, 10.7. ESI-MS: m/z 569.5 [M+H]+.
4.14.4. Compound 13e
A 2 N aqueous LiOH solution (0.5 mL) was slowly added to an
iced cooled, stirred solution of 13d (74 mg, 0.13 mmol) in 1,4-diox-
ane (1 mL). The reaction mixture was then stirred at room temper-
ature until complete hydrolysis of the starting material. After
reaction completion, the cloudy solution was concentrated, the
residue was taken up in CH2Cl2 (10 mL) and water (10 mL), and
acidiﬁed to pH 3 with 2 N aqueous HCl. The mixture was ex-
tracted with CH2Cl2 (2  10 mL), the combined organic layers were
dried over Na2SO4, and then the solvent was removed under re-
duced pressure. Crude 13e was used without puriﬁcation in the
next reaction step.
4.14.5. Compound 14i
HOBt (16.2 mg, 0.12 mmol), HBTU (45.5 mg, 0.12 mmol) and
Sym-collidine (26.4 lL, 0.2 mmol) were sequentially added to a
stirred solution of 17b (39.3 mg, 0.055 mmol) and crude 13e
(72.1 mg, 0.13 mmol) in dry DMF (2 mL) at 0 C. The reaction mix-
ture was left stirring and monitored by LC–MS. After reaction com-
pletion, the mixture was diluted with EtOAc (20 mL) and
sequentially washed with 5% aqueous citric (20 mL) acid, saturated
aqueous sodium bicarbonate (20 mL) and brine (2  20 mL). The
organic layer was dried over Na2SO4, and then the solvent removed
under reduced pressure. The residue was puriﬁed by Biotage™
ﬂash chromatography, eluant conditions: from 10% of EtOAc and
90% of petroleum ether to 100% of EtOAc. Yield 77% (66 mg, MW
1559.97, 0.042 mmol) of pure 7. Analytical characterization: 1H
NMR (400 MHz, CDCl3): d: 8.03 (d, J = 4.5 Hz, 2H), 7.32–7.02 (m,
10H), 7.01 (d, J = 8.4 Hz, 2H), 6.85 (bs, 2H), 5.32 (d, J = 4.5 Hz,
2H), 4.68 (d, J = 7.2 Hz, 2H), 4.48 (bs, 2H), 4.45 (dd, J = 9.6, 4.0 Hz,
2H), 3.86 (m, 2H), 3.62–3.25 (m, 16H), 3.10 (m, 4H), 2.86 (s, 6H),
2.32–2.15 (M, 4H), 2.05–1.60 (m, 24H), 1.52 (s, 18H), 1.43 (s,
18H), 1.28 (m, 2H), 0.93 (t, J = 7.2 Hz, 6H); 13C NMR (100 MHz,
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127.2, 70.5, 70.0, 69.6, 61.2, 58.7, 57.3, 54.8, 38.1, 37.3, 34.5,
33.2, 28.5, 26.6, 10.8. ESI-MS: m/z 1559.9 [M+H]+.
4.14.6. Compound 9g
TFA (270 lL, 3.0 mmol) was added to a stirred solution of com-
pound 14i (61 mg, 0.04 mmol) in CH2Cl2 (5 mL). The reaction mix-
ture was left stirring at room temperature overnight and then
concentrated under reduced pressure. The residue was puriﬁed
by chromatography on a C18 reverse phase semi-preparative hplc
column, eluant conditions: from 70% of H2O (0.2% TFA) and 30%
of CH3CN (0.2% TFA) to 30% of H2O (0.2% TFA) and 70% of CH3CN
(0.2% TFA), ﬂow rate 12 ml/min, 20 min runs. Yield 80% (52 mg,
MW 1615.57, 0.032 mmol) of pure 9g. Analytical characterization:
1H NMR (400 MHz, D2O): d: 7.47 (m, 10H), 5.28 (s, 2H), 4.60 (d,
J = 9.6 Hz, 2H), 4.49 (dd, J = 8.0, 5.2 hz, 2H), 4.05 (m, 2H), 3.50
(dd, J = 6.4, 3.2 Hz, 4H), 3.43 (dd, J = 5.2, 3.2 Hz, 4H), 3.32 (t,
J = 6.4 Hz, 4H), 3.29 (t, J = 6.8 Hz, 2H), 3.20–3.00 (m, 4H), 2.95 (m,
2H), 2,67 (s, 6H), 2.25 (m, 2H), 2.15 (m, 2H), 2.03 (m, 4H), 1.90
(m, 6H), 1.85–1.55 (m, 16H), 0.92 (t, J = 7.6, Hz, 6H); (100 MHz,
D2O): d: 173.3, 171.8, 170.4, 168.6, 135.9, 129.3, 127.3, 69.4, 69.3,
68.0, 62.6, 61.6, 58.4, 58.3, 56.1, 37.3, 36.4, 35.1, 32.4, 31.6, 30.5,
29.8, 29.1, 28.1, 27.9, 23.5, 8.1. ESI-MS: m/z 580.6 [M+H]2+,
1159.7 [M+H]+.
4.15. Head–tail dimer 10a—Schemes 12 and 13
4.15.1. Compound 16e
HOBt (81 mg, 0.6 mmol), HBTU (227.5 mg, 0.6 mmol) and Sym-
collidine (132.1 lL, 1 mmol) were sequentially added to a stirred
solution of commercially available 15e (110 mg, 0.503 mmol) and
N-Boc-(S)-2-Phenylglycine (158 mg, 0.63 mmol) in dry DMF
(3 mL) at 0 C . The reactionmixture was left stirring andmonitored
by LC–MS. After reaction completion, the mixture was diluted with
EtOAc (20 mL) and sequentially washed with 5% aqueous citric acid
(20 mL), saturated aqueous sodium bicarbonate (20 mL) and brine
(2  20 mL). The organic layer was dried over Na2SO4, and then
the solvent was removed under reduced pressure. The residue was
puriﬁedbyBiotage™ﬂash chromatography, eluant conditions: from
1% of MeOH and 99% of CH2Cl2 to 10% of MeOH and 90% of CH2Cl2.
Yield 74% (167 mg, MW 451.53, 0.37 mmol) of pure 16e. Analytical
characterization: 1H NMR (400 MHz, CDCl3): d: 7.32.7.20 (m, 5H),
6.28 (bs, 1H), 5.77 (bs, 1H), 5.07 (bs, 1H), 3.6–3.28 (m, 16H), 1.35
(s, 9H); 13C NMR (100 MHz, CDCl3): d: 129.0, 128.3, 127.2, 70.7,
70.6, 70.5, 70.3, 70.0, 69.6, 68.8, 58.5, 50.7, 39.6, 28.3. ESI-MS: m/z
452.5 [M+H]+, 474.5 [M+Na]+.
4.15.2. Compound 18a
TFA (900 lL, 10 mmol) was added to a stirred solution of com-
pounds 16e (95 mg, 0.27 mmol) in CH2Cl2 (3 mL). The reaction
mixture was left stirring at room temperature and then concen-
trated under reduced pressure. The crude product was used in
the next reaction step without further puriﬁcation.
HOBt (74.6 mg, 0.55 mmol), HBTU (208.6 mg, 0.55 mmol) and
sym-collidine (132.1 lL, 1 mmol) were sequentially added to a
stirred solution of the crude residue (theoretically 0.27 mmol)
and compound 4d (150 mg, 0.034 mmol) in dry DMF (3 mL) at
0 C. The reaction mixture was left stirring and monitored by LC–
MS. After reaction completion, the mixture was diluted with EtOAc
(20 mL) and washed with 5% aqueous citric acid (20 mL), saturated
aqueous sodium bicarbonate (20 mL) and brine (2  20 mL). The
organic layer was dried over Na2SO4, and then the solvent was re-
moved under reduced pressure. The residue was puriﬁed by
Biotage™ ﬂash chromatography, eluant conditions: from 1% of
MeOH and 99% of CH2Cl2 to 10% of MeOH and 90% of CH2Cl2. Yield
82% (170 mg, MW 774.92, 0.220 mmol) of pure 18a. Analyticalcharacterization: 1H NMR (400 MHz, CDCl3): d: 7.93 (d, J = 6.8 Hz,
1H), 7.51 (d, J = 8.0 Hz, 1H), 7.36–7.27 (m, 5H), 6.37 (bs, 1H), 5.38
(d, J = 7 Hz, 1H), 4.71 (d, J = 6.8 Hz, 1H), 4.48 (m, 2H), 3.68 (m,
1H), 3.65 (m, 8H), 3.55 (m, 4H), 3.45 (m, 4H), 3.38 (m, 2H), 3.32
(m, 1H), 2.87 (s, 3H), 2.32 (m 1H), 2.22 (m, 1H), 2.10–1.40 (m,
3H), 1.35–1.70 (m, 5H), 1.52 (s, 9H), 1.30 (m, 2H), 0.93 (t,
J = 7 Hz, 3H); 13C NMR (100 MHz, CDCl3): d: 173.2, 172.4, 171.4,
170.0, 169.5, 138.2, 128.9, 128.2, 127.2, 70.7, 70.6, 70.5, 70.3,
70.0, 69.5, 64.3, 61.4, 61.0, 59.1, 58.8, 57.4, 53.9, 50.6, 41.6, 39.7,
34.4, 33.0, 32.8, 30.4, 28.4, 26.4, 21.6, 10.7 . ESI-MS: m/z 775.5
[M+H]+, 797.5 [M+Na]+.
4.15.3. Compound 11e
DCC (22.7 mg, 0.11 mmol) and DMAP (2.4 mg, 0.02 mmol) were
sequentially added to a stirred solution of compound 4h (60 mg,
0.1 mmol) and 4-pentynoic acid (9.8 mg, 0.1 mmol) in dry CH2Cl2
(4 mL) at 0 C. The reaction mixture was warmed to room temper-
ature over a period of 1 h. After reaction completion, the reaction
mixture was ﬁltered, and the ﬁltrate was washed with diethyl
ether. The organic phase was removed under reduced pressure,
and the crude product was puriﬁed by Biotage™ ﬂash chromatog-
raphy, eluant conditions: from 1% of MeOH and 99% of CH2Cl2 to
10% of MeOH and 90% of CH2Cl2. Yield 93% (64 mg, MW 685.87,
0.093 mmol) of pure 11e. Analytical characterization: ½aD20
116.0 ( c 0.90, CHCl3); 1H NMR (400 MHz, CDCl3): d: 7.90 (d,
J = 6.8 Hz, 1H), 7.28–7.09 (m, 11H), 6.13 (d, J = 8.0 Hz, 1H), 4.64
(d, J = 7.0 Hz, 1H), 4.45 (bs, 1H), 4.34 (m, 1H), 3.67 (m, 1H), 3.35
(m, 1H), 3.00–2.60 (m, 4H), 2.50–2.30 (m, 5H), 2.15 (m, 1H),
2.00–1.50 (m, 9H), 1.45 (m, 1H), 1.40 (s, 9H), 1.35–1.05 (m, 1H),
0.91 (t, J = 7.6 Hz, 3H); 13C NMR (100 MHz, CDCl3): d: 172.8,
171.7, 171.3, 169.3, 142.0, 141.2, 128.7, 128.6, 127.5, 127.4,
127.3, 127.2, 80.7, 69.0, 62.0, 58.9, 56.8, 54.0, 41.8, 39.9, 35.4,
34.5, 33.3, 33.0, 32.0, 28.3, 27.5, 25.5, 21.9, 15.1, 10.8. ESI-MS: m/
z 686.5 [M+H]+, 703.5 [M+Na]+.
4.15.4. Compound 19a
A 0.9 M aqueous solution of sodium ascorbate (70 lL) and a
0.3 M aqueous solution of Cu(OAc)2 (50 lL) were sequentially
added to a stirred solution of compound 18a (44 mg, 0.057 mmol)
and compound 11e (38 mg, 0.057 mmol) in a 1:1 mixture of
H2O/tBuOH (1 mL). The reaction mixture was stirred overnight at
room temperature and then the solvent was removed under re-
duced pressure. The residues were puriﬁed by Biotage™ ﬂash chro-
matography, eluant conditions: from 1% of MeOH and 99% of
CH2Cl2 to 10% of MeOH and 90% of CH2Cl2. Yield 61% (51 mg,
MW 1460.79, 0.035 mmol) of pure 19a. Analytical characteriza-
tion: 1H NMR (400 MHz, CDCl3): d: 7.95 (d, J = 6.8 Hz, 2H), 7.51
(m, 2H), 7.35–7.20 (m, 15H), 7.16 (d, J = 9.2 Hz, 2H), 6.75 (bs,
1H), 6.22 (d, J = 6.8 Hz, 1H), 5.43 (d, J = 7.2 Hz, 1H), 4.72 (dd,
J = 16, 7.6 Hz, 2H), 4.48 (m, 6H), 3.82 (m, 4H), 3.70–3.30 (m,
15H), 3.07 (t, J = 7.6 Hz, 2H), 2.85 (m, 6H), 2,.67 (m, 3H), 2.48 (m,
1H), 2.25 (m, 3H), 2.05 (m, 1H), 2.00–1.80 (m, 5H), 1.80–1.65 (m,
7H), 1.52 (s, 9H), 1.48 (s, 9H), 1.35 (m, 1H), 1.25 (m, 2H), 1.10
(m, 1H), 0.94 (t, J = 7.2 Hz, 6H); 13C NMR (100 MHz, CDCl3): d:
173.1, 171.4, 169.6, 169.4, 146.1, 142.1, 138.4, 128.8, 128.7,
128.6, 127.3, 127.2, 127.1, 123.0, 70.5, 70.4, 70.2, 69.5, 69.3, 64.3,
61.4, 61.1, 58.8, 57.2, 56.8, 53.9, 53.7, 50.4, 41.7, 39.6, 35.5, 34.5,
33.2, 33.0, 31.2, 28.4, 28.3, 26.4, 25.6, 21.6, 21.3, 10.7. ESI-MS:
m/z 1461.7 [M+H]+, 1482.7 [M+Na]+.
4.15.5. Compound 10a
TFA (270 lL, 3.0 mmol) was added to a stirred solution of com-
pound 19a (54 mg, 0.030 mmol) in CH2Cl2 (5 mL). The reaction
mixture was left stirring at room temperature overnight and then
concentrated under reduced pressure. The residue was puriﬁed by
chromatography on a C18 reverse phase semi-preparative hplc
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CH3CN (0.1% TFA) to 25% of H2O (0.1% TFA) and 75% of CH3CN (0.1%
TFA), ﬂow rate 15 ml/min, 22 min runs. Yield 90% (41 mg, MW
1488.60, 0.027 mmol) of pure 10a. Analytical characterization: 1H
NMR (400 MHz, D2O): d: 8.77 (s, 1H), 7.39–7.29 (m, 15H), 6.04 (s,
1H), 5.33 (s, 1H), 4.67 (d, J = 10.0 Hz, 2H), 4.60–4.40 (m, 5H), 4.00
(m, 2H), 3.90 (m, 2H), 3.79 (m, 2H), 3.58 (d, J = 3.6 Hz, 2H), 3.55–
38 (m, 11H), 3.35–3.20 (m, 2H), 2.96 (m, 3H), 2.67 (s, 6H), 2.57
(t, J = 7.2 Hz, 2H), 2.23 (m, 2H), 2.12 (m, 2H), 2.07–1.85 (m, 8H),
1.85–1.62 (m, 7H), 1.55 (m, 1H), 1.50–1.30 (m, 2H), 0.95 (m, 6H);
13C NMR (100 MHz, D2O): d:174.8, 173.2, 172.7, 171.8, 171.1,
169.9, 168.4, 168.2, 146.0, 141.0, 140.8, 135.9, 129.2, 129.0,
128.8, 127.8, 127.3, 127.1, 123.9, 69.5, 69.4, 68.7, 68.6, 63.2, 62.7,
62.6, 61.7, 58.7, 58.3, 58.0, 57.6, 54.5, 54.4, 50.0, 40.7, 39.2, 38.9,
37.2, 35.1, 32.4, 31.5, 31.4, 30.1, 29.4, 27.9, 27.7, 23.4, 21.0, 8.2.
ESI-MS: m/z 631.3 [M+H]2+, 1260.8 [M+H]+, 1282.7 [M+Na]+.4.16. Head–tail dimer 10b—Schemes 12 and 14
4.16.1. Compound 18b
A 1.0 M aqueous citric acid solution (250 lL) was added to a
solution of 18a (170 mg, 0.220 mmol) in H2O/EtOH 1:9 (3 mL).
The solution was hydrogenated by ﬂowing through a 10% Pd/C cat-
alyst cartridge (hydrogen pressure 10 bar, temperature 35 C, ﬂow
rate 0.5 mL/min) using the H-Cube™ system. After reaction com-
pletion, the solvent was removed under reduced pressure. The
crude product was used without any further puriﬁcation, and only
an analytical sample was puriﬁed by semi-preparative HPLC re-
verse phase chromatography, eluant conditions: from 90% H2O
(1% CH3COOH) and 10% CH3CN (1% CH3COOH) to 100% CH3CN
(1% CH3COOH). Yield 98% (162 mg, MW 748.95, 0.219 mmol) of
pure 18b. Analytical characterization: 1H NMR (400 MHz, CD3OD):
d: 8.6 (bs, 1H), 7.44–7.33 (m, 5H), 5.40 (s, 1H), 4.67 (dd, J = 5.2,
2.8 Hz, 1H), 4.53 (m, 2H), 4.01 (m, 1H), 3.67 (m, 5H), 3.65–3.47
(m, 8H), 3.39 (m, 2H), 3.09 (bs, 2H), 2.85 (s, 3H), 2.27 (m, 1H),
2.16 (m, 1H), 2.10- 1.88 (m, 4H), 1.82–1.65 (m, 4H), 1.55 (m, 1H),
1.50 (s, 9H), 1.42 (bs, 2H), 0.94 (t, J = 7.2 Hz, 3H); 13C NMR
(100 MHz, CD3OD): d: 172.3, 171.8, 171.0, 137.6, 128.4, 127.9,
127.2, 70.1, 69.8, 69.0, 67.4, 63.9, 61.4, 58.5, 57.3, 40.3, 39.6,
39.2, 33.2, 32.8, 30.7, 29.5, 27.3, 27.2, 26.9, 9.6. ESI-MS: m/z
749.6 [M+H]+, 771.7 [M+Na]+.4.16.2. Compound 18c
DCC (24.8 mg, 0.12 mmol) and DMAP (3 mg, 0.025 mmol) were
sequentially added to a stirred solution of compound 18b (83 mg,
0.11 mmol) and 4-pentynoic acid (0.11 mmol) in dry CH2Cl2 (4 mL)
at 0 C. The reaction mixture was warmed to room temperature
over a period of 1 h. After reaction completion, the reaction mix-
ture was ﬁltered, and washed with diethyl ether. The combined
solvents were removed under reduced pressure, and the crude
product was puriﬁed by Biotage™ ﬂash chromatography, eluant
conditions: : from 1% of MeOH and 99% of CH2Cl2 to 10% of MeOH
and 90% of CH2Cl2. Yield 74% (67 mg, MW 829.01, 0.081 mmol) of
pure 18c. Analytical characterization: 1H NMR (400 MHz, CDCl3):
d: 7.98 (d, J = 7.0 Hz, 1H), 7.51 (d, J = 6.8 Hz, 1H), 7.45–7.25 (m,
5H), 6.68 (bs, 1H), 5.43 (d, J = 7.2 Hz, 1H), 4.71 (d, J = 6.8 Hz, 1H);
4.48 (bs, 2H), 3.8 (m, 1H), 3.70- 3.30 (m, 18H), 2.87 (s. 3H), 2.48
(m, 2H), 2.40–2.15 (m, 4H), 2.15–1.65 (m, 9H), 1.52 (s, 9H), 1.40–
1.25 (m, 2H), 0.93 (t, J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3):
d: 173.4, 173.2, 171.4, 171.3, 170.1, 169.5, 138.2, 128.8, 128.2,
127.2, 83.2, 70.6, 70.5, 70.4, 70.3, 70.1, 69.8, 69.5, 69.2, 64.3, 61.4,
58.8, 57.2, 53.9, 41.6, 39.7, 39.6, 39.1, 35.1, 34.5, 33.0, 31.2, 28.4,
26.6, 21.6, 20.6, 14.8, 10.6. ESI-MS: m/z 829.6 [M+H]+, 851.5
[M+Na]+.4.16.3. Compound 19b
A 0.9 M aqueous solution of sodium ascorbate (60 lL) and a
0.3 M aqueous solution of Cu(OAc)2 (40 lL) were sequentially
added to a stirred solution of compound 19c (37 mg, 0.045 mmol)
and compound 4f (29 mg, 0.045 mmol) in a 1:1 mixture of
H2O/tBuOH (750 lL). The reaction mixture was stirred overnight
at room temperature and then the solvent was removed under re-
duced pressure. The residues were puriﬁed by Biotage™ ﬂash chro-
matography, eluant conditions: from 1% of MeOH and 99% of
CH2Cl2 to 10% of MeOH and 90% of CH2Cl2. Yield 80% (52 mg,
MW 1460.79, 0.036 mmol) of pure 19b. Analytical characteriza-
tion: 1H NMR (400 MHz, CDCl3): d: 7.89 (d, J = 6.8 Hz, 1H), 7.71
(d, J = 7.0 Hz, 1H), 7.47 (m, 1H), 7.35–7.12 (m, 15H), 7.08 (d,
J = 7.2 Hz, 1H), 6.85 (bs, 1H), 6.55 (bs, 1H), 6.10 (d, J = 8.8 Hz, 1H),
5.36 (d, J = 7.2 Hz, 1H), 4.56 (m, 3H), 4.38 (m, 4H), 4.10 (bs, 1H),
3.75 (m, 2H), 3.60–3.20 (m, 18H), , 2.97 (bs, 2H), 2.75 (s, 6H),
2.55 (m, 3H), 2.32 (m, 1H), 2.15 (m, 3H), 1.95–1.60 (m, 13H),
1.43 (s, 9H), 1.38 (s, 9H); 1.35–1.15 (m, 3H), 1.02 (m, 1H), 0.85 (t,
J = 7.2 Hz, 6H); 13C NMR (100 MHz, CDCl3): d: 171.9, 171.4, 170.7,
169.6, 141.8, 141.2, 138.4, 128.8, 128.7, 128.1, 127.6, 127.5,
127.3, 127.2, 127.1, 70.4, 70.1, 69.9, 69.8, 69.5, 64.3, 61.4, 61.3,
58.8, 57.2, 56.9, 53.9, 53.6, 41.6, 40.4, 39.6, 39.2, 34.4, 33.6, 33.3,
33.0, 31.1, 28.4, 28.3, 26.5, 25.9, 21.7, 21.2, 10.7. ESI-MS: m/z
681.2 [M+H]2+,1461.0 [M+H]+, 1483.0 [M+Na]+.
4.16.4. Compound 10b
TFA (180 lL, 2.0 mmol) was added to a stirred solution of com-
pound 19b (30 mg, 0.022 mmol) in CH2Cl2 (4 mL). The reaction
mixture was left stirring at room temperature overnight and then
concentrated under reduced pressure. The residue was puriﬁed by
chromatography on a C18 reverse phase semi-preparative hplc col-
umn, eluant conditions: from 40% of H2O (0.1% TFA) and 60% of
CH3CN (0.1% TFA) to 25% of H2O (0.1% TFA) and 75% of CH3CN
(0.1% TFA), ﬂow rate 15 ml/min, 22 min runs. Yield 86% (28 mg,
MW 1488.60, 0.019 mmol) of pure 10b. Analytical characteriza-
tion: 1H NMR (400 MHz, D2O): d: 7.78 (s, 1H), 7.37–7.28 (m,
15H), 6.04 (s, 1H), 5.34 (s, 1H), 4.78 (d, J = 10.4 Hz, 1H), 4.66 (m,
1H), 4.53 (m, 3H), 4.36 (m, 1H), 4.03 (m, 2H), 3.88 (t, J = 6.0 Hz,
2H), 3.60–3.25 (m, 16H), 3.28 (m, 3H), 2.94 (t, J = 14.4 Hz, 2H),
2.70 (s, 3H), 2.58 (s, 3H), 2.56 (t, J = 7.2 Hz, 2H), 2.35–2.05 (m,
5H), 2.05–1.88 (m, 9H), 1.85–1.65 (m, 6H), 1.62–1.46 (m, 3H),
0.95 (m, 6H); 13C NMR (100 MHz, D2O): d: 174.9, 173.2, 172.7,
171.1, 169.5, 168.7, 146.5, 141.0, 140.9, 136.0, 129.2, 129.0,
128.9, 127.8, 127.4, 127.3, 127.1, 69.6, 69.4, 68.8, 68.7, 63.2, 62.8,
62.6, 61.9, 61.8, 58.7, 58.2, 58.0, 57.6, 54.5, 54.4, 52.0, 39.3, 39.0,
38.1, 35.0, 32.4, 32.3, 31.8, 31.5, 27.9, 27.7, 23.5, 23.4, 20.9, 8.2,
8.1. ESI-MS: m/z 631.1 [M+H]2+, 1260.8 [M+H]+, 1282.7 [M+Na]+.
4.17. Head–tail dimer 10c—Schemes 12 and 15
4.17.1. Compound 18d
Diglycolic anhydride (25.5 mg, 0.22 mmol) and pyridine
(36.4 lL, 0.45 mmol) were sequentially added to a stirred solution
of compound 18b (83 mg, 0.11 mmol) in DMF (3 mL). The reaction
mixture was stirred at room temperature for 4 h. After reaction
completion, water (20 mL) was added to the reaction mixture.
The mixture was diluted with EtOAc (20 mL) and washed with
5% aqueous citric acid (20 mL), saturated aqueous sodium bicar-
bonate (20 mL) and brine (2  20 mL). The combined organic layer
was dried over Na2SO4, and then the solvent was removed under
reduced pressure. Finally, the crude product was puriﬁed by ﬂash
chromatography on a Biotage™ C18 reverse phase column, eluant
conditions: from 90% H2O (1% CH3COOH) and 10% CH3CN (1%
CH3COOH) to 100% CH3CN (1% CH3COOH). Yield 58% (55 mg, MW
865.00, 0.064 mmol) of pure 18d. Analytical characterization: 1H
L. Manzoni et al. / Bioorg. Med. Chem. 20 (2012) 6687–6708 6707NMR (400 MHz, CDCl3): d: 8.01 (d, J = 7.0 Hz, 1H), 7.61 (bs, 1H),
7.53 (d, J = 6.8 Hz, 1H), 7.40–7.28 (m, 5H), 6.98 (bs, 1H), 4.52 (d,
J = 7.2 Hz, 1H), 4.71 (d, J = 6.8 Hz, 1H), 4.5 (m, 2H), 4.10 (m, 3H),
3.82 (m, 1H); 3.70–3.30 (m, 18H), 2.88 (s, 3H), 2.25 (m, 2H), 2.08
(s, 2H), 2.05–1.70 (m, 8H), 1.51 (s, 9H), 1.39 (m, 2H), 0.93 (t,
J = 7.2 Hz, 3H); 13C NMR (100 MHz, CDCl3): d: 175.2, 173.0, 171.9,
171.4, 169.8, 169.8, 137.9, 128.8, 128.3, 127.2, 77.3, 77.0, 76.8,
71.4, 70.4, 70.0, 69.7, 69.5, 69.2, 64.3, 61.6, 58.9, 57.2, 54.0, 41.5,
39.7, 38.8, 34.3, 33.0, 31.2, 28.4, 26.7, 21.6, 20.6, 10.6. ESI-MS: m/
z 865.4 [M+H]+, 887.4 [M+Na]+.
4.17.2. Compound 19c
HOBt (9.5 mg, 0.078 mmol), HBTU (29.6 mg, 0.078 mmol) and
sym-collidine (33 lL, 0.25 mmol) were sequentially added to a
stirred solution of compound 18d (54 mg, 0.063 mmol) and com-
pound 4h (52 mg, 0.08 mmol) in dry DMF (1 mL) at 0 C. The reac-
tion mixture was left stirring and monitored by LC–MS. After
reaction completion, the mixture was diluted with EtOAc (20 mL)
and washed with 5% aqueous citric acid (20 mL), saturated aque-
ous sodium bicarbonate (20 mL) and brine (2  20 mL). The organ-
ic layer was dried over Na2SO4, and then the solvent was removed
under reduced pressure. The residue was puriﬁed by Biotage™
ﬂash chromatography, eluant conditions: from 1% of MeOH and
99% of CH2Cl2 to 10% of MeOH and 90% of CH2Cl2. Yield 67%
(61 mg, MW 1457.77, 0.042 mmol) of pure 19c. Analytical charac-
terization: 1H NMR (400 MHz, CDCl3): d: 7.87 (d, J = 7.2 Hz, 1H),
7.76 (d, J = 6.8 Hz, 1H), 7.63 (d, J = 6.0 Hz, 1H), 7.46 (m, 2H),
7.35–7.10 (m, 15H), 6.72 (bs, 1H), 6.15 (d, J = 8.4 Hz, 1H), 5.35 (d,
J = 7.2 Hz, 1H), 4.64 (dd, J = 19.2, 7.2 Hz, 2H), 4.40 (m, 4H), 3.95
(m, 4H), 3.72 (m, 3H), 3.6–3.20 (m, 18H), 2.79 (s, 3H), 2.75 (s,
3H), 2.52 (m, 2H), 2.35 (m, 1H), 2.18 (m, 2H), 1.90–1.55 (m,
14H), 1.43 (s, 9H), 1.41 (s, 9H), 1.30–1.10 (m, 4H), 0.85 (m, 6H);
13C NMR (100 MHz, CDCl3): d: 172.7, 171.3, 169.6, 168.9, 168.9,
142.2, 138.4, 128.8, 128.6, 128.5, 128.1, 127.4, 127.3, 127.2, 70.7,
70.5, 70.4, 70.3, 70.1, 69.6, 69.5, 64.3, 61.7, 61.4, 61.3, 60.5, 58.9,
58.8, 57.2, 56.8, 53.9, 53.5, 41.6, 40.0, 39.7, 39.6, 38.7, 34.4, 34.3,
33.1, 33.0, 31.1, 28.4, 28.3, 26.4, 25.7, 21.7, 21.3, 10.7, 10.6. ESI-
MS: m/z 1452.9 [M+H]+, 1475.0 [M+Na]+.
4.17.3. Compound 10c
TFA (360 lL, 4.0 mmol) was added to a stirred solution of com-
pound 19c (58 mg, 0.040 mmol) in CH2Cl2 (5 mL). The reaction
mixture was left stirring at room temperature overnight and then
concentrated under reduced pressure. The residue was puriﬁed by
chromatography on a C18 reverse phase semi-preparative hplc col-
umn, eluant conditions: from 40% of H2O (0.1% TFA) and 60% of
CH3CN (0.1% TFA) to 25% of H2O (0.1% TFA) and 75% of CH3CN
(0.1% TFA), ﬂow rate 15 ml/min, 22 min runs. Yield 88% (55 mg,
MW 1480.57, 0.037 mmol) of pure 10c. Analytical characteriza-
tion: 1H NMR (400 MHz, D2O): d: 7.41–7.30 (m, 15H), 6.06 (s,
1H), 5.36 (s, 1H), 4.67 (d, J = 8.4 Hz, 2H), 4.55 (m, 2H), 4.10 (d,
J = 5.2 hz, 4H), 4.05 (m, 2H), 3.93 (t, J = 6.4 Hz, 1H), 3.89 (t,
J = 5.6 Hz, 1H), 2.70 (s, 3H), 2.69 (s, 3H), 2.25 (m, 2H), 2.15 (m,
2H), 2.08–1-68 (m, 17H), 1.65–1.50 (m, 3H), 0.97 (m, 6H) ; 13C
NMR (100 MHz, D2O): d: 172.8, 171.8, 171.7, 171.1, 170.1, 168.5,
168.3, 141.0, 140.9, 129.2, 129.0, 128.9, 127.8, 127.4, 127.3,
127.2, 70.0, 69.9, 69.6, 69.4, 68.8, 68.7, 63.2, 62.8, 62.7, 61.9,
61.8, 58.8, 58.5, 58.0, 57.7, 54.6, 54.5, 40.7, 39.3, 39.0, 38.6, 37.4,
32.4, 31.6, 31.5, 30.5, 29.5, 29.0, 27.9, 27.7, 23.4, 8.2, 8.1. ESI-MS:
m/z 627.1 [M+H]2+, 1252.8 [M+H]+, 1274.8 [M+Na]+.
4.18. Head–tail dimer 10d—Schemes 12 and 16
4.18.1. Compound 19d
A 0.9 M aqueous solution of sodium ascorbate (45 lL, 0.4 mmol)
and a 0.3 M aqueous solution of Cu(OAc)2 (65 lL, 0.02 mmol) wereadded to A stirred solution of compound 4e (61.8 mg, 0.10 mmol)
and of the alkyne 20a55 (70.8 mg, 0.10 mmol) in a 1:1 mixture of
H2O/tBuOH (300 lL). The reaction mixture was stirred overnight
at room temperature, and then the solvent was removed under
reduced pressure. Finally, the residue was puriﬁed by ﬂash chro-
matography, eluant conditions: isocratic, CH2Cl2/MeOH 95/5. Yield
57% (76 mg, MW 1324.62, 0.057 mmol) of pure 19d. Analytical
characterization: ½aD20 55.6 (c 0.54, MeOH); 1H NMR (400 MHz,
CDCl3): d: 7.83 (d, J = 7.2 Hz, 1H), 7.76 (d, J = 7.2 Hz, 2H), 7.57 (m,
5H), 7.49 (bd, 1H), 7.45–7.13 (m, 18H), 6.17 (d, J = 8.2 Hz, 1H),
5.23 (bd, J = 7.2 Hz, 1H), 4.80–4.30 (m, 9H), 4.30–3.90 (m, 6H),
3.90–3.50 (m, 4H), 2.87 (s, 3H), 2.38 (m, 1H), 2.21 (m, 1H), 2.02
(m, 1H), 1.94–1.45 (m, 10H), 1.43–1.32 (m, 11H), 1.30–1.05 (m,
6H), 0.93 (t, 3H); 13C NMR (100 MHz, CDCl3): d: 173.0, 171.2,
170.7, 169.4, 169.3, 155.7, 153.3, 143.9, 141.8, 141.3, 133.0,
129.8, 128.8, 127.7, 127.4, 127.3, 127.2, 127.1, 125.0, 120.0, 80.1,
74.6, 68.0, 62.6, 61.2, 58.7, 56.8, 56.3, 54.9, 54.6, 53.7, 51.8, 48.4,
47.7, 47.2, 40.4, 33.5, 33.2, 31.1, 28.5, 27.2, 26.0, 25.6, 24.0, 16.3,
10.2. ESI-MS: m/z 1325.4 [M+H]+, 1347.4 [M+Na]+.
4.18.2. Compound 10d
Compound 19d (59.7 mg, 0.045 mmol) was dissolved into a 20%
solution of piperidine in CH2Cl2 (2 mL). The reaction mixture was
stirred for 30 min at room temperature. and then concentrated in
vacuo. The residue was used as such in the next reaction step.
A 3 N solution of HCl in MeOH (0.5 mL) was added to a stirred
solution of crude (theoretically 0.045 mmol) in MeOH (2 mL). The
reaction mixture was left stirring at room temperature overnight
and then concentrated under reduced pressure. The residue was
puriﬁed by chromatography on a C18 reverse phase semi-prepara-
tive hplc column, eluant conditions: from 80% of H2O (0.1% TFA)
and 20% of CH3CN (0.1% TFA) to 50% of H2O (0.1% TFA) and 50%
of CH3CN, ﬂow rate 20 ml/min, 10 min runs. Yield 90% (45 mg,
MW 1231.29, 0.040 mmol) of pure 10d. Analytical characteriza-
tion: ½aD20 29.0 (c 0.88, H2O); 1H NMR (400 MHz, D2O): d: 7.86
(s, 1H); 7.43–7.05 (m, 15H), 5.91 (s, 1H), 4.63–4.10 (m, 10H),
3.95–3.80 (m, 4H), 3.48 (m, 2H), 2.59 (s, 3H), 2.25–1.38 (m, 16H),
1.23 (m, 2H), 1.14 (m, 3H), 0.96 (m, 3H); 13C NMR (100 MHz,
D2O): d: 172.0, 169.7, 169.5, 154.7, 144.5, 141.2, 141.0, 134.0,
133.3, 130.2, 130.0, 128.7, 127.6, 127.3, 127.0, 126.6, 125.2, 74.0,
61.5, 58.1, 57.4, 57.0, 56.5, 56.0, 54.3, 54.1, 51.8, 48.9, 47.6, 38.6,
32.3, 31.0, 29.6, 28.6, 27.7, 26.9, 24.4, 23.5, 16.0, 15.3, 8.4. ESI-
MS: m/z 1025.7 [M+Na]+, 502.4 [M+2H]2+.
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Selective CDK9 inhibition overcomes TRAIL resistance
by concomitant suppression of cFlip and Mcl-1
J Lemke1,2, S von Karstedt1, M Abd El Hay1, A Conti1,3, F Arce4, A Montinaro1, K Papenfuss1, MA El-Bahrawy5 and H Walczak*,1
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) can induce apoptosis in many cancer cells without causing
toxicity in vivo. However, to date, TRAIL-receptor agonists have only shown limited therapeutic benefit in clinical trials. This can,
most likely, be attributed to the fact that 50% of all cancer cell lines and most primary human cancers are TRAIL resistant.
Consequently, future TRAIL-based therapies will require the addition of sensitizing agents that remove crucial blocks in the
TRAIL apoptosis pathway. Here, we identify PIK-75, a small molecule inhibitor of the p110a isoform of phosphoinositide-3 kinase
(PI3K), as an exceptionally potent TRAIL apoptosis sensitizer. Surprisingly, PI3K inhibition was not responsible for this activity.
A kinome-wide in vitro screen revealed that PIK-75 strongly inhibits a panel of 27 kinases in addition to p110a. Within this panel,
we identified cyclin-dependent kinase 9 (CDK9) as responsible for TRAIL resistance of cancer cells. Combination of CDK9
inhibition with TRAIL effectively induced apoptosis even in highly TRAIL-resistant cancer cells. Mechanistically, CDK9 inhibition
resulted in downregulation of cellular FLICE-like inhibitory protein (cFlip) and Mcl-1 at both the mRNA and protein levels.
Concomitant cFlip and Mcl-1 downregulation was required and sufficient for TRAIL sensitization by CDK9 inhibition. When
evaluating cancer selectivity of TRAIL combined with SNS-032, the most selective and clinically used inhibitor of CDK9, we found
that a panel of mostly TRAIL-resistant non-small cell lung cancer cell lines was readily killed, even at low concentrations of
TRAIL. Primary human hepatocytes did not succumb to the same treatment regime, defining a therapeutic window. Importantly,
TRAIL in combination with SNS-032 eradicated established, orthotopic lung cancer xenografts in vivo. Based on the high
potency of CDK9 inhibition as a cancer cell-selective TRAIL-sensitizing strategy, we envisage the development of new, highly
effective cancer therapies.
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Introduction
De novo and acquired resistance to conventional chemother-
apy remains the major obstacle in treating many cancers
today. Intrinsic apoptosis resistance of cancer cells often
involves disabling of the intrinsic apoptotic machinery.1
Therefore, targeting cancer cells via the extrinsic cell death
machinery involving death receptors of the tumor necrosis
factor (TNF) superfamily has become an attractive approach
in cancer research. However, attempts to use cell death-
inducing CD95L or TNF for systemic therapy were hampered
by severe toxicity.2,3 In contrast, TNF-related apoptosis-
inducing ligand (TRAIL) can induce apoptosis selectively in
tumor cells in vitro and in vivo.4,5
Based on these findings, TRAIL-receptor (TRAIL-R) ago-
nists, comprising recombinant soluble TRAIL and agonistic
TRAIL-R antibodies, are currently evaluated in clinical trials.
However, so far these trials only showed very limited
therapeutic benefit.6 It has emerged that, although TRAIL is
capable of inducing apoptosis in many cancer cell lines in vitro
and in vivo, about 50% of cancer cell lines and the majority of
primary tumor cells are TRAIL resistant.7 The limited success
of clinical trials conducted so far is likely to be attributable to
this fact. However, combinatorial treatment with sensitizing
agents can break TRAIL apoptosis resistance resulting in
synergistic and selective killing of tumor cells.4 These
findings have encouraged extensive research into identifying
potent TRAIL-sensitizing agents that do not sensitize non-
transformed cells.
Binding of TRAIL to cognate apoptosis-inducing TRAIL-R1
(DR4)8 and/or TRAIL-R2 (DR5)9 results in receptor trimeriza-
tion. The adaptor protein FAS-associated protein with death
domain (FADD) is recruited to the death domain (DD) of
trimerized TRAIL-Rs and, in turn, enables caspase-8 and -10
recruitment to and activation at the death-inducing signaling
complex (DISC).10–14 In type-I cells, activation of caspase-8
and -10 at the DISC results in sufficient activation of the
effector caspase-3, ultimately resulting in apoptosis. In type-II
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cells, additional activation of the mitochondrial pathway is
required to neutralize X-linked inhibitor of apoptosis protein
(XIAP)-mediated effector caspase inhibition via release of
Smac/DIABLO from mitochondria.15
In order to prevent excessive apoptosis induction by TRAIL,
several mechanisms that negatively regulate the TRAIL
apoptosis pathway have evolved that are frequently exacer-
bated by cancer cells. The cellular FLICE-like inhibitory
protein (cFlip) competes with caspase-8 for binding to FADD,
thereby preventing caspase-8 activation and, consequently,
apoptosis induction.16 Other cellular factors that antagonize
apoptosis induction by TRAIL include the inhibitor of apoptosis
proteins (IAPs).17 Among these, XIAP has been shown to
have a major role in mediating resistance to TRAIL-induced
apoptosis.18 In type-II cells, resistance to TRAIL-induced
apoptosis can be mediated by high expression of anti-
apoptotic Bcl-2 family members such as Bcl-2, Bcl-xL and
Mcl-1 that antagonize truncated Bid-triggered Bax/Bak-
mediated mitochondrial outer membrane permeabilization
and the consequent release of the pro-apoptotic factors
cytochrome c and Smac/DIABLO.19
Kinase inhibitors have emerged as a novel class of targeted
small molecule agents with great therapeutic potential in
cancer treatment. This is owed to the fact that kinases are
crucial components of most cellular signaling pathways that
promote tumor cell survival, growth, migration, invasion and
metastasis. Several inhibitors of the phosphoinositide-3
kinase (PI3K) pathway are currently in clinical trials20 and,
interestingly, pan-PI3K inhibitors, inhibiting all four catalytic
isoforms (p110a, b, g and d), have been shown to sensitize to
TRAIL-induced apoptosis.21,22 Activating mutations of the
a-isoform of PI3K (p110a) occur with frequencies of up to 30%
in cancer23 and, recently, mutated p110a was suggested to
render cancer cell lines resistant to TRAIL-induced apopto-
sis.24 Therefore, we set out to test whether specific inhibition
of p110a would render cancer cells sensitive to TRAIL-
induced apoptosis.
Results
The p110a inhibitor PIK-75 potently sensitizes tumor
cells to TRAIL-induced apoptosis independently of PI3K
inhibition. To investigate whether inhibition of one of the
PI3K isoforms is sufficient to sensitize cancer cells to TRAIL-
induced apoptosis, we treated HeLa cells with TRAIL in the
presence or absence of pharmacological inhibitors that have
been reported to be isoform specific (PIK-75 (p110a), TGX-
221 (p110b), AS-252424 (p110g) and IC-87114 (p110d)) (for
IC50 values see Supplementary Figure S1a). Whereas
co-treatment with inhibitors of the b-, g- and d-isoforms of
PI3K showed only marginal effects, co-treatment with PIK-75
profoundly increased TRAIL sensitivity of HeLa cells shifting
the sensitivity of these cells by 3–4 orders of magnitude
(Figure 1a and Supplementary Figure S1b). HeLa cells are
sensitive to higher concentrations of TRAIL; however, many
other cancer cell lines and most primary cancer cells are
TRAIL resistant.7 Therefore, we next tested whether the
exceptionally potent TRAIL sensitization exerted by PIK-75 in
HeLa cells would translate into sensitization of the highly
TRAIL resistant non-small cell lung cancer (NSCLC) cell line
A549. Indeed, when treated with PIK-75 A549 cells became
sensitive to apoptosis induction by TRAIL, even at concentra-
tions of TRAIL as low as 10ng/ml (Supplementary Figure S1c).
Intriguingly, when examining clonogenic survival, we
observed that this novel combination almost completely
obliterated clonogenic survival of A549 cells (Figure 1b).
Having shown that PIK-75, a potent inhibitor of p110a, is a
very effective TRAIL sensitizer, we next investigated whether
specific inhibition of the p110a isoform of PI3K was capable of
breaking TRAIL resistance in cancer cells and, hence,
responsible for the PIK-75-mediated effect. To this end, we
performed RNAi-mediated silencing of p110a as compared to
p110b and DNA-PK, which has been shown to be inhibited by
PIK-75 in addition to p110a.25 Surprisingly, silencing of p110a,
p110b and DNA-PK, or any combination thereof, did not
sensitize HeLa cells to TRAIL-induced apoptosis (Figure 1c,
knockdown efficiency in Supplementary Figure S1d). In order
to test the possibility that very low amounts of protein
remaining after knockdown may be sufficient to maintain
resistance, we also used two pan-PI3K inhibitors, GDC-0941
and BEZ-235, which both inhibit p110a with even lower IC50s
than PIK-75.26,27 In addition, we also used A66, a novel
p110a-specific inhibitor28 (for IC50 values see Supplementary
Figure S1e). However, when testing these three compounds,
we found that none of them reproduced the extent of
sensitization observed with PIK-75 co-treatment (Figure 1d).
Interestingly, BEZ-235 was more efficient than PIK-75 at
suppressing PI3K activity as assessed by phosphorylation of
AKT (Supplementary Figure S1f). Moreover, concentrations of
up to 10 mM of A66 were not able to suppress pan-PI3K
activity in HeLa cells, which have been reported to harbor wild-
type (WT) PI3K p110a (Supplementary Figure S1f). This is in
line with a recent report that selective inhibition of p110a using
A66 is only efficient in preventing phosphorylation of AKT in
cells with activating mutations in p110a.28
These results were unexpected but led us to conclude that
PIK-75 sensitizes cancer cells to TRAIL-induced apoptosis
either independently of p110a or by inhibiting p110a and (an)
additional kinase(s). We therefore used PIK-75 in an in vitro
screen testing its capability to inhibit a panel of 451 kinases
(80% of the kinome). This revealed that, in addition to p110a,
PIK-75 potently inhibited 27 other kinases when used at
200 nM (Figure 1e), a concentration at which it effectively
sensitizes cancer cells to TRAIL. In conclusion, we estab-
lished that PIK-75 potently breaks TRAIL resistance, but its
p110a-inhibitory activity is either not responsible or alone not
sufficient to sensitize cancer cells to TRAIL.
CDK9 is the PIK-75-target responsible for TRAIL
sensitization. To evaluate which of the 27 kinases inhibited,
or which combination thereof, was responsible for PIK-75-
mediated sensitization to TRAIL-induced apoptosis, we
screened all 27 kinases identified in the in vitro screen by
siRNA knockdown for sensitization to TRAIL (Supplementary
Figure S2a). Knockdown of 26 of these kinases did not affect
sensitivity to TRAIL. Silencing of cyclin-dependent kinase 9
(CDK9), however, potently sensitized HeLa and A549 cells to
TRAIL-induced apoptosis (Figures 2a and b). CDK9 is a
member of the family of CDKs, which are mainly known for
their function in cell cycle regulation.29 Recently, it was
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shown that a subset of CDKs, namely CDK7 and CDK9
regulate transcription.30,31 Our screen revealed that
PIK-75 also inhibits CDK7. However, a role of CDK7 in
mediating TRAIL resistance could be excluded, as CDK7
knockdown did not sensitize to TRAIL-induced apoptosis
(Figures 2a and b). Moreover, a contributing role of the most
prominent members of the cell cycle-regulating CDKs,
CDK1, 2, 4 and 6 could also be excluded by knockdown
experiments (Supplementary Figures S2b and c).
CDK9 inhibition by SNS-032 potently sensitizes to
TRAIL-induced apoptosis. Several CDK inhibitors targeting
different subsets of CDKs are currently evaluated in clinical
trials.32 Among them, SNS-032 (BMS-387032) appears to be
the most selective CDK9 inhibitor. It inhibits CDK2, CDK7
and CDK9 selectively over other CDKs and kinases, but
its inhibitory capacity is about 10-fold selective for CDK9
(IC50¼ 4 nM) over CDK2 (IC50¼ 38 nM) and 15-fold over
CDK7 (IC50¼ 62 nM).33 CDK9, in a complex with its partner
Cyclin-T/K, constitutes the positive transcription elongation
factor b (P-TEFb) that promotes transcriptional elongation by
phosphorylation of substrates.34,35 The most important
substrate of P-TEFb is the carboxy-terminal domain of
RNA-polymerase II (RNA-Pol II), which is phosphorylated
by CDK9 at Ser-2. Analysis of Ser-2 phosphorylation of
RNA-Pol II showed that PIK-75 and SNS-032 exerted similar
inhibitory activity towards CDK9 (Supplementary Figure
S3a). We next evaluated a novel combinatorial therapy
consisting of the clinically used CDK9 inhibitor SNS-032 and
TRAIL. Indeed, SNS-032 markedly sensitized HeLa
and A549 cells to TRAIL-induced cell death (Figure 3a).
Sensitized cells died apoptotically (Figure 3b) and this cell
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Figure 1 PIK-75 profoundly sensitizes cancer cells to TRAIL-induced apoptosis independently of PI3K inhibition. (a) HeLa cells were preincubated for 1 h with the
indicated PI3K inhibitors and subsequently stimulated with izTRAIL at the indicated concentrations. Cell viability was quantified after 24 h. (b) A549 cells were treated with
DMSO or PIK-75 (200 nM) for 1 h and subsequently stimulated with izTRAIL for 24 h. Long-term survival was visualized after 7 days by crystal violet staining. One of two
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death was prevented by the caspase-inhibitor zVAD (Supple
mentary Figure S3b). Finally, SNS-032 in combination with
TRAIL almost completely abrogated clonogenic survival of
A549 cells (Figure 3c). These data demonstrate that
cancer cell lines can be strongly sensitized to TRAIL-
induced apoptosis via CDK9 inhibition using SNS-032, a
small molecule inhibitor that is already undergoing clinical
testing.
In line with these findings, cancer cells treated with TRAIL in
the presence of SNS-032 showed a drastic increase in the
cleavage of caspase-8, Bid, caspase-9, -3 and poly ADP
ribose polymerase (PARP) (Figure 3d and Supplementary
Figure S3c). Moreover, cells in which CDK9 was silenced
using siRNA also showed increased activation of the apoptotic
caspase cascade (Supplementary Figure S3d). As expected
from this finding, DISC analysis upon CDK9 inhibition using
SNS-032 (Figure 3e) or upon CDK9 knockdown
(Supplementary Figure S3e) revealed that caspase-8
cleavage generating the p18 fragment was enhanced upon
CDK9 inhibition or suppression at the DISC (Figure 3e,
Supplementary Figure S3e). Thus, CDK9 inhibition facilitates
initiation of the caspase cascade at the DISC as part of its
sensitization mechanism.
CDK9 mediates TRAIL resistance by promoting
concomitant transcription of cFlip and Mcl-1. Having
established that CDK9 inhibition efficiently sensitizes cancer
cell lines to TRAIL-induced apoptosis, we next addressed
which molecular changes are responsible for this effect.
Upregulation of TRAIL-R1 and/or TRAIL-R2 often correlates
with, and sometimes also contributes to, TRAIL apoptosis
sensitization.36 However, treatment of HeLa or A549 cells
with PIK-75 or SNS-032 did not alter TRAIL-R1/R2 surface
expression (Figure 4a), in line with similar recruitment of
TRAIL-R1/2 in the DISC analysis (Figure 3e). Consequently,
TRAIL sensitization by CDK9 inhibition is likely to require
changes in intracellular modulators of the TRAIL apoptosis
pathway that should enhance DISC activity and possibly
additional downstream steps in the pathway. We, therefore,
next investigated whether known components of the TRAIL–
DISC and the downstream apoptosis pathway it activates are
regulated by PIK-75 or SNS-032 treatment. Whereas the
majority of the DISC components and downstream pro- and
anti-apoptotic proteins remained unchanged, cFlip and Mcl-1
protein levels were rapidly suppressed by pharmacological
CDK9 inhibition by SNS-032 or PIK-75 (Figure 4b and
Supplementary Figure S4a). Because siRNA-mediated
suppression of CDK9, performed in the presence or absence
of pan-caspase inhibition to exclude a possible impact of
CDK9-silencing-induced apoptosis, also resulted in down-
regulation of cFlip and Mcl-1, we can conclude that CDK9 is
required to maintain high expression of these anti-apoptotic
proteins in cancer cells (Figure 4c).
CDK9 is known for its role in transcriptional elongation,
suggesting that the observed downregulation of cFlip and
Mcl-1 protein levels could be caused by suppression of their
transcripts. In line with this hypothesis, SNS-032 treatment
rapidly decreased the amount of mRNA for cFlip and Mcl-1
(Figure 4d). The effect was a consequence of direct inhibition
of transcription, because co-treatment with SNS-032 and the
transcriptional inhibitor actinomycin D37 did not further reduce
mRNA levels (Supplementary Figure S4b). Moreover,
preincubation with the translational inhibitor cycloheximide
before SNS-032 treatment did not inhibit SNS-032-mediated
mRNA suppression (Supplementary Figure S4b). Co-incubation
with actinomycin D and cycloheximide induced a steady-state
level of mRNA. Additional treatment with SNS-032 did not
reduce Mcl-1 mRNA, showing that SNS-032 does not induce
degradation of mRNA. Next, we analyzed cFlip and Mcl-1
mRNA upon CDK9 knockdown. In slight contrast to CDK9
inhibition using SNS-032, prolonged silencing of CDK9 using
siRNA also strongly affected mRNA levels of housekeeping
genes. Therefore, we normalized mRNA amounts to cell
numbers used for RNA extraction. The amplification of cFlip
and Mcl-1 transcripts by real-time PCR (RT-PCR) required a
higher cycle threshold, demonstrating that their transcripts are
indeed suppressed when normalized to the cell number
(Supplementary Figure S4c). We conclude that SNS-032-
induced suppression of cFlip and Mcl-1 is mediated by
direct inhibition of global transcription that will preferentially
affect expression levels of short-lived proteins such as
cFlip and Mcl-1.
Concomitant downregulation of cFlip and Mcl-1 is
sufficient and required for CDK9 inhibition-induced
TRAIL sensitization. To evaluate whether concomitant
suppression of cFlip and Mcl-1 was sufficient for CDK9
inhibition-mediated TRAIL sensitization, we silenced cFlip
and/or Mcl-1 in HeLa and A549 cells. Hela cells were
sensitized to die by Mcl-1 knockdown alone only when high
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concentrations of TRAIL were used. Knockdown of cFlip, in
turn, sensitized at lower TRAIL concentrations, whereas at
higher TRAIL concentrations HeLa cells were rendered more
resistant by cFlip knockdown (Figure 5a). The latter may be
attributable to the interesting observation that knockdown of
cFlip brought about the upregulation of Mcl-1. In A549 cells,
silencing of neither cFlip nor Mcl-1 alone was sufficient to
sensitize to TRAIL-induced apoptosis (Figure 5b). Combined
knockdown of both components, however, resulted in a
striking synergistic sensitization rendering both, HeLa and
A549 cells, highly susceptible to TRAIL-induced apoptosis
(Figures 5a and b). Thus, combined downregulation of cFlip
and Mcl-1 is sufficient to break TRAIL resistance.
To further investigate the interesting observation that
silencing of either cFlip or Mcl-1 resulted in the inverse
upregulation of the respective other protein, we also analyzed
transcripts of cFlip and Mcl-1 upon knockdown. Silencing of
cFlip, Mcl-1 or the combination thereof resulted in comparable
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and efficient suppression of the respectively targeted tran-
scripts (Supplementary Figure S5a). Interestingly, the inverse
upregulation we observed on the protein level was also
apparent on the transcriptional level (Supplementary Figure
S5a), suggesting that this phenomenon is, at least partially,
regulated on the transcriptional level.
To test whether cFlip and/or Mcl-1 were responsible for the
block of TRAIL-induced apoptosis that is specifically removed
by CDK9 inhibition, we overexpressed cFlip and/or Mcl-1 in
HeLa cells before treatment with SNS-032 and TRAIL.
Transfection was highly efficient (Supplementary Figure
S5b) and nontoxic to the cells (Supplementary Figure S5c).
Overexpression of cFlip or Mcl-1 alone rendered these cells
slightly more TRAIL resistant but could only marginally inhibit
SNS-032-mediated sensitization (Figure 5c). Combined over-
expression, however, rendered HeLa cells almost completely
resistant to TRAIL-induced apoptosis and prevented SNS-
032-mediated sensitization (Figure 5c). Thus, SNS-032
sensitizes cancer cell lines to TRAIL-induced apoptosis by
concomitant suppression of cFlip and Mcl-1.
We next investigated whether CDK9 inhibition-induced
TRAIL sensitization requires activation of the mitochondrial
pathway. To do so, we used the isogenic HCT-116 colon
carcinoma cell lines in which Bax and Bak are either both
expressed (parental HCT-116 WT cells) or both genetically
deleted (BAX/BAK-deficient HCT-116 cells). HCT-116 WT
cells were partially TRAIL sensitive but profoundly sensitized
by co-treatment with SNS-032 (Supplementary Figure S5d).
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Their Bax/Bak-deficient counterparts, however, were com-
pletely resistant to SNS-032-mediated TRAIL sensitization.
Thus, TRAIL sensitizationmediated by CDK9 inhibition uses a
type-II apoptosis pathway that requires both, effective DISC-
mediated caspase-8 activation with consequent Bid cleavage,
enabled by cFlip downregulation, and efficient triggering of the
mitochondrial apoptosis pathway by cleaved Bid, enabled by
Mcl-1 downregulation.
Combined CDK9 inhibition and TRAIL selectively kills
NSCLC cell lines but not primary human hepatocytes
within a therapeutic window. On all cancer cell lines
tested, including primarily TRAIL-resistant A549 cells,
already low concentrations of TRAIL (1–10 ng/ml) in the
presence of SNS-032 (300 nM) were sufficient to reach
maximum efficiency in killing these cells. To investigate
whether this was a coincidence or may be applicable
more broadly, we extended our study to an established
panel of NSCLC cell lines.38 This panel includes cells
that are mutated in KRAS and/or p53 (Supplementary
Figure S6a). The majority of the cell lines were TRAIL
resistant, resembling TRAIL sensitivity of primary cancer
cells (Figure 6a and Supplementary Figure S6b). However,
all cell lines tested were potently sensitized to 10 ng/ml of
TRAIL by co-treatment with SNS-032 at 300 nM, irrespective
of their oncogenic mutations (Figure 6a and Supplementary
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Figure S6b). Thus, SNS-032/TRAIL co-treatment enables
efficient killing in a broad range of cancer cell lines,
irrespective of their p53-status.
Considering the remarkable sensitization observed with
combination of TRAIL and SNS-032, we next tested the
cancer selectiveness of this new combination. Hepatotoxicity
is a major concern for the clinical application of novel cancer
therapeutics and special care should be taken in the
development of therapies containing TNF superfamily
members.3 We therefore next assessed the effect of TRAIL
and/or SNS-032 treatment on primary human hepatocytes
(PHH). In line with our previous results,39 the recombinant
form of TRAIL used in our study (izTRAIL) did not reduce
viability of PHH (Figure 6b). In contrast, PHH were readily
killed by recombinant CD95L that served as a control (Figure 6c).
Treatment of PHH with SNS-032 at 300 nM in combination
with TRAIL used at different concentrations revealed that at
high concentrations of TRAIL (100 ng/ml and 1000ng/ml)
hepatocytes died when co-treated with SNS-032 (Figure 6b).
However, co-treatment with SNS-032 at 300 nM and TRAIL at
10 ng/ml, the concentrations at which these drugs were highly
efficient at killing cancer cells when combined, did not affect
viability of hepatocytes. The same nontoxic window was
confirmed for the levels of aspartate transaminase (AST),
which is released when liver cells are damaged (Figure 6d),
and the levels of caspase-cleaved cytokeratin 18 (Figure 6e).
Therefore, our novel therapeutic combination can be applied
within a considerable therapeutic window. At the same time,
toxicity would be expected at higher levels of TRAIL.
TRAIL combined with CDK9 inhibition eradicates
established orthotopic lung tumors. Having established
an applicable therapeutic window for our newly identified
combination of TRAIL with SNS-032 in vitro, we next
assessed this combination’s potency in an orthotopic model
of lung cancer in vivo. To this end, we induced lung tumors
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via tail vein injection of A549 cells stably expressing
luciferase (A549-luc). After 7 days, mice were randomized
to create treatment groups of mice with comparable tumor
burden in each group (Supplementary Figure S7). Subse-
quently, a 4-day treatment regime was started with either
vehicle, TRAIL, SNS-032 or the combination of SNS-032 and
TRAIL (Figure 7a). Whereas TRAIL treatment alone had a
slight growth inhibitory effect, and SNS-032 only marginally
affected lung tumor burden, combined treatment with TRAIL
and SNS-032 induced a drastic antitumor effect. TRAIL/SNS-
032 treatment completely eradicated established lung tumors
in most mice, as determined by in vivo bioluminescence
imaging (Figure 7b) and subsequent histopathological
inspection of lung sections (Figure 7c). Strikingly, and in line
with the bioluminescence data, seven out of eight mice that
had received TRAIL combined with SNS-032 were histolo-
gically tumor free after a 4-day treatment cycle.
Discussion
We found that the supposedly p110a-specific inhibitor PIK-75
potently sensitizes to TRAIL-induced apoptosis. Surprisingly,
however, PI3K inhibition was not responsible for this effect. A
kinome-wide screen revealed that PIK-75 strongly inhibits 27
kinases in addition to p110a. Off-target activity is a common
feature among kinase inhibitors, as most inhibitors are ATP-
competitive compounds and the ATP-binding pocket is highly
conserved among the human kinome.40,41 We show that
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PIK-75 exerts off-target effects toward CDK7 and CDK9. This
is in line with a recent report on the effects of PIK-75 on acute
myeloid leukemia.42 Moreover, we demonstrate that PIK-75’s
activity to sensitize cancer cells to TRAIL-induced apoptosis is
exclusively due to inhibition of CDK9. CDKs are mainly known
for their regulatory role in cell cycle, and development of CDK
inhibitors for cancer therapy is aimed at suppressing exacer-
bated cell cycle progression.43 Recently, a subset of CDKs,
namely CDK7 and CDK9, has been implicated in regulating
transcription.30,31 CDK9 inhibition has been shown to block
transcriptional elongation, thereby suppressing expression of
short-lived proteins such asMcl-1 that can result in induction of
apoptosis in cancer cells.30 This finding has paved the way for
targeting transcriptional CDKs in addition to cell cycle-regulat-
ing CDKs in cancer therapy. Here we provide evidence that
selective inhibition of CDK9 achieves an exceptionally potent
sensitization to TRAIL-induced apoptosis. Interestingly, the
pan-CDK inhibitors Flavopiridol44–46 and Roscovitine (Selici-
clib)47–49 have previously been shown to synergize with TRAIL.
However, so far, it remained unclear which CDK, inhibited by
these pan-CDK inhibitors, was responsible for these effects.
When combining our result with the fact that Flavopiridol and
Roscovitine also inhibit CDK9, it appears reasonable to
assume that their previously described TRAIL-sensitizing
capacity is likely owed to their CDK9-inhibitory capacity.
Inhibition of certain CDKs can potentially cause toxicity, and
CDK1 inhibition is currently thought to be most problematic in
this respect.50 To avoid potential dose-limiting toxicity, we
devised a novel combinatorial therapy consisting of TRAIL
and SNS-032, an inhibitor targeting CDK9 preferentially over
cell cycle CDKs.33 Importantly, the safety of SNS-032 was
already confirmed in clinical trials51,52 and SNS-032 has been
shown to be more potent in inhibiting transcription than
Flavopiridol and Roscovitine.53 The fact that CDK9 inhibition
was found to be nontoxic in clinical trials implies that normal
cells have possibly developed coping mechanisms that might
not be present in transformed cells. In line with this notion, our
results show that CDK9 inhibition in combination with TRAIL
can selectively kill tumor cells, but not PHH within a significant
therapeutic window. Of note, the concentration at which SNS-
032 effectively sensitizes cancer cells to TRAIL-induced
apoptosis, 300 nM, is commonly reached and sustained in
the plasma of patients.51
Investigating the underlying mechanism of how CDK9
inhibition sensitizes to TRAIL-induced apoptosis revealed that
Mcl-1 downregulation is required, but not sufficient, for TRAIL
sensitization. In addition, CDK9 inhibition-induced suppression
of another short-lived protein, cFlip, was required to achieve
potent TRAIL sensitization. Hence, the synergistic effect of
CDK9 inhibition and TRAIL is due to a dual mechanism:
downregulation of cFlip enables caspase-8 activation at the
DISC and downregulation of Mcl-1 facilitates activation of the
mitochondrial apoptosis pathway for enhanced caspase-9 and,
ultimately, caspase-3 activation. As a consequence, the
combination of TRAIL and CDK9 inhibition is exquisitely
powerful in killing tumor cells with a cFlip-imposed block to
initiator caspase activation at the DISC and an Mcl-1-imposed
block to activation of the mitochondrial apoptosis pathway.
Chemotherapy mostly induces apoptosis by induction of
DNA damage that is sensed by p53.54 However, impairment
of functional p53, either by mutation or loss of expression, is
frequently detected in cancer. Therefore, therapies that
function independently of p53-status are likely to be more
effective than chemotherapy. Importantly, we determined that
CDK9 inhibition sensitizes cancer cells to TRAIL irrespective
of their p53-status, thereby providing a therapeutic option also
for cancers with mutated p53 in which conventional che-
motherapy is largely ineffective. Moreover, the high efficacy of
the newly devised treatment combination was also apparent
in vivo. In an orthotopic lung cancer xenograft model, the
combination of SNS-032 with TRAIL eradicated established
lung tumors after a 4-day treatment cycle. This striking result
provides further support for the high therapeutic potential of
combinations of TRAIL-R agonists with CDK9 inhibitors.
Recent reports on first clinical trials with TRAIL and other
TRAIL-R agonists showed, on the one hand, that these
biotherapeutics were well tolerated but, on the other, that the
clinical activity they exerted, evenwhen combinedwith standard
chemotherapy, was rather limited.6 Cancer cell resistance to
TRAIL-induced apoptosis is likely to be a significant factor in this
outcome, indicating that a TRAIL-comprising therapy will only
be effective when a potent TRAIL sensitizer is applied in
combination with a TRAIL-R agonist. Based on our results, we
propose CDK9 inhibition as an effective means to overcome
TRAIL resistance in a cancer-selective manner.
Materials and Methods
Reagents. Antibodies: a-RNA-Pol II, a-pSer2 and a-pSer5 were purchased
from Covance (Princeton, NJ, USA); a-Caspase-3 and a-cIAP from R&D Systems
(Abingdon, UK); a-cFlip (NF6) and a-Caspase-8 (C15) are available from Enzo
(Exeter, UK); a-PARP was purchased from BD Biosciences (Oxford, UK); a-FADD
was purchased from BD Biosciences (IgG1) or Santa Cruz (Heidelberg,
Germany) (rabbit). a-Caspase-10 and a-Caspase-9 from MBL (Woburn, MA,
USA); a-b-Actin from Sigma (Gillingham, UK) and a-DNA-PK, a-p110a, a-p110b,
a-Bak, a-Bax, a-Mcl-1, a-Bcl-2, a-Bcl-xL, a-XIAP, a-CDK1, a-CDK2, a-CDK4,
a-CDK6, a-CDK7, a-CDK9, a-AKT and a-pAKT(Ser473) from Cell Signaling
(Danvers, MA, USA); a-Bid was obtained from or Cell Signaling (rabbit) or R&D
Systems (goat). HS101 and HS201 were used for surface staining of TRAIL-R1/–
R2 and are available from Enzo (Exeter, UK). Recombinant TRAIL was used as an
isoleucine zipper-tagged version of the extracellular domain of human TRAIL
(izTRAIL) as described previously.39 PIK-75, TGX-221 AS-252424, IC-87144, A66,
BEZ-235, GDC-0941 and SNS-032 were purchased from Selleck Chemicals
(Houston, TX, USA); actinomycin D from Merck Millipore (Darmstadt, Germany);
cycloheximide and crystal violet from Sigma, z-VAD(OMe)-FMK from Abcam
(Cambridge, UK) and D-Luciferin from Caliper Life Science (Waltham, MA, USA).
Cell lines. The human lung adenocarcinoma panel (H460, H522, H322, H441,
Calu-1 and H23) was kindly provided by J Downward and cultured in RPMI
supplemented with 10% FCS. A549-luc cells were purchased from Caliper Life
Science and cultured in RPMI supplemented with 10% FCS. HeLa cells were
cultured in DMEM supplemented with 5% FCS. HCT-116 WT and HCT-116 Bax-/-Bak-/-
were kindly provided by B Vogelstein and R Youle and were cultured in DMEM
supplemented with 10% FCS. PHHs were purchased from Gibco/Invitrogen
(Paisley, UK) and cultured according to the manufacturer’s instructions.
RNA interference. siRNA pools (ON-TARGET plus) containing four different
siRNA sequences targeting each gene of interest were purchased from
Dharmacon/Thermo Scientific (Loughborough, UK). Cells were transfected using
Dharmafect reagent according to the manufacturer’s instructions. Cells were used
for further analysis at 48 or 72 h after transfection. Knockdown efficiency was
assessed by western blot in parallel.
Cell viability and cell death assays. Cell viability was determined using
the Cell Titer Glo assay (Promega, Southampton, UK) according to the
manufacturer’s instructions. As a direct measurement of apoptotic cell death,
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DNA fragmentation was quantified as described before.55 To analyze long-term
survival (clonogenic assay), cells were seeded into six-well plates. The next day,
cells were preincubated with DMSO, PIK-75 or SNS-032 for 1 h before izTRAIL
was added. After 24 h, dead cells were washed away and surviving cells were
cultured for additional 6 days in fresh medium without any treatment. After 7 days,
cells were washed twice with PBS, fixed with 10% formaldehyde in PBS for 30 min
at room temperature and stained with crystal violet (1% in 50% ethanol).
Western blot analysis. Cells were treated as indicated and then lysed in
lysis buffer (30 mM Tris-HCl; pH 7.4, 150 mM NaCl, 2 mM EDTA, 2 mM KCl, 10%
glycerol, 1% Triton X-100 and 1 complete protease-inhibitor cocktail (Roche,
Burgess Hill, UK)). Proteins were separated by SDS-PAGE (NuPAGE) and
analyzed by western blotting. Membranes were stripped with 50 mM glycine
(pH 2.3) before reprobing with other antibodies.
DISC analysis. We performed ligand affinity precipitations using Flag-tagged
TRAIL in combination with M2 beads (Sigma). Cells were incubated for 1 h at
37 1C in the presence or absence of 1mg/ml Flag-TRAIL. For the precipitation of
the non-stimulated receptors, Flag-TRAIL was added to the lysates prepared from
non-stimulated cells. Precipitates were prepared as described previously.56
TRAIL-R surface staining. Cells were detached using Accutase (Sigma) and
counted. Cells (2 105) were incubated with 10mg/ml anti-TRAIL-R1 (HS101) or
anti-TRAIL-R2 (HS201) or IgG1 isotype control antibody in 2% BSA in 100ml PBS
(BSA/PBS) for 30 min on ice. Cells were washed twice with ice-cold BSA/PBS before
incubation with secondary goat–anti-mouse-APC (BioLegend, London, UK) at a
dilution of 1:200 in BSA/PBS for 20 min on ice. Cells were washed three times in ice-
cold BSA/PBS and surface expression was assessed by flow cytometry.
Overexpression of cFlip and Mcl-1. HeLa cells were transfected with
control, PEGZ-cFlip, pEF 3xFLAG-hMcl-1 or both using Lipofectamine LTX
(Invitrogen, Paisley, UK) according to the manufacturer’s instructions. Cells were
left untreated for 24 h before any treatment to ensure efficient expression of the
respective protein. Efficient expression of the respective protein was controlled by
SDS-PAGE and subsequent western blot. Furthermore, cells were transfected with a
GFP-containing plasmid and transfection efficiency was quantified by flow cytometry.
Determination of AST values. Supernatant (30 ml) of treated PHHs was
used to determine AST levels using a Reflovet Analyzer (Roche) and Reflotron
GOT test strips according to the manufacturer’s instructions.
Caspase-cleaved CK 18-ELISA. Supernatant (50 ml) of treated PHHs was
used in the M30 Apoptosense ELISA (Peviva, Bromma, Sweden) according to the
manufacturer’s instructions.
High-Throughput kinase selectivity profiling (Kinomescan).
High-throughput kinase selectivity profiling assay (Kinomescan, DiscoveRx,
Fremont, CA, USA) was used to determine the promiscuity of PIK-75 as a
kinase inhibitor. The capacity of PIK-75 to bind to a panel of 451 human kinases
was determined by analyzing the binding interaction (%) compared with DMSO
(¼ 100%). We chose to use PIK-75 at 200 nM in this screen because this was
twice the concentration of this agent required to sensitize cancer cells to TRAIL.
Hits were visualized using the TREEspot visualization tool provided by DiscoveRx.
Kinases were considered hits if their activity was inhibited by 490% leaving
o10% remaining activity.
RNA analysis by RT-PCR. RNA was extracted using the RNeasy Kit
(Qiagen, Manchester, UK) and treated with the TURBO DNA-free Kit (Ambion,
Paisley, UK) according to the manufacturer’s instructions. cDNA was generated
using the RevertAid H Minus Strand cDNA Synthesis Kit (Thermo Scientific,
Loughborough, UK) and used in combination with the FastStart Universal
ProbeLibrary Mastermix (Roche) for the RT-PCR. Quantification of gene products
was performed using the Eppendorf Mastercycler. When fold changes are shown,
the gene product was normalized to GAPDH as a housekeeping gene and were
calculated using the method described by Pfaffl et al.57
Primers for RT-PCR. Primers and probe combinations were determined
using the Universal ProbeLibrary Design Center (Roche) and are as follows.
cFLIP(s) forward: 50–TTGGAAATTGTTCCATGTGATT-30
cFLIP(s) reverse: 50-GCAACAAGAAAGGGCTAAACA-30
cFLIP(s) Essay Universal ProbeLibrary Number: 34
cFLIP(l) forward: 50-GCTCACCATCCCTGTACCTG-30
cFLIP(l) reverse: 50-CAGGAGTGGGCGTTTTCTT-30
cFLIP(l) Essay Universal ProbeLibrary Number: 14
CDK9 forward: 50-TTCGGGGAGGTGTTCAAG-30
CDK9 reverse: 50-ATCTCCCGCAAGGCTGTAAT-30
CDK9 Essay Universal ProbeLibrary Number: 21
MCL-1 forward: 50-AAGCCAATGGGCAGGTCT-30
MCL-1 reverse: 50-TGTCCAGTTTCCGAAGCAT-30
MCL-1 Essay Universal ProbeLibrary Number: 49
GAPDH forward: 50-AGCCACATCGCTCAGACAC-30
GAPDH reverse: 50-GCCCAATACGACCAAATCC-30
GAPDH Essay Universal ProbeLibrary Number: 60
Orthotopic lung cancer xenograft. Female Fox Chase SCID Beige Mice
(6–12 week old; Charles River, Germany) were injected with 2 106 A549-luc
cells via the lateral tail vein. After 1 week, all mice were imaged for
bioluminescence using the Ivis Spectrum (Caliper Life Science). Photons
per second (Photon Flux) were quantified using the Ivis Spectrum software. Mice
with established tumor burden were included in the study and randomized into the
treatment groups (eight mice/group). Subsequently, mice were treated for 4
consecutive days with daily i.p. injections of 600 mg SNS-032 (30 mg/kg) and/or
100mg izTRAIL or 200 ml buffer as control. After 3 weeks, tumor burden was
quantified by bioluminescence imaging. For preparation of lung tissue sections,
mice were killed according to Guidance on Operation of Animals (Scientific
Procedures) Act 1986. Lungs were removed, fixed in 10% formalin for 1 week and
then transferred to 70% ethanol. Paraffin embedding, preparation of sections and
H&E stainings were performed as part of a histological staining service at the
National Heart & Lung Institute. H&E stainings were examined and quantified by
an experienced pathologist (MAE-B) who was blinded to the study. Tumor burden
was quantified as percentage of tumor tissue in the lung. SCID beige mice were
maintained in individually ventilated cages, received autoclaved food, water and
bedding according to the institutional guidelines under a UK Home Office project
license. The required risk assessments were obtained for this study.
Statistical analysis. Data were analyzed using GraphPad Prism 6 software
(GraphPad Software). Statistical significance between groups was determined
using Student’s t-test. Significant P-values are denoted as *Po0.05; **Po0.01;
***Po0.001.
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Running title:  TRAIL/TRAIL-R2 promote KRAS-driven cancer progression  
Highlights: 
 TRAIL-R2 promotes tumor growth, migration, invasion and metastasis 
 Endogenous TRAIL/TRAIL-R2 constitutively activate Rac1/ PI3K  
 mTRAIL-R promotes KRAS-driven lung and pancreatic cancer and metastasis 
 TRAIL-R2 expression positively correlates with onset of metastasis in patients 
 
Abstract 
Many cancers harbor oncogenic mutations of KRAS. Effectors mediating cancer progression, 
invasion and metastasis in KRAS-mutated cancers are only incompletely understood. An 
apparently unrelated observation is that many cancers highly express TRAIL-receptors 
(TRAIL-Rs), which seems counterintuitive given that the main function ascribed to TRAIL-Rs is 
induction of apoptosis. Here we identify cancer-cell-expressed TRAIL-R2 as a mediator of 
KRAS-driven cancer progression, invasion and metastasis. This cancer-cell-autonomous 
signal originates from the membrane-proximal domain (MPD) of TRAIL-R2, a domain with 
previously unknown function. Cancer-cell-autonomous TRAIL-R2 stimulation promotes 
activation of a Rac1/PI3K signaling axis responsible for increased migration. Cancer-cell-
restricted deletion of murine TRAIL-R in autochthonous models of lung and pancreatic cancer 
(LsL-KRASG12D and LsL-KRASG12D/LsL-p53R172H) reduces tumor growth, consequently 
substantially prolonging survival, and blunts metastasis. Consistent with this, high TRAIL-R2 
expression in pancreatic cancer patients correlates with tumor invasion into lymph vessels and 
with shortened metastasis-free survival of KRAS-mutated colorectal cancer patients. 
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Smac mimetics induce inflammation and necrotic
tumour cell death by modulating macrophage activity
D Lecis*,1, M De Cesare1, P Perego1, A Conti1, E Corna1, C Drago2, P Seneci3,4, H Walczak5, MP Colombo1, D Delia1 and S Sangaletti*,1
Smac mimetics (SMs) comprise a class of small molecules that target members of the inhibitor of apoptosis family of
pro-survival proteins, whose expression in cancer cells hinders the action of conventional chemotherapeutics. Herein, we
describe the activity of SM83, a newly synthesised dimeric SM, in two cancer ascites models: athymic nude mice injected
intraperitoneally with IGROV-1 human ovarian carcinoma cells and immunocompetent BALB/c mice injected with murine Meth
A sarcoma cells. SM83 rapidly killed ascitic IGROV-1 and Meth A cells in vivo (prolonging mouse survival), but was ineffective
against the same cells in vitro. IGROV-1 cells in nude mice were killed within the ascites by a non-apoptotic, tumour necrosis
factor (TNF)-dependent mechanism. SM83 administration triggered a rapid inflammatory event characterised by host secretion
of TNF, interleukin-1b and interferon-c. This inflammatory response was associated with the reversion of the phenotype
of tumour-associated macrophages from a pro-tumoural M2- to a pro-inflammatory M1-like state. SM83 treatment was also
associated with a massive recruitment of neutrophils that, however, was not essential for the antitumoural activity of this
compound. In BALB/c mice bearing Meth A ascites, SM83 treatment was in some cases curative, and these mice became
resistant to a second injection of cancer cells, suggesting that they had developed an adaptive immune response. Altogether,
these results indicate that, in vivo, SM83 modulates the immune system within the tumour microenvironment and, through its
pro-inflammatory action, leads cancer cells to die by necrosis with the release of high-mobility group box-1. In conclusion, our
work provides evidence that SMs could be more therapeutically active than expected by stimulating the immune system.
Cell Death and Disease (2013) 4, e920; doi:10.1038/cddis.2013.449; published online 14 November 2013
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Resistance to death is a hallmark of cancer cells1 that renders
them unresponsive to chemotherapy. Chemoresistance is
often attributed to the inhibitor of apoptosis (IAP) proteins that
control many aspects of cellular life, including the response to
environmental stimuli, the regulation of cell death2 and cellular
motility.3,4 X-linked IAP (XIAP) is the only IAP to directly
interact with caspases, which occurs through conserved
domains named baculoviral IAP repeats.5 This interaction
hinders the activity of both initiator caspase-96 and effector
caspases-3 and -7.7 XIAP activity is antagonised by second
mitochondria-derived activator of caspases/direct IAP-
binding protein with low pI (Smac/DIABLO), which binds to
its baculoviral IAP repeats, thereby releasing the caspases6
and favouring the apoptotic cascade. Starting from this
observation, many groups have designed small peptidomi-
metics that mimic the structure of the N-terminal tetrapeptide
(AVPI) of Smac/DIABLO in order to prevent XIAP from
inhibiting caspases.8–10 These compounds, referred to as
Smac mimetics (SMs), enhanced the antitumour activity of
radiation or chemotherapeutic treatments in combination
experiments.11 Furthermore, they have been shown to
potentiate the cytotoxic effects of ‘death ligands’, in particular,
than that of tumour necrosis factor (TNF)-related apoptosis-
inducing ligand (TRAIL).9,12–14 Therefore, these compounds
have been proposed as novel cancer treatments and are
currently being tested, as part of combination therapies, in
clinical trials.2
Despite the ability of SMs to enhance the cytotoxicity of
other compounds, they are often ineffective in monotherapy.
Still, some cancer cell lines undergo a TNF-dependent
apoptotic process in response to the administration of a SM
alone. In fact, although these compounds were designed to
target XIAP, they also bind other IAPs, such as cellular IAP1
(cIAP1) and cIAP2, leading to their self-ubiquitination15,16 and
rapid proteasomal degradation.17,18 As cIAPs are negative
regulators of NF-kB-inducing kinase, their SM-triggered
depletion results in the stabilisation of NF-kB-inducing
kinase19 with consequent induction of the non-canonical
NF-kB pathway.17 In cell lines sensitive to these compounds,
this event is sufficient to trigger the secretion of high
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levels of TNF, thus killing the cells through an autocrine
or paracrine mechanism.17,18 Despite the clear in vitro
assessment of this process, the role of TNF in SM-induced
cell death in vivo is still controversial. In fact, the employment
of these compounds in pre-clinical models, either as mono-
therapy or in combination with other drugs, has resulted in
conflicting evidence,11,20,21 indicating a need to clarify the
mechanism of action of SMs in vivo.
One way to study the mechanisms of action of antitumoural
agents involves the use of animal models of cancer ascites.
The formation of ascites characterises the advanced-stage of
various types of tumours, especially ovarian carcinomas.
This condition depends on a mechanical constriction exerted
by the tumour and is determined by a peritoneal increase of
fluid production associated with decreased lymphatic absorp-
tion. Ascites is often the cause of death for ovarian cancer
patients, while rarely there is metastatic spread of tumour cells
outside the peritoneum.22 In peritoneal ovarian carcinoma-
tosis, the ascitic fluid represents the microenvironment in
which soluble factors are interchanged between cancer
and stromal and inflammatory cells, in order to support
tumour growth and invasion. This microenvironment also
promotes immunosuppression favouring tumour escape from
immune control. Thus, although the ascitic fluid is normally
enriched in immune cells, they are often anergic and
unable to elicit an antitumour immune response. Animal
models of cancer ascites facilitate the study of immune
cells such as macrophages in response to antitumoural
treatments.
Macrophages are plastic cells characterised by different
states of activation.23 Classically activated macrophages (M1)
and ‘alternatively’ activated macrophages (M2) represent
the two extremes in the spectrum of the macrophage
phenotype. Tumour-associated macrophages are classified
as M2 macrophages because of their cytokine expression
profile;24 they produce high amounts of immunosuppressive
cytokines such as interleukin-10 (IL-10) and, mostly in solid
tumours, share some tissue repair functions with fibro-
blasts.23,25 In contrast, M1 macrophages produce large
amounts of pro-inflammatory cytokines including interferon-g
(IFNg) and IL-12, and can be involved in the elicitation of
an effective antitumour immune response. The plasticity of
macrophages has suggested new therapeutic approaches
aiming to revert the M2 phenotype26 especially in tumours that
strictly relies on the macrophage infiltration such as ovarian
carcinomas. Accordingly, macrophages have been repro-
grammed in a mouse ovarian ascites model by modulating
NF-kB signalling.27
We recently described the synthesis of novel dimeric
molecules that target XIAP, cIAP1 and cIAP2.28,29 One of
these molecules, SM83, inhibited the growth of SM-sensitive
human mammary adenocarcinoma MDA-MB231 and rhab-
domyosarcoma Kym-1, but not of other cell lines. Here, we
use two murine xenograft models of cancer ascites to show
that SM83, when administered in monotherapy, increases the
survival of these mice by targeting tumour-associated macro-
phages. Through TNF, SM83 rapidly induces necrosis
of the intraperitoneally (i.p.) injected cancer cells, which are
otherwise completely resistant in vitro to the antitumoural
effects of SM83. Therefore, our work shows that SM83
displays different mechanisms of action in vitro and in vivo,
and that in vivo it exerts its antitumoural activity by stimulating
the immune system.
Results
SM83 sensitises the IGROV-1 ovarian carcinoma cell line
to the apoptotic effects of TRAIL. SM83 (Figure 1a) is a
novel inhibitor of XIAP, cIAP1 and cIAP2. When administered
to human IGROV-1 ovarian carcinoma cells, SM83 in
monotherapy at two doses had no inhibitory effect on cell
growth (Figure 1b). Instead, when administered together with
TRAIL, cell growth was substantially reduced to about
50 (2 ng/ml TRAIL) and 28% (10 ng/ml TRAIL) of that of
untreated cells, without a dose-dependent effect for
SM83. TRAIL treatment alone had a negligible effect at this
concentration, whereas SM83 monotherapy was ineffective
on a panel of other human cancer cell lines (A2780, H460,
SW48, HCT-116 and DLD-1 cells; data not shown).
The apoptotic effects of these treatments on IGROV-1 cells
at 3 and 24 h were assessed by western blotting (Figure 1c).
Treatment with SM83 alone decreased cIAP1 and cIAP2 to
almost undetectable levels already at 3 h. Treatment with
SM83 and TRAIL, at 24 h, strongly increased cleaved poly
(ADP-ribose) polymerase (PARP), a marker of activated
apoptosis. Similar results were obtained when cells were
treated with SM59 (Figure 1d). These results suggest that
SMs sensitise IGROV-1 cells to TRAIL-induced cell death
without causing death themselves.
SMs in monotherapy increase the survival of mice
bearing cancer ascites. SM83 and SM59 were then tested
in vivo using a murine xenograft model in which IGROV-1
cells are injected i.p. into athymic nude mice, leading to
ascites and death. Treatment with both SM83 (Figure 2a)
and SM59 (Figure 2b) increased mouse survival (Po0.05
versus control mice), but SM83 was slightly more effective
than SM59 (T/C% 180 versus 164). Furthermore, SM83
administration significantly reduced the formation of the
ascites (Figure 2c). Treatment with TRAIL alone did not
increase mouse survival, and the combination of TRAIL plus
SM83 had no additive effect (Figure 2a). These findings,
which are contrary to the in vitro results, suggest that SMs
alone slow the progression of ovarian ascites but are not
curative in these mice, whereas TRAIL alone is ineffective at
the concentration used.
To test whether the in vivo activity of SM83 was cell line-
specific or limited to immunodeficient mice, we used another
ascites model in which murine Meth A sarcoma cells are
injected i.p. into immunocompetent syngeneic BALB/c mice.
Similar to IGROV-1 cells, Meth A cells were not growth-
inhibited by SM83 in vitro (data not shown). In mice, SM83
reduced the progression of the ascites, seen as a smaller
increase in body weight (Figure 2d), and augmented the
median survival time from 15 days for untreated animals to
26 days (P¼ 0.0721; Figure 2e). Also in this model, combination
with TRAIL was not beneficial (data not shown). Moreover,
when mice cured by SM83 (4 of 14 mice tested) were
challenged with a new injection of 4 105 Meth A cells (twice
that of the first administration) none formed new ascites
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(data not shown). These results strongly suggest that these
animals developed an adaptive immunity.
SM83 rapidly kills cancer cells floating in the ascites by
a non-apoptotic mechanism. To investigate the mecha-
nism of SM83 activity in vivo, the ascitic fluid from mice
injected with IGROV-1 cells and treated or not with SM83 for
3, 6 or 24 h was collected and tumour cells were counted.
The results showed a striking decrease (Po0.001) in the
total number of ascites tumour cells in SM83-treated mice at
24 h compared with control untreated mice, without appreci-
able changes at 3 or 6 h (Figure 3a). Autopsy revealed no
adhesion of single cancer cells to the peritoneal wall nor
migration outside the peritoneum. Furthermore, we detected
a significant increase of human cytokeratin-18 (Po0.0001),
a protein released from dying human epithelial cells, in the
Figure 1 SM83 induces apoptosis in vitro when combined with TRAIL. (a) Chemical structure of the dimeric SM SM83. (b) IGROV-1 cells were treated with 0.1 or 1.0mM
SM83 alone or in combination with 2 or 10 ng/ml TRAIL. Cell growth is expressed as a percentage relative to cells mock-treated with vehicle. Values are mean and S.D. from
one experiment representative experiment of three performed. (c and d) Western blot analysis of XIAP, cIAP1, cIAP2 and cleaved PARP (Cl PARP) in IGROV-1 cells treated 3
or 24 h with SM83 (c) or SM59 (SM-164) (d) in the absence or presence of 10 ng/ml TRAIL. Actin is shown as loading control. Arrow, specific XIAP band
Figure 2 Treatment with SM83 in monotherapy increases the survival of mice bearing cancer ascites. (a) Nude mice were injected i.p. with IGROV-1 cells and left
untreated (J) or treated 5 times a week, for 2 consecutive weeks starting the day after injection, with 5 mg/kg SM83 (m), 2.5 mg/kg TRAIL (r) or with the same doses of
SM83 and TRAIL together (’). One experiment representative of two performed is shown. Each treatment group contained seven mice. Survival curve for SM83-treated mice
and controls. (b) Survival curve for SM59-treated and control mice. Untreated (J) or treated with SM SM59 (r). (c) The formation of ascites was checked by monitoring body
weight on day 17. (d and e) BALB/c mice were injected with Meth A cells and, starting on day 7, were treated daily with 5mg/kg SM83. (d) The formation of ascites was
checked by monitoring body weight on day 13. The horizontal line represents the mean. (e) Survival curve for untreated (K) or SM83-treated mice (J) starting from day 7
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serum of mice treated for 24 h (Figure 3b), suggesting
that SM83 triggered tumour cell death. Corroborating these
in vivo findings, western blot analysis of proteins from floating
tumour cells within the ascites confirmed that SM83 induced
the degradation of cIAP1 and cIAP2, but not of XIAP
(Figure 3c).
To understand the mechanism of cell death accounting
for the decrease in the number of floating tumour cells
within ascites, we examined the expression of mediators of
apoptosis in these cells at different time points. At 24 h, SM83
treatment led to only a faint increase of cleaved PARP, no
evidence of cleaved, active caspase-8 (which was expected
because these cells are killed in vivo by SM monotherapy30)
and only a modest effect on cleavage of caspase-3
(Figure 3d). In contrast, cells treated with TRAIL showed a
greater activation of these apoptotic markers even though
TRAIL was ineffective in reducing the ascitic cell number
(Supplementary Figure S1). In an attempt to detect the
apoptotic events, western blotting was done on the cells
collected after 3 and 6 h of treatment (Figure 3e). Also in this
case, SM83 caused the complete degradation of cIAP1 and
cIAP2, but there was only a faint accumulation of the cleaved
forms of PARP, caspase-8 and caspase-3. This low activation
of the apoptotic cascade suggested that the cause of death of
the ascites tumour cells was not primarily apoptotic.
To assess the possibility that autophagy – another
mechanism that can cause cell death when abnormally and
continuously activated – was responsible for the loss of
ascites tumour cells, we measured the levels of beclin-1 and
cleaved LC3B. Treatment with SM83 did not increase
the levels of these proteins (Supplementary Figure S2),
suggesting that autophagy is not involved in SM83-induced
tumour cell death.
SM83 triggers an inflammatory event in vivo. Having
excluded apoptosis and autophagy in SM83-mediated
cell death, we investigated the involvement of necrosis by
measuring the levels of murine inflammatory cytokines in the
ascites. There was a basal level of murine TNF in the ascites
of untreated mice, whereas in mice treated with SM83, the
level of murine TNF was significantly higher at 3 and 6 h but
not at 24 h (Figure 4a). On the contrary, human TNF was not
affected by SM83 treatment (Supplementary Figure S3).
We tested the relevance of TNF in this model by pretreating
mice with two inhibitors of TNF, etanercept and infliximab.
Etanercept at the higher dose tested completely blocked the
cytotoxic effects of SM83 (Figure 4b), without preventing
SM83-triggered degradation of cIAPs (Figure 4c). Pretreat-
ment of mice with infliximab, instead, did not block the
cytotoxic effects of SM83 on ascites tumour cells (data not
shown), probably owing to its lower affinity for mouse TNF or
to an insufficient concentration. Overall, these data suggest
that SMs are effective in vivo by stimulating the release of
murine TNF that activates the TNF receptor leading to
the creation of a pro-inflammatory microenvironment.
Accordingly, the murine inflammatory cytokines IL-1b
(Figure 4d) and IFN-g (Figure 4e) were upregulated in the
peritoneal ascites in response to SM83 administration.
Figure 3 SM83 kills ascites tumour cells through a rapid, non-apoptotic event. Ascitic fluids were collected from nude mice injected with IGROV-1 cells and left untreated
or treated with a single injection of SM83 (5 mg/kg). (a) Number of tumour cells within the ascites of untreated animals (n¼ 11) or of animals treated for 3 (n¼ 4), 6 (n¼ 4) and
24 h (n¼ 9). Data are mean and S.D. (b) Levels of human cytokeratin-18 in the serum collected 24 h after a single dose of SM83 (5 mg/kg) or no treatment. (c) Western blot of
apoptosis markers in IGROV-1 cells cultured in vitro or recovered from the ascites of control mice (n¼ 2) or mice treated with SM83 (n¼ 2) or TRAIL for 24 h. (d) Western blot
to detect activated apoptosis markers cleaved PARP (p89), caspase-8 (precursor p55 and cleaved form p43/41) and cleaved caspase-3 (p19/p17) in IGROV-1 cells cultured
in vitro or recovered from the ascites (24 h) of control mice (n¼ 2) and of mice treated with 5mg/kg SM83 (n¼ 2) or 10mg/kg TRAIL. (e) Western blot of apoptotic markers in
tumour cells collected from the ascites of untreated mice (n¼ 2) or from mice treated for 3 or 6 h with SM83 (n¼ 2 for both) or with TRAIL for 24 h. Arrow, specific band
for XIAP
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In contrast, levels of the immunosuppressive cytokines IL-10
(Figure 4f), transforming growth factor-b (Figure 4g) and IL-4
(Figure 4h) remained mostly unchanged, with the exception
of IL-4 that increased significantly at 24 h; this increase could
be explained by the anti-inflammatory role of this cytokine,
secreted after 24 h to restrain the strong inflammation in
process.
SM83 promotes macrophage activation towards an
M1-like phenotype. To evaluate whether the pro-
inflammatory effect of SM83 depends on the activation
of tumour-associated macrophages, bone marrow (BM)-
derived macrophages (BMDM) from BALB/c mice were
treated in vitro with SM83, and the cell supernatants were
assayed for TNF and IL-1b. SM83 induced the secretion of
TNF starting at 6 h (Figure 5a) and of IL-1b at 24 h
(Figure 5b). Moreover, as macrophage activation is regulated
by NF-kB, we checked whether SM83 activated this pathway
using a macrophage cell line stably expressing a luciferase
reporter gene under control of the NF-kB-response element.
NF-kB activation was detectable after 3 h of treatment with
SM83 but returned to basal levels at 24 h (Figure 5c).
In agreement with an earlier study,31 SM83 treatment also
promoted the death of BMDM through necroptosis, which
was seen 24 h after treatment both morphologically
(Figure 5d, second panel) and with the CellTiter-Glo assay
Figure 4 SM83 treatment induces the expression of inflammatory cytokines in vivo. Nude mice were injected i.p. with IGROV-1 cells and treated or not with a single dose
of 5mg/kg SM83; ascites was collected 3, 6 and 24 h after SM83 administration. (a) SM83 transiently increased the level of murine TNF measured by ELISA. (b) SM83
treatment reduced ascites cell counts but this action was blocked when TNF was sequestered with the higher dose of etanercept (P¼ 0.0118 relative to treated with SM83
alone). (c) Western blots of ascites tumour cell protein from untreated mice and mice treated with SM83 alone or in combination with 150mg/kg etanercept. Arrow, specific
band for XIAP. (d–h) ELISA results for IL-1b (d), IFN-g (e), IL-10 (f), transforming growth factor-b (TGF-b) (g) and IL-4 (h) in the ascitic fluid of mice treated as above.
Results for IL-10 are shown as fold induction owing to the lack of recombinant protein standard
SM induce inflammation and tumour cell death
D Lecis et al
5
Cell Death and Disease
(Figure 5e, first bar). This cytotoxicity was prevented
by pretreatment with necrostatin-1, a specific inhibitor of
receptor-interacting protein-1 (a crucial mediator of necrop-
tosis), but not by the pan-caspase inhibitor z-vad-fmk,
which actually increased BMDM death (Figures 5d and e).
Overall, these data suggest that macrophages could
be the first target of SM83 activity that fosters their
production of pro-inflammatory M1-like molecules such as
TNF and IL-1b.
To exclude the possibility that the SM83-induced IL-1b
secretion was due to contamination with lipopolysaccharides
(LPS), by the stimulation of toll-like receptor-4 (TLR432), we
prepared BMDM from TLR4-knockout (KO) mice and found
that IL-1b was secreted to a similar extent as it was secreted
from BALB/c cells (Supplementary Figure S4). Furthermore,
SM83 preparations for injection were found to not contain
detectable levels of LPS on the Endosafe-PTS (Charles River
Laboratories, Calco, Italy) test (data not shown). These
results indicate that the SM83-induced IL-1b production was
not due to LPS contamination.
Bystander accumulation of neutrophils in the ascites.
Having demonstrated a pro-inflammatory effect of SM83 in
the tumour microenvironment, we next evaluated whether
SM83 treatment affected the innate immune cells infiltrating
the ascites. To this end, we used immunofluorescence
to examine the expression of leucocyte antigens on
cells harvested from the ascites of nude mice. This assay
allowed us to identify both macrophages (CD11bþ Gr-1 )
and neutrophils (CD11bþ Gr-1þ ) in mice that were either
untreated or treated for 3 and 6 h before harvesting
(Figure 6a), without noticeable differences in cell density.
However, after 24 h of treatment, neutrophils (but not
macrophages) had massively accumulated in the ascitic
fluid (Figure 6a, Supplementary Figure S5). Neutrophils had
also infiltrated the tumour nodules (Supplementary Figure S6).
This massive neutrophil recruitment was likely because of
the presence, in the ascites, of high-mobility group box-1
(HMGB-1; Figures 6b and c) and TNF (Figure 4a). HMGB-1,
which is released during necrosis and immunogenic
cell death, behaves as an ‘alarmin’ that, together with TNF,
attracts and activates neutrophils.33 In our IGROV-1 model,
HMGB-1 was detected in the ascitic fluid starting 6 h after
SM83 treatment (Figure 6b) and was located within the
cytoplasm of dying tumour cells (Figure 6c).
Next, neutrophils were isolated from spleens of BALB/c
(wild-type) and TNF-receptor-1 (TNF-R1)-deficient mice
to investigate in vitro the role of neutrophils in the antitumoural
activity of SM83. In Transwell assays, the migration of
wild-type neutrophils towards ascites from SM83-treated
mice was greater than that from untreated mice (Figure 6d).
The HMGB-1 inhibitor partially reduced the migration,
whereas neutrophils from TNF-R1-deficient mice did not
migrate in response to ascites from SM83-treated mice.
Ascites from mice treated with SM83 activated wild-type
neutrophils to produce superoxide even in the presence of the
TNF blocker etanercept, whereas glycyrrhizin completely
blocked such activity (Figure 6e). These findings suggest
that neutrophil migration in the presence of ascites from
SM83-treated mice is stimulated by TNF while activation is
attributable to HMGB-1. The importance of TNF in neutrophil
migration was also shown in vivo, where etanercept pretreat-
ment blocked the recruitment of these cells into the ascites
(Supplementary Figure S5).
Figure 5 SM treatment activates macrophage and sensitises them to necroptotic death. (a and b) BALB/c BMDM (5 105) were seeded in 96-well plates, left to adhere
for 16 h and treated or not with 1mM SM83 for up to 24 h. SM83 treatment promoted the secretion of the pro-inflammatory cytokines TNF (a) and IL-1b (b). (c) NF-kB
activation by SM83 evaluated in the macrophage cell line RAW stably transfected with a NF-kB luciferase reporter gene. One representative experiment of two performed is
shown. Values are mean and S.D.; n¼ 3. (d and e) BALB/c BMDM were seeded in six-well plates, left to adhere for 16 h and treated with serial dilutions of SM83 in the
absence or presence of necrostatin-1 or z-vad-fmk to inhibit necroptosis or apoptosis, respectively. (d) Representative images showing cell morphology after 24 h of treatment.
(e) Cell viability after treatments evaluated using the CellTiter-Glo assay
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Figure 6 SM83 treatment promotes peritoneal neutrophil recruitment and activation. Cells were harvested from the ascitic fluid of mice treated with 5 mg/kg SM83.
(a) Immunofluorescence for CD11b (green) and Gr-1 (red) was performed on Cytospin cell preparations. SM83 treatment induced a massive recruitment of neutrophils
(CD11bþ Gr-1þ ) at 24 h but not at earlier time points. (b) Dot blot of HMGB-1 (left panel) was performed on cleared ascitic fluids collected from untreated (un) or treated mice
at 3, 6 and 24 h after a single injection of 5mg/kg SM83. Right panel, loading control. (c) Infiltration of neutrophils (Gr-1; red) and HMGB-1 expression in dying tumour cells
(green) in ascites untreated (upper row) and treated for 24 h (lower row) with a single injection of SM83. Left and right panels show two different magnifications ( 10 and  40).
(d) PMN migration assessed by Transwell assay. Wild-type PMN from BALB/c mice (WT) or TNF-R1-deficient PMN from TNF-R1-KO mice (KO) were seeded into the upper
chamber in the absence or presence of the HMGB-1 inhibitor glycyrrhizin (GLZ), whereas the ascitic fluid of mice untreated or treated for 6 h (1:20 in medium) was added to the
lower chamber of the Transwell insert. PMN were left to migrate overnight, harvested and counted. (e) Activation of wild-type PMNs was colorimetrically evaluated on the basis
of the ability of cells to oxidise the cytochrome c in presence of the ascitic fluid collected from mice 6 h after treating with a single injection of SM83. The experiment was also
performed in the presence of GLZ and the TNF inhibitor etanercept. (f) Tumour cell counts in the ascites of untreated mice (UN), mice treated with a single injection of SM83
alone or mice treated with SM83 24 h after depletion of neutrophils by injection with the 1A8 mAb. (g) BALB/c mice were injected i.p. with Meth A cells and treated with 1A8
alone (’) or in combination with 5 mg/kg SM83 (&), starting from day 7
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Considering that, in certain conditions, neutrophils can be
responsible for tumour cell killing,34,35 we depleted ascites-
bearing mice of neutrophils before SM83 treatment. In nude
mice bearing IGROV-1 ascites, neutrophil depletion
did not impede the ability of SM83 to reduce the number of
floating tumour cells in the ascites (Figure 6f). Furthermore, in
immunocompetent BALB/c mice bearing Meth A ascites,
depletion of neutrophils (Supplementary Figure S7) did not
prevent SM83 from prolonging survival (Figure 6g), even
though these mice have CD8þ T cells that are known to
support the activity of neutrophils.36 On the contrary,
neutrophil depletion improved the efficacy of SM83 treatment
by significantly augmenting the overall survival of mice
treated with SM83 (P¼ 0.0458 versus 1A8 alone). These
results support the notion that, in our models, neutrophil
recruitment is a bystander effect due to SM83-induced
TNF secretion. The accumulation of neutrophils has no role
in SM-dependent cancer cell killing but rather, at least in the
Meth A model, could be in some way detrimental to the host.
In conclusion, our work shows that SM83 acts in vivo in
cancer ascites by reverting macrophages from an M2-like
phenotype, supporting the tumour, to an M1-like phenotype,
endowed with antitumour activity. M1 macrophages secrete
cytokines such as TNF, IL-1b and IFNg that cause a rapid
TNF-dependent necrotic death of the ascites cancer cells
(Figure 7); subsequently, the dying cells release HMGB-1
that, together with TNF, stimulates a massive infiltration of
neutrophils.
Discussion
In this study, we describe the in vivo activity of newly
synthesised SM SM83 in two murine xenograft models
of cancer ascites. We show that SM83 is active as
monotherapy in vivo on human and murine cancer cells that
are refractory to SMs in vitro, and demonstrate that these cells
die through a non-apoptotic, TNF-dependent mechanism.
We also provide evidence that SM83 exerts its activity by
inducing inflammation and immune cell activation, resulting in
immunogenic death of cancer cells. Moreover, our study
shows that the activity of SM83 (and possibly other SMs) in
the complex in vivo environment is different from that already
observed in vitro.
The activity of SMs in vitro has been widely shown to
depend on the secretion of TNF from tumour cells leading
to apoptosis in an autocrine manner.17,18 Our in vivo work
confirms that the antitumoural activity of SM83 depends on
TNF production. However, in our xenograft models, TNF
originated primarily from the host rather than from the tumour
cells. TNF was secreted by the immune cells, and by
macrophages in particular, and this effect was preceded
temporally by activation of the NF-kB-response element.
Following SM83 treatment, macrophages acquired an M1-like
phenotype characterised by the release of pro-inflammatory
cytokines such as TNF and IL-1b. Both cytokines have been
associated with the cytotoxic activity of macrophages on
tumour cells.23,37 Our experiments show that SM83 treatment
increased the concentration of these cytokines in the ascites
without a major influx of macrophages. Thus, SM83 treatment
may revert existing M2 macrophages to the M1 phenotype
rather than recruit new macrophages to the ascites.
A mechanistic interpretation of these results (Figure 7) is that
the cytokines secreted by M1 macrophages cause necrotic
death of the ascites cancer cells; the dying cells release
HMGB-1 that, together with TNF, recruits neutrophils as a
side effect rather than a needed step in the antitumoural
activity of SM83.
In tumour microenvironment, including ovarian cancer,
macrophages acquire an M2-like phenotype.38,39 Neverthe-
less, some authors have proposed various strategies23,24 that
are able to interchange the status of macrophages towards an
efficient antitumour response. On this line, it has also been
Figure 7 Proposed mechanism of action of SM83 in cancer ascites. SM83 stimulates the reversal of macrophages from M2 to M1 phenotype. TNF secreted by M1
macrophages triggers necrotic death of the cancer cells within the ascitic fluid; the dying cells release HMGB-1 that, together with TNF, recruits neutrophils
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shown the possibility of increasing efficacy of standard
therapies interfering with M2 macrophages,40 particularly
in tumours whose progression strictly relies on their support
such as ovarian carcinomas. These tumours establish a
complex relationship with the associated immune cells within
the ascites,41 developing an immunosuppressive microenvi-
ronment elicited by macrophages. Thus, in ovarian cancer,
the re-polarisation of macrophages or the inhibition of their
recruitment could be a new effective therapeutic strategy.
Our results suggest that SMs regulate the immune
response to cancer ascites by polarising macrophages and
thus have therapeutic potential. In fact, Smac/DIABLO42
and its mimetic SM83, as shown here, trigger necrotic
or necroptotic cell death. Necrotic cells, different from
apoptotic ones, release a non-oxidised, immunogenic form
of the alarmin HMGB-143 that activates dendritic cells by
engaging receptor for advanced glycation endproducts,
TLR4, TLR7 and TLR9 receptors.44 Furthermore, necrotic
cells can prime CD4þ T cells, essential for the development
of an adaptive immune response.45 The possibility that
SM83-induced necrosis primed an adaptive immune
response is raised by our results using BALB/c-immunocom-
petent mice bearing Meth A ascites. Some of these mice were
cured by SM83 treatment and, when challenged with
a new, double dose of Meth A cells, they did not form another
ascites, suggesting that they were immune to Meth A
sarcoma cells.
In conclusion, our data demonstrate that the SM SM83
is active in monotherapy by promoting inflammation
and immunogenic cell death. These observations provide
an explanation for why SMs increase the effectiveness of
standard therapies, namely by stimulating the immune
system. Finally, the evidence that SMs can induce an
inflammatory response and activate the immune system
provides an interpretation of why SMs can be more effective
in vivo than in vitro,11,46 and our results in cancer cell killing.
Materials and Methods
SMs, cell lines and mice strains. The compounds used in this study
were SM83 (called 9a elsewhere29,47), SM59 (also called SM-16448) and TRAIL.
Recombinant TRAIL was purchased from Enzo Life Sciences (Farmingdale, NY,
USA), whereas SM83 and SM59 were synthesised by CISI scrl (purity499%).
Synthesis and chemical structure of these SMs have been described elsewhere.28,29
Human ovarian carcinoma IGROV-1 and A2780, lung cancer H460, colon cancer
SW48, HCT-116 and DLD-1, and murine sarcoma Meth A cell lines were cultured
in vitro with RPMI plus 10% foetal calf serum. The murine macrophage cell line RAW
264.7, stably transfected with an NF-kB luciferase reporter plasmid, was cultured in
DMEM plus 10% foetal calf serum.
KO C57/BL6 mice strains deficient in TNF-R1 (TNF-R1-KO49) or in TLR4-KO50
and female athymic Swiss nude mice, all 8–10 weeks of age (Charles River
Laboratories), were maintained in laminar flow rooms keeping temperature and
humidity constant. Female BALB/c mice 7–8 weeks of age (Charles River
Laboratories) were housed in filter-top cages. Room sentinels were checked for
pathogens every 6 months by Charles River Laboratories staff. Experiments were
approved by the Ethics Committee for Animal Experimentation of the Fondazione
IRCCS Istituto Nazionale dei Tumori of Milan according to institutional guidelines.
Cell treatments and assays. Cells were plated at a density of about 60%
and grown overnight before being treated with SM83 or SM59 in the absence or
presence of 2 or 10 ng/ml TRAIL. Cell growth was determined after 3 days by cell
counting, whereas viability was tested using the CellTiter-Glo (Promega Italia srl,
Milan, Italy) assay for ATP after 24 h of treatment. For apoptosis assays, cells
were harvested after 3 or 24 h of treatment and used in western blotting.
Western blotting. Cells were harvested at the end of the treatment and
lysed in 125mM Tris HCl pH 6.8, 5% SDS by boiling; protein concentration was
quantified. Lysates (50mg) were fractionated by SDS-PAGE and proteins were
blotted onto PVDF membranes. Free protein-binding sites were blocked with 5%
non-fat dry milk in phosphate-buffered saline (PBS) and the membranes were
incubated overnight with primary antibodies diluted in non-fat dry milk-PBS.
The primary antibodies used were directed against: cleaved caspase-3, beclin-1,
cleaved PARP and LC3B (Cell Signaling Technology, Danvers, MA, USA);
caspase-8 (Enzo Life Sciences); XIAP and cIAP2 (BD Biosciences, Milan, Italy),
b-actin (Sigma, Rome, Italy); and cIAP1 (R&D Systems, Minneapolis, MN, USA).
After washing, the membranes were exposed to horseradish peroxidase-linked
secondary antibody (GE Healthcare, Milan, Italy) for 1 h and the bound antibodies
were detected using ECL (Thermo Scientific, Rockford, IL, USA).
Animal models of cancer ascites. The in vivo effects of SMs were tested
using two murine xenograft models of ovarian cancer. In one model, human
ovarian carcinoma IGROV-1 cells are injected i.p. into athymic nude mice.51
The cells adapt to grow i.p. and are maintained by i.p. serial passages of ascitic cells.
Mice develop haemorrhagic ascites and diffuse carcinomatosis and eventually
die.51 In order to assess the effects of SMs on survival, mice were inoculated i.p.
with 2.5 106 cells in 0.2 ml saline and, starting the day after cell injection,
injected i.p. with the compounds (dissolved in saline) at 5 mg/kg body weight, once
daily for 5 days per week for 2 weeks (qdx5/wx2w). The animals were inspected
and weighed daily. The progression of ascites was assessed from an increase in
body weight (measured on day 17). For ethical reasons, they were killed before
impending death, recognised by their suffering status and loss of reactivity to
external stimuli. The day of killing was taken as the day of death for calculating the
median survival time. The antitumour activity of treatments was expressed as
the ratio of median survival time in treated mice to that of untreated control
mice 100 (T/C%).
In the other ascites model, murine Meth A cells are injected i.p. into
immunocompetent syngeneic BALB/c mice.52 Here, 2 105 Meth A cells were
injected i.p., and treatment, starting 7 days later, consisted of five consecutive daily
i.p. injections of SM83 at a dose of 5mg/kg body weight. The progression of ascites
was assessed from both an increase in body weight (measured on day 13) and
overall survival, as calculated above. Mice in whom the ascites resolved and did not
relapse within 60 days were considered to be cured, and were challenged with a
new injection of 4 105 Meth A cells.
To assess the effects of SMs on ascites tumour cells, athymic nude mice were
injected with IGROV-1 cells as above. Ten days after IGROV-1 inoculation, ascites-
bearing mice were treated with a single injection of SM83 (5 mg/kg) or left untreated;
in some experiments, mice were pretreated 1 h before SM83 administration by i.p.
injection with one of two TNF inhibitors: 5 or 150mg/kg etanercept (Wyeth
Pharmaceuticals, Collegeville, PA, USA)53 or 5 mg/kg infliximab (Schering-Plough,
Milan, Italy). Mice were killed 3, 6 or 24 h after SM83 treatment, and ascitic fluid was
collected with a heparinised syringe, transferred to a centrifuge tube on ice and
centrifuged to pellet the cells for blotting. The supernatant was removed and stored
at  80 1C until it was assayed for cytokines (human and murine TNF, and murine
IL-1b, IL-4, IL-10, IFNg and transforming growth factor-b enzyme-linked
immunosorbent assay (ELISA) kits (Affymetrix, San Diego, CA, USA) or used in
blotting and in neutrophil assays. The pellet was suspended in 0.17M ammonium
chloride for 10min at 41 1C to lyse red blood cells; after washing in saline, the
remaining tumour cells were counted using the trypan blue exclusion assay and
used in immunofluorescence. Death of IGROV-1 cells was also checked by
quantifying human cytokeratin-18, a cytokeratin released by dying cells, in the serum
collected from killed ascites-bearing mice using M65 ELISA (Enzo Life Sciences).
Animals were subjected to autopsy to search for adherent tumour cells or
extraperitoneal migration. As IGROV-1 cells injected i.p. in nude mice also form
solid nodules, these were collected and fixed in formalin. After 24 h, tumours were
washed in PBS and kept in 70% ethanol until they were embedded in paraffin and
prepared for haematoxylin and eosin staining.
To deplete neutrophils, nude mice bearing IGROV-1 ascites were injected
i.p. with the anti-Ly-6G antibody (clone 1A8; Affymetrix) 24 h before SM83
administration. In the Meth A model, mice were injected with 20 mg 1A8 antibody
every second day, for 14 consecutive days, starting one day before SM83 treatment
(day 7). The efficiency of polymorphonuclear leucocytes (PMNs) depletion in nude
mice was tested by sampling the bone marrow (BM) 24 h after injection of the
anti-Ly-6G antibody. Cells were double-stained with anti-CD11b/Ly-6G and cell
populations were quantified by flow cytometry.54
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Macrophage primary cultures and reporter gene assays.
BM precursors were obtained from BALB/c and TLR4-KO mice and used to
isolate macrophages as previously described.26 Briefly, macrophages were
isolated from the precursors by cultivation in RPMI medium 10% foetal calf serum
containing 5 ng/ml macrophage colony-stimulating factor. On day 5, the medium
was replaced with fresh medium containing macrophage colony-stimulating factor.
On day 7, adherent cells were harvested and phenotypically characterised by
immunofluorescence using mAb to the macrophage markers CD11b and F4/80
(BD Biosciences). Up to 90% of the adherent population consisted of BMDM.
For in vitro experiments, 5 105 BMDM were seeded in six-well plates, allowed
to attach for 1 h at 37 1C and then treated or not with 1mM SM83. The release of
TNF and IL-1b to the culture medium, after 3, 6 and 24 h, was evaluated using
ELISA kits (Affymetrix). In viability experiments, 1 104 cells were seeded in
96-well plates and exposed to serial dilutions of SM83 in the absence or presence of
either 50mM necrostatin-1 (Enzo Life Sciences) or 20 mM z-vad-fmk (Enzo Life
Sciences). After 24 h, cells were examined morphologically by microscopy and
tested for viability using the CellTiter-Glo (Thermo Scientific) assay.
In other experiments, 104 RAW 264.7 macrophages were plated in 96-well
plates, grown for 16 h and then treated or not with 1mM SM83 for up to 24 h.
The activation of the NF-kB promoter was assayed using the Dual-Luciferase
Reporter Assay System (Thermo Scientific).
Immunofluorescence and dot blotting. Floating cells harvested from
the ascites were prepared for double-marker immunofluorescence by centrifuga-
tion on slides using a Cytospin cytocentrifuge. Briefly, acetone-fixed cells were
re-hydrated in PBS and incubated 1 h with a primary antibody. Cells were then
washed in PBS and incubated for 30min with the appropriate Alexa Fluor
488-conjugated secondary antibody. After washing, slides were incubated for
30min with another primary antibody, washed and incubated for 30min with an
Alexa Fluor 546-conjugated secondary antibody. The primary antibodies used
were: rat anti-mouse CD11b mAb (1:200; BD Biosciences); rat anti-mouse Ly-6G
mAb (1:200; BD Biosciences); and rabbit anti-HMGB-1 Ab (1:400; Abcam,
Cambridge, UK). In some experiments, nuclei were stained with 40,6-diamidino-
2-phenylindole. Slides were mounted with Prolong medium (Life Technologies,
Monza, Italy) and examined under a RADiance-2000 (Bio-Rad, Milan, Italy) Nikon-
TE300 laser scanning confocal microscope (Nikon Instruments S.p.A, Florence, Italy).
For dot blotting, ascitic fluid samples cleared of cells were spotted on PDVF
membranes and let to dry. After saturation with non-fat dry milk-PBS, filters were
hybridised with anti-HMGB-1 Ab (Abcam, 1:2000). The HMGB-1 was then detected
as for western blotting.
Spleen neutrophil preparation and assays. Neutrophils were obtained
from BALB/c (wild-type) or TNF-R1-KO mice through immunomagnetic cell
separation of a spleen cell suspension, using the Anti-Ly-6G MicroBead Kit
(Miltenyi Biotec, Bologna, Italy), as already described.54
Migration of neutrophils PMNs was tested using the Transwell system (Corning,
Tewksbury, MA, USA). Briefly, 5 105 PMNs were placed in serum-free RPMI in
the upper chamber of the Transwell insert. The lower chamber was filled with ascites
(1:20) or TNF in serum-free DMEM. PMNs were allowed to migrate for 24 h and then
collected from the lower chamber. In some cases, experiments were performed by
adding 100mM of the HMGB-1 inhibitor glycyrrhizin (Sigma-Aldrich, St. Louis, MO,
USA) to the top chamber.55
Neutrophil activation by cleared ascites was evaluated by measuring the rate of
formation of superoxide. Briefly, neutrophils (2 106/0.1ml cells/PBS solution) were
incubated with 20ml of cytochrome c (0.1mM final, bovine, Sigma), 20ml of ascites or
10mg/ml of PMA (as positive control for the neutrophil stimuli) in 1.76ml PiCM-G buffer
(138mMNaCl, 2.7mM KCl, 0.6mM CaCl2, 1.0 mMMgCl2, 5mM glucose and 10mM
NaH2PO4/Na2HPO4, pH 7.4). The mixture was added to cuvettes for spectro-
photometer and absorbance was read at 550 nm every 15min as described.56
Statistical analyses. For survival analyses, the percent survivorship over
time was estimated using the two-sided Kaplan–Meier product method; differences
between groups were compared using the log-rank test. In other analyses,
differences between groups were tested for significance using a two-tailed
unpaired t-test. A value of Po0.05 indicated significance. The analyses were
performed using Graphpad Prism v.5.02 (GraphPad Software, La Jolla, CA, USA).
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PeptidomimeticsNon-covalent (NP-1/3) and covalent (NP-A-1/3) pro-apoptotic SPION-Smac mimetic nano-conjugates
antitumor agents are reported. The solution synthesis of key Smac mimetics, their support onto SPIONs
through non-covalent adsorption (NP-1/3) or APTES-mediated covalent binding (NP-A-1/3), the analyti-
cal characterization of SPION-Smac mimetic conjugates, their target afﬁnity in cell-free assays, and their
cytotoxicity against tumor cells are thoroughly described.
 2014 Elsevier Ltd. All rights reserved.Nanoparticles are popular tools in cancer detection and treat-
ment, due to major advancements in nanosynthesis, bioengineer-
ing and imaging technology.1 Super Paramagnetic Iron Oxide
Nanoparticles (SPIONs) are particularly attractive as diagnostics
(e.g. biomarker-targeted magnetic resonance imaging/MRI
contrast agents) and therapeutics (e.g. magnetic nanoparticle-
enhanced hyperthermia).2 Their large surface areas to conjugate
targeting ligands and load therapeutic agents,3 their unique
magnetic properties,4 their biocompatibility5 and low toxicity6
make them suitable technology platforms in oncology.
Anti-apoptotic Inhibition of Apoptosis Proteins (IAPs)7 bind
Cysteine ASPartic acid-speciﬁc proteASEs (caspases, CASP),8 the
major apoptotic effectors, through their baculovirus inhibitor re-
peat (BIR) domains. CASP-IAP interactions inactivate caspases
and block apoptosis. The endogenous Smac protein9 (Second Mito-
chondria-derived Activator of Caspases) binds to IAPs through its
N-terminus AVPI sequence. The tetrapeptide binds to BIR3, the
CASP-9 binding domain of IAPs, and prevents linker-BIR2-CASP-
3/7 interactions through a weaker interaction.10 Thus, Smac is a
pro-apoptotic IAP ligand that restores caspase-dependent apoptosis
in cancer cells.We introduced 4-substituted, aza-bicyclo [5.3.0] decane (ABD)-
based N-AVPI mimetics as potent, pro-apoptotic cytotoxic agents
(see Fig. 1 for ABD structure and numbering). Monomers such as
1 (Smac136, Fig. 1) are potent, orally available BIR3 binders with
moderate cytotoxicity.11 Dimers such as 2 (Smac83, Fig. 1) bind
IAPs on both BIR domains, resulting in a stronger cytotoxic activity,
but possess a sub-optimal PK proﬁle and cannot be administered
orally.12
We reasoned that SPION-Smac mimetic nano-conjugates may
take advantage of nanoparticle-speciﬁc access to cytosolic com-
partments (e.g. receptor-mediated endocytosis, macropinocyto-
sis).13 The spatial arrangement of monomeric Smac mimetics on
the surface of SPIONs may allow, or even promote, the binding of
two SPION-grafted Smac mimetics to a single IAP molecule
(dimer-like binding). Finally, a single SPION-Smac mimetic nano-
conjugate may bind several IAPs (multi-presentation mode). Thus,
we decided to synthesize and biologically characterize a small
library of SPION-Smac mimetic nano-conjugates.
4-CH2OR and 4-CH2NR1R2-substituted ABD Smac mimetics pos-
sess strong BIR/IAP afﬁnity.11 N-Boc-protected hydroxyacid 4 and
N-Boc-protected aminoamide 5 were prepared from the tricyclic
intermediate 314 as previously reported11a (Scheme 1), although
several reaction conditions were optimized. 4-Connected
Smac-linker carboxylate constructs (6, ester connection, and 7,
amide connection) were obtained in good yields respectively from
compounds 4 and 5 (Scheme 1).
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methyl amide of Smac mimetic 1 is replaced by an (R)-phenylgly-
cine amide. N-protected hydroxyacid 4 was used to prepare in
good yields the C terminus-connected Smac-linker carboxylate
construct 8 (Scheme 2).Smac-linker constructs 6–8 and all previously unreported inter-
mediates were analytically and spectroscopically characterized
(LC–MS, 1H and 13C NMR).
The carboxy group of Smac-linker constructs 6–8 is used to
non-covalently adsorb the compounds onto surface-exposed OH
ba) Naked SPIONs, H2O, sonication, 60°C, 4hrs, loading 0.272 mmol/gSPION (NP-1), 0.485 mmol/gSPION (NP-2); 
b) Naked SPIONs, dry toluene, sonication, 60°C, 4hrs, loading 0.168 mmol/gSPION.
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a) Naked SPIONs, dry toluene, N2, sonication, 60°C, 4hrs, loading 0.836 mmol/gSPION ; b) NP-A, 
EDC.HCl, dry CH3 CN, N2, sonication, 60°C, 4hrs, loading 0.167 mmol/gSPION (NP-A-1), 0.308
mmol/gSPION (NP-A-2), 0.718 mmol/gSPION (NP-A-3).
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Scheme 4. Synthesis of covalent SPION-Smac mimetic nano-conjugates NP-A-1/3.
2376 P. Seneci et al. / Bioorg. Med. Chem. Lett. 24 (2014) 2374–2378groups of commercial SPIONs. Non-covalent nano-conjugates
NP-1/3 are obtained with moderate to good Smac mimetic loadings
(Scheme 3), as judged by elemental analysis.
Commercially available- maghemite c-Fe2O3 SPIONs may be re-
acted with 3-aminopropyl triethoxysilane (APTES) to give the highloading SPION-APTES-NH2 construct NP-A (Scheme 4). NP-A is
then covalently coupled with the carboxy group of Smac-linker
constructs 6–8. Covalent nano-conjugates NP-A-1/3 are obtained
with moderate to good Smac loadings (Scheme 4) in unoptimized
reaction conditions.
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gates NP-1/3 and NP-A-1/3were analytically and spectroscopically
characterized (FT-IR, elemental analysis). Single reaction runs for
each nanoconjugate often lead to good loadings (0.272–0.718
mmol/gSPION; NP-1, NP-2, NP-A-2, NP-A-3). Observed moderate
loadings (<0.200 mmol/gSPION) could be improved by repeating
the synthetic procedure for NP-3 and NP-A-1.
The afﬁnity of the six SPION-Smac mimetic nano-conjugates for
mono-functional (BIR3 domains from X-linked IAP/XIAP, and from
cellular IAPs/cIAP1 and cIAP2) and bi-functional IAP constructs
(linker-BIR2-BIR3 multi-domain region from XIAP) was measured
in a cell-free assay format. Standard reference compounds 4-acet-
oxymethyl/9, 4-acetamidomethyl/10 and C terminus (R)-phenyl-
glycinamide methyl ester/11 (Fig. 2) were prepared in solution as
previously described.11a They were biologically tested as soluble
analogues respectively of non covalent/covalent SPION-Smac mi-
metic nano-conjugate pairs NP-1/A-1 (9), NP-2/A-2 (10) and
NP-3/A-3 (11).
The IC50 values determined for ABD-based Smac mimetics 9–11
and SPION-Smac mimetic non-covalent (NP-1/3) and covalent
(NP-A-1/3) nano-conjugates are listed in Table 1.
SPION-Smac mimetic nano-conjugates generally maintain the
nanomolar binding afﬁnity of reference compounds 9–11 for single
BIR3 domains from IAPs. Both non-covalent adsorption and cova-
lent drafting of Smac mimetics onto SPIONs are compatible with
IAP binding (Table 1). For example, the non-covalent conjugate
NP-1 and the reference standard 9 show similar binding strength
in presence of BIR3 from XIAP and L-BIR2-BIR3 from XIAP; and
the same behavior is shown by covalent conjugate NP-A-3 and ref-
erence standard 11 (Table 1). Loading may inﬂuence afﬁnity, as
NP-3 and NP-A-1 (loading <0.2 mmol/gSPION) show extremely re-
duced afﬁnity for IAP proteins. Unfortunately, there is no evidence
of a dimer-like binding/increase of afﬁnity (expected IC50 < 10 nM
for dimer-like compounds) for any nano-conjugate against the
bifunctional L-BIR2-BIR3 construct from XIAP.
The cytotoxicity of cell free-active NP-1/2 and NP-A-2/3
nano-conjugates was tested on three human tumor cell lines
(breast cancer, MDA-MB-231, ovarian carcinoma, IGROV-1, cervicalTable 1
Binding afﬁnity on BIR domains, IC50 (nM)
Compd BIR3 XIAP BIR3 cIAP1 BIR3 cIAP2 L-BIR2-3 XIAP
9 400 NTa NT 320
NP-1 360 38 78 300
NP-A-1 >2000 >2000 >2000 >2000
10 330 NT NT 190
NP-2 560 150 62 240
NP-A-2 230 38 NT 120
11 760 160 180 190
NP-3 >2000 1400 >2000 410
NP-A-3 580 270 180 410
a Not tested.cancer, HeLa cells). The nano-conjugates were generally inactive
against tumor cells, with slight signs of cytotoxicity at the highest
concentrations (25 lM). NP-1/2 and NP-A-2/3 show monomer-
like cell free binding to IAP constructs, and reference monomers
9–11 show moderate cytotoxicity (IC50 between 10 and 25 lM
against MDA-MB-231 cells). Thus, the weak cytotoxicity of nano-
conjugates is likely due to a surprising lack of multimeric behavior
that prevents their expected, dimer-like interaction with multiple
bifunctional L-BIR2-BIR3 construct from XIAP.
In summary, we report here the synthesis, the spectroscopical
and biological characterization of non-covalent (NP-1/3) and
covalent (NP-A-1/3) SPION-Smac mimetic nano-conjugates as
IAP-targeted pro-apoptotic agents. SPION-Smac mimetic nano-
conjugates behave as their soluble monomer analogues, retaining
monomer-like cell free binding afﬁnity for IAP targets, while being
almost inactive in cellular assays. Further efforts will aim to
achieve cellular and in vivo activity for SPION-Smac mimetic
nano-conjugates in suitable cellular apoptosis/oncology models.
Namely, we will vary the connection between Smac mimetics
and SPIONs (chemical bond, linker/spacer length, hydro/lipophilic-
ity, etc.), and we will decorate SPIONs with more potent mono-
meric and dimeric Smac mimetics.
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